var title_f36_6_36960="Posterior leg splint";
var content_f36_6_36960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior leg splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The posterior leg (or ankle) splint is used for distal leg, ankle, tarsal, and metatarsal fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36960=[""].join("\n");
var outline_f36_6_36960=null;
var title_f36_6_36961="Paraseptal emphysema I";
var content_f36_6_36961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paraseptal emphysema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several subpleural emphysematous spaces are present in the periphery of the left upper lobe (arrows) in a patient with accompanying severe centrilobular emphysema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36961=[""].join("\n");
var outline_f36_6_36961=null;
var title_f36_6_36962="Patient information: Fungal meningitis and septic arthritis outbreak (The Basics)";
var content_f36_6_36962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86783\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/42/1701\">",
"         Map of states where contaminated steroid medicine was distributed",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/1/33823\">",
"          Healthcare facilities that had contaminated steroid medicine",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/23/44402\">",
"         Patient information: Lumbar puncture (spinal tap) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Fungal meningitis and septic arthritis outbreak (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/fungal-meningitis-and-septic-arthritis-outbreak-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H112110718\">",
"      <span class=\"h1\">",
"       What is fungal meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Fungal meningitis is an infection caused by a fungus that affects the brain and spinal cord. This type of infection is normally very rare. But in early October of 2012, there was a fungal meningitis outbreak in the United States. It has affected people who were given injections into the spine of a medicine called a steroid. This steroid medicine was contaminated with different types of fungus, including a fungus called &ldquo;Exserohilum.&rdquo;",
"     </p>",
"     <p>",
"      Steroid medicines are often given as an injection into the spine in people who have back or neck pain, or other problems affecting the spine. This type of injection is called an &ldquo;epidural injection.&rdquo; It delivers medicine into the area surrounding the spinal cord.",
"     </p>",
"     <p>",
"      Fungal meningitis is not spread from person to person. You cannot catch it from a person who has the infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112110733\">",
"      <span class=\"h1\">",
"       What is septic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Septic arthritis is an infection in a joint, such as the knee, shoulder or hip. Some people have developed this type of infection after getting an injection of the contaminated steroid into a joint.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15675860\">",
"      <span class=\"h1\">",
"       Were there problems besides fungal meningitis and septic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some people who got the contaminated steroid have had other types of infections. For example, some people have developed local infections affecting the bones of the spine or the tissues that surround the spinal cord. These infections are called &ldquo;spinal infections&rdquo; or &ldquo;paraspinal infections.&rdquo; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112110748\">",
"      <span class=\"h1\">",
"       What if I am worried that I might be affected?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you live in the United States and were given a steroid injection into your spine, a joint, or another part of your body sometime since May 21, 2012, find out if it had the contaminated medicine.",
"     </p>",
"     <p>",
"      To find out if you might have gotten the contaminated medicine, follow these steps:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Check to see if the facility where you got your injection had the contaminated medicine. The table lists all of the facilities that had the contaminated medicine (",
"        <a class=\"graphic graphic_table graphicRef86785 \" href=\"mobipreview.htm?33/1/33823\">",
"         table 1",
"        </a>",
"        ). The figure shows a map with all the states that were affected (",
"        <a class=\"graphic graphic_figure graphicRef86784 \" href=\"mobipreview.htm?1/42/1701\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        If the facility where you were treated",
"        <strong>",
"         is",
"        </strong>",
"        on the list, call them and ask if the contaminated medicine was given to you.",
"       </li>",
"       <li>",
"        If you did get the contaminated medicine, do not panic. Many people who got the contaminated medicine have not gotten sick. But watch for any symptoms that could mean you are infected. The symptoms are listed below.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112110831\">",
"      <span class=\"h1\">",
"       What are the symptoms of fungal meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        New or worse headache",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Nausea",
"       </li>",
"       <li>",
"        Sensitivity to light",
"       </li>",
"       <li>",
"        Neck stiffness",
"       </li>",
"       <li>",
"        New weakness or numbness in any part of your body",
"       </li>",
"       <li>",
"        Slurred speech",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most people have started having symptoms 1 to 4 weeks after getting an injection of the contaminated medicine. But the symptoms could start sooner or later for some people. Some people have had only mild symptoms, such as a mild headache but no fever or other symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112110846\">",
"      <span class=\"h1\">",
"       What are the symptoms of septic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Increased pain, redness, warmth, or swelling in the joint that got the injection or at the injection site",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H76294544\">",
"      <span class=\"h1\">",
"       What are the symptoms of spinal or paraspinal infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Increased pain, redness, or swelling at the injection site",
"       </li>",
"       <li>",
"        Weakness or changes in sensation in the lower back or legs",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Back pain",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112110861\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you got the contaminated medicine and you develop any of the symptoms above, see your doctor or go to the emergency room right away. Even if all you have is a mild headache or you feel weak, you should seek immediate medical care. Fungal meningitis, septic arthritis, and the other infections caused by the contaminated medicine can be very serious. It is very important to get treated right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112110876\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you were treated with the contaminated medicine and have any symptoms that could be caused by fungal meningitis, you will need a test called a &ldquo;lumbar puncture,&rdquo; also called a &ldquo;spinal tap.&rdquo; For this test, a doctor will insert a small needle into your back to collect a sample of fluid from around your spinal cord. This fluid will then be checked for infection.",
"     </p>",
"     <p>",
"      If you were treated with the contaminated medicine and have any symptoms that could be caused by septic arthritis, you will need a test called an &ldquo;arthrocentesis,&rdquo; also called a &ldquo;joint aspiration&rdquo; or &ldquo;joint tap.&rdquo; For this test, a doctor will insert a small needle into your joint to collect a sample of fluid. This fluid will then be checked for infection.",
"     </p>",
"     <p>",
"      If you were treated with the contaminated medicine and have any symptoms of a local infection near your spine, your doctor will probably do an MRI and try to get a sample of fluid from the infected area. That way, he or she can have the fluid checked for infection. &nbsp;",
"     </p>",
"     <p>",
"      If you were treated with the contaminated medicine, but do not have any symptoms, you will",
"      <strong>",
"       not",
"      </strong>",
"      need tests. But if you develop even mild symptoms, you will need to have a lumbar puncture, joint aspiration, or other test right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H112110891\">",
"      <span class=\"h1\">",
"       How are the infections caused by the contaminated medicine treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have fungal meningitis, septic arthritis, or a spinal or paraspinal infection, you will be treated in the hospital with medicines called &ldquo;anti-fungals.&rdquo; These medicines kill different types of fungus. At first, these medicines are usually given through a small tube called an &ldquo;IV&rdquo; that goes into a vein. Later, 1 of these medicines can be given in pill form. Treatment lasts for months. Even if you feel better after taking the anti-fungals for some time, do not stop them unless your doctor or nurse tells you to. The infection can come back if it hasn&rsquo;t been treated long enough.",
"     </p>",
"     <p>",
"      For more information about the fungal meningitis outbreak, visit the Centers for Disease Control and Prevention (CDC) Web site at:",
"      <a class=\"external\" href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\">",
"       www.cdc.gov/hai/outbreaks/meningitis.html",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H115147625\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/23/44402?source=see_link\">",
"       Patient information: Lumbar puncture (spinal tap) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/6/36962?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86783 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36962=[""].join("\n");
var outline_f36_6_36962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112110718\">",
"      What is fungal meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112110733\">",
"      What is septic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15675860\">",
"      Were there problems besides fungal meningitis and septic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112110748\">",
"      What if I am worried that I might be affected?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112110831\">",
"      What are the symptoms of fungal meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112110846\">",
"      What are the symptoms of septic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76294544\">",
"      What are the symptoms of spinal or paraspinal infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112110861\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112110876\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112110891\">",
"      How are the infections caused by the contaminated medicine treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115147625\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86783\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/42/1701\">",
"      Map of states where contaminated steroid medicine was distributed",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/1/33823\">",
"       Healthcare facilities that had contaminated steroid medicine",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/23/44402?source=related_link\">",
"      Patient information: Lumbar puncture (spinal tap) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_6_36963="Decubitus x-ray intraperitoneal free air";
var content_f36_6_36963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Decubitus x-ray of intraperitoneal free air",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain film examination of the abdomen in decubitus position reveals a large amount of free air collecting in the right flank, clearly outlining the bowel wall (open arrows). When air is present on both sides of the bowel, the wall is outlined with clear distinction because of the contrast differences created on both sides. This is called Rigler's sign and is pathognomonic for free air in the peritoneal cavity. The yellow arrows show air-fluid levels in distended bowel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36963=[""].join("\n");
var outline_f36_6_36963=null;
var title_f36_6_36964="Audiogram conductive loss";
var content_f36_6_36964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Audiogram conductive loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 741px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36964=[""].join("\n");
var outline_f36_6_36964=null;
var title_f36_6_36965="Starting laser cone procedure";
var content_f36_6_36965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Marking surgical boundaries for laser cervical (uterine cervix) conization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exocervical margin of planned laser cone is marked with a circle of dots placed with the laser.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36965=[""].join("\n");
var outline_f36_6_36965=null;
var title_f36_6_36966="Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults";
var content_f36_6_36966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36966/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36966/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36966/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36966/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36966/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36966/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/6/36966/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term candidemia describes the presence of Candida species in the blood. Candida in a blood culture should never be viewed as a contaminant and should always prompt a search for the source. For many patients, candidemia is a manifestation of disseminated candidiasis, whereas for others it reflects colonization of an indwelling intravenous catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all cases, candidemia requires treatment with an antifungal agent; it should never be assumed that removal of a catheter alone is adequate therapy for candidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical issues related to the clinical manifestations and diagnosis of candidemia will be reviewed here. The epidemiology, pathogenesis, and treatment of candidemia are discussed separately; Candida endocarditis; hepatosplenic candidiasis (chronic disseminated candidiasis); Candida endophthalmitis; Candida infections of the central nervous system, bladder, and kidneys; and an overview of Candida infections, are also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37638?source=see_link\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40566?source=see_link\">",
"     \"Candida endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10071?source=see_link\">",
"     \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39559?source=see_link\">",
"     \"Candida infections of the central nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=see_link\">",
"     \"Candida infections of the bladder and kidneys\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Candidemia in neonates and children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9991?source=see_link\">",
"     \"Prevention of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/6/25703?source=see_link\">",
"     \"Clinical features and diagnosis of candidemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=see_link\">",
"     \"Overview of Candida infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3336?source=see_link\">",
"     \"Treatment of candidemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidiasis is an increasingly important nosocomial infection. Although C. albicans is the most common cause of candidemia, there has been increased isolation of non-albicans species of Candida in recent years. Patients in the intensive care unit and those who are immunocompromised are most at risk for the development of candidemia.",
"   </p>",
"   <p>",
"    The epidemiology of and risk factors for candidemia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37638?source=see_link\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of candidemia vary from minimal fever to a full-blown sepsis syndrome that is indistinguishable from severe bacterial infection. Invasive candidiasis is defined by hematogenous spread to multiple viscera (eg, eye, kidney, heart valves, brain). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=see_link\">",
"     \"Candida infections of the bladder and kidneys\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40566?source=see_link\">",
"     \"Candida endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39559?source=see_link\">",
"     \"Candida infections of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical clues on physical examination to hematogenous spread of Candida include characteristic eye lesions (chorioretinitis with or without vitritis), skin lesions, and much less commonly, muscle abscesses.",
"   </p>",
"   <p>",
"    The frequency of eye lesions in patients with candidemia has been variable, ranging from 2 to 26 percent in different studies. There appears to be a decrease in cases of chorioretinitis that present with vitritis. This is due, in part, to early examination at the time when only chorioretinitis is present and the widespread treatment of every patient who has candidemia. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13849?source=see_link&amp;anchor=H27883735#H27883735\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin lesions tend to appear suddenly as clusters of painless pustules on an erythematous base; they can occur on any area of the body. The lesions vary from tiny pustules that can be easily missed (",
"    <a class=\"graphic graphic_picture graphicRef55977 \" href=\"mobipreview.htm?33/63/34815\">",
"     picture 1",
"    </a>",
"    ) to others that are nodular, several centimeters in diameter, and appear necrotic in the center (",
"    <a class=\"graphic graphic_picture graphicRef75717 \" href=\"mobipreview.htm?24/42/25248\">",
"     picture 2",
"    </a>",
"    ). In severely neutropenic patients, the lesions may be macular rather than pustular. In patients with negative blood cultures, the recognition of these lesions as a manifestation of candidemia and subsequent punch biopsy may lead to the diagnosis (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Less commonly, patients describe soreness in a discrete muscle group caused by Candida microabscesses. Examination reveals a tender muscle that may be warm and swollen (",
"    <a class=\"graphic graphic_picture graphicRef64945 \" href=\"mobipreview.htm?42/9/43167\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to these typical peripheral sites of involvement, signs of multiorgan system failure may be present due to involvement of the kidneys, heart, liver, spleen, lungs, eyes, and brain (",
"    <a class=\"graphic graphic_picture graphicRef52139 \" href=\"mobipreview.htm?37/49/38672\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for the diagnosis of candidemia is a positive blood culture; blood cultures should be obtained in all patients with suspected candidemia. In patients with focal findings (eg, skin lesions or parenchymal involvement), biopsy should be performed for staining, culture, and histopathologic evaluation. When available, we suggest sending the beta-D-glucan assay since it can be a useful adjunct to blood cultures and biopsy. It is particularly useful in patients with deep-seated invasive candidiasis (eg, intra-abdominal candidiasis) because blood cultures are insensitive in this setting. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Blood cultures'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Culture and stain of biopsy material'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Biopsy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Beta-D-glucan and other antigen assays'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinicians frequently must rely upon clinical judgment about the probability of candidemia as an explanation for a patient's symptoms while awaiting the return of blood cultures. Certain findings on physical examination, especially the presence of suggestive skin or eye lesions, can alert the clinician to the possibility of Candida infection. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most obvious method to detect candidemia is to grow the organism from the blood. Unfortunately, blood culture techniques are relatively insensitive. Studies from several decades ago showed that blood cultures were positive in only approximately 50 percent of patients who were found to have disseminated candidiasis at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although similar autopsy-based studies have not been reported since the advent of modern blood culture techniques, there have been many studies comparing the sensitivity of different blood culture systems for the detection of yeasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The introduction of the lysis-centrifugation method (Dupont Isolator tube) improved the detection of yeasts when compared with other blood culture systems. Subsequent changes in the culture media used in the BACTEC and BactiAlert systems, allowing enhanced growth of yeasts, have made these systems as sensitive as the lysis-centrifugation technique for detecting Candida species in blood.",
"   </p>",
"   <p>",
"    A drawback of all blood culture systems for the diagnosis of candidemia is that one to three days are required for growth and an additional one to two days for identification of the organism after subculture onto agar medium. For a seriously ill patient, more rapid and more sensitive techniques are essential.",
"   </p>",
"   <p>",
"    Several techniques have been developed that decrease the time to identification of the most common Candida species once a blood culture bottle shows growth and yeasts are seen on the smear of the bottle contents. Using the technique of peptide nucleic acid fluorescence in situ hybridization (PNA-FISH), C. albicans and C. glabrata can be identified within hours of a blood culture becoming positive for yeast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Another technique is matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. Using this technique, proteins released from Candida spp are detected in a blood culture and are compared to a large database of proteins from many species of yeast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/8\">",
"     8",
"    </a>",
"    ]. MALDI-TOF mass spectrometry can be used directly on material taken from a blood culture bottle that is positive for yeast, and results can be read in as short a period as 30 minutes.",
"   </p>",
"   <p>",
"    A study that compared the performance of blood cultures with the polymerase chain reaction and the beta-D-glucan assay is discussed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Polymerase chain reaction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Culture and stain of biopsy material",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directed biopsy of sites of involvement often leads to a definitive diagnosis. Material obtained by scraping the base of a pustule should be submitted to the microbiology laboratory for Gram stain (",
"    <a class=\"graphic graphic_picture graphicRef70812 \" href=\"mobipreview.htm?34/21/35166\">",
"     picture 5",
"    </a>",
"    ) and culture. More commonly, a punch biopsy is performed and the tissue submitted for culture and for histopathologic examination using special stains for fungi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Non-culture methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last several decades, substantial efforts have been directed at the development of non-culture based method for the diagnosis of candidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antibody assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, no sensitive and specific Candida antibody assay has been developed that is useful for diagnosis. Because Candida are part of the normal flora, healthy persons have antibodies against these organisms, thereby decreasing the specificity of the assay. On the other hand, an immunosuppressed host may be unable to generate a vigorous antibody response to Candida infection, thereby decreasing the sensitivity of the assay in this high-risk population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Beta-D-glucan and other antigen assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of circulating Candida antigens or metabolites were thought to hold more promise than antibody-based methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Assays for several cell wall components, cytoplasmic antigens, and the metabolite arabinitol were not sufficiently sensitive for diagnostic purposes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most promising antigen assay is based on the detection of beta-D-glucan, which is present in the cell wall of many fungi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Thus, this assay is not specific for Candida. In one multicenter study of 163 patients with proven or probable invasive fungal infections and 170 patients without invasive fungal infections, 107 patients had proven candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/14\">",
"     14",
"    </a>",
"    ]. Depending on the cutoff value chosen as positive, between 78 and 81 percent of the 107 patients with proven candidiasis had positive results using the beta-D-glucan assay.",
"   </p>",
"   <p>",
"    Researchers in Japan have a longer experience with this assay, and the commercial kits available in Japan differ from those available in the United States. In an autopsy series of 456 patients that included 54 with invasive fungal infections, 41 patients had a beta-D-glucan assay performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/15\">",
"     15",
"    </a>",
"    ]. Using a cut-off value of 60",
"    <span class=\"nowrap\">",
"     picograms/mL,",
"    </span>",
"    the positive predictive value of the assay was found to be 70 percent, and the negative predictive value was 98 percent.",
"   </p>",
"   <p>",
"    Another study suggested a potential role of this assay in determining whether a Candida-related biofilm plays a role in persistence of infection with central venous catheter-associated candidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study showed that a combination of blood cultures with the beta-D-glucan assay or the polymerase chain reaction increase the sensitivity of diagnostic testing compared with blood cultures alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/18\">",
"     18",
"    </a>",
"    ]. This is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Polymerase chain reaction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directed biopsy of sites of involvement can be submitted for histopathology. Punch biopsies of skin or tissue biopsy will show microabscesses and special stains will show budding yeasts and often pseudohyphae characteristic of Candida species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;One current focus of non-culture methods is on the development of a polymerase chain reaction (PCR) assay for candidemia and invasive candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/19\">",
"     19",
"    </a>",
"    ]. As is true of cultures, PCR can identify Candida to the species level. However, to date, there is no commercially available approved PCR test to detect Candida species.",
"   </p>",
"   <p>",
"    For the detection of candidemia, the sensitivity of PCR has been previously reported to be similar to that of blood cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] and in occasional cases of invasive candidiasis, PCR has assisted in establishing the diagnosis when cultures were negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study compared the performance of a newer real-time PCR assay, the beta-D-glucan assay, and blood cultures for diagnosing invasive candidiasis in 55 patients with invasive candidiasis (17 with candidemia, 33 with deep-seated candidiasis, and 5 with both) and 73 hospitalized controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36966/abstract/18\">",
"     18",
"    </a>",
"    ]. The PCR assay was more sensitive than the beta-D-glucan assay for diagnosing invasive candidiasis (80 versus 56 percent) but had comparable specificity (70 versus 73 percent). The PCR assay and the beta-D-glucan assay had similar sensitivity for candidemia, but PCR was more sensitive for deep-seated candidiasis (89 versus 53 percent). Both PCR and the beta-D-glucan assay were more sensitive than blood cultures among patients who had invasive candidiasis. In patients with invasive candidiasis, the sensitivity of blood cultures combined with PCR or the beta-D-glucan assay was 98 and 79 percent, respectively. Thus, these two non-culture-based assays, when combined with blood cultures, have the potential to increase the sensitivity of culture methods for invasive candidiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida in a blood culture should never be viewed as a contaminant and should always prompt a search for the source. For many patients, candidemia is a manifestation of invasive candidiasis, whereas for others it reflects colonization of an indwelling intravenous catheter. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of candidemia vary from minimal fever to a full-blown sepsis syndrome that is indistinguishable from severe bacterial infection. Invasive candidiasis is defined as hematogenous spread to multiple viscera (eg, eye, kidney, heart valves, brain). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical clues on physical examination to hematogenous spread of Candida include characteristic eye lesions (chorioretinitis with or without vitritis), skin lesions, and much less commonly, muscle abscesses. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gold standard for the diagnosis of candidemia is a positive blood culture; blood cultures should be obtained in all patients with suspected candidemia. However, blood cultures can be negative in patients with invasive candidiasis, and the diagnosis in such cases is often based on clinical suspicion. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Blood cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with focal findings (eg, skin lesions or parenchymal involvement), biopsy should be performed for staining, culture, and histopathologic evaluation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Culture and stain of biopsy material'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When available, we suggest sending the beta-D-glucan assay since it can be a useful adjunct to blood cultures and biopsy. It is particularly useful in patients with deep-seated candidiasis (eg, intra-abdominal candidiasis) because blood cultures are insensitive in this setting. Beta-D-glucan is present in the cell wall of many fungi and the beta-D-glucan assay is therefore not specific for Candida spp. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Beta-D-glucan and other antigen assays'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/1\">",
"      Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/2\">",
"      Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis 1966; 19:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/3\">",
"      Hart PD, Russell E Jr, Remington JS. The compromised host and infection. II. Deep fungal infection. J Infect Dis 1969; 120:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/4\">",
"      Wilson ML, Davis TE, Mirrett S, et al. Controlled comparison of the BACTEC high-blood-volume fungal medium, BACTEC Plus 26 aerobic blood culture bottle, and 10-milliliter isolator blood culture system for detection of fungemia and bacteremia. J Clin Microbiol 1993; 31:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/5\">",
"      Mu&ntilde;oz P, Bernaldo de Quir&oacute;s JC, Berenguer J, et al. Impact of the BACTEC NR system in detecting Candida fungemia. J Clin Microbiol 1990; 28:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/6\">",
"      Gherna M, Merz WG. Identification of Candida albicans and Candida glabrata within 1.5 hours directly from positive blood culture bottles with a shortened peptide nucleic acid fluorescence in situ hybridization protocol. J Clin Microbiol 2009; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/7\">",
"      Shepard JR, Addison RM, Alexander BD, et al. Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. J Clin Microbiol 2008; 46:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/8\">",
"      Spanu T, Posteraro B, Fiori B, et al. Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol 2012; 50:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/9\">",
"      Matthews RC. Comparative assessment of the detection of candidal antigens as a diagnostic tool. J Med Vet Mycol 1996; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/10\">",
"      Reiss E, Obayashi T, Orle K, et al. Non-culture based diagnostic tests for mycotic infections. Med Mycol 2000; 38 Suppl 1:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/11\">",
"      Walsh TJ, Hathorn JW, Sobel JD, et al. Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med 1991; 324:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/12\">",
"      Walsh TJ, Merz WG, Lee JW, et al. Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum D-arabinitol. Am J Med 1995; 99:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/13\">",
"      Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/14\">",
"      Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1--&gt;3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/15\">",
"      Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1--&gt;3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/16\">",
"      Mohr JF, Sims C, Paetznick V, et al. Prospective survey of (1&rarr;3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011; 49:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/17\">",
"      Nett J, Lincoln L, Marchillo K, Andes D. Beta -1,3 glucan as a test for central venous catheter biofilm infection. J Infect Dis 2007; 195:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/18\">",
"      Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, &beta;-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012; 54:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/19\">",
"      Kourkoumpetis TK, Fuchs BB, Coleman JJ, et al. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis 2012; 54:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/20\">",
"      Ahmad S, Khan Z, Mustafa AS, Khan ZU. Seminested PCR for diagnosis of candidemia: comparison with culture, antigen detection, and biochemical methods for species identification. J Clin Microbiol 2002; 40:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/21\">",
"      McMullan R, Metwally L, Coyle PV, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008; 46:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36966/abstract/22\">",
"      Lau A, Halliday C, Chen SC, et al. Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. J Clin Microbiol 2010; 48:811.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2462 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-0DF129FE3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36966=[""].join("\n");
var outline_f36_6_36966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Culture and stain of biopsy material",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Non-culture methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antibody assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Beta-D-glucan and other antigen assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2462|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/63/34815\" title=\"picture 1\">",
"      Disseminated candidiasis skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/42/25248\" title=\"picture 2\">",
"      Disseminated candidiasis nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/9/43167\" title=\"picture 3\">",
"      Disseminated candidiasis muscle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/49/38672\" title=\"picture 4\">",
"      Disseminated candidiasis kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/21/35166\" title=\"picture 5\">",
"      Budding yeast Gram stain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40566?source=related_link\">",
"      Candida endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15128?source=related_link\">",
"      Candida infections of the bladder and kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39559?source=related_link\">",
"      Candida infections of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/6/25703?source=related_link\">",
"      Clinical features and diagnosis of candidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=related_link\">",
"      Epidemiology and risk factors for Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13849?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10071?source=related_link\">",
"      Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=related_link\">",
"      Overview of Candida infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9991?source=related_link\">",
"      Prevention of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3336?source=related_link\">",
"      Treatment of candidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_6_36967="Paragonimiasis";
var content_f36_6_36967=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paragonimiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36967/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36967/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36967/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36967/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36967/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36967/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36967/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/6/36967/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paragonimiasis is a trematode (fluke) infection transmitted via consumption of raw or undercooked crab or crayfish. Almost 50 species and subspecies of Paragonimus have been described, most of which are found in carnivorous animal hosts. Approximately 16 species have been reported to cause disease in humans, the most common of which is the oriental lung fluke, P. westermani. Paragonimiasis can have pulmonary and extrapulmonary manifestations, as discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paragonimiasis occurs in several parts of the Far East, West Africa, and the Americas. It is estimated that 20 million people are infected worldwide, and more than 290 million are at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The prevalence of infection increases in areas with numerous human and animal reservoir hosts, an abundance of first and second intermediate hosts (snails and crabs or crayfish, respectively), and social customs of eating raw or undercooked seafood. In addition, paragonimiasis can be acquired by ingesting raw meat from carnivorous animal hosts that contain young flukes (such as wild boars). Transmission has also been reported via contaminated utensils, such as knives or chopping boards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Species distribution varies by geographic region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/3\">",
"     3",
"    </a>",
"    ]. P. westermani is found in the Far East, particularly in China, Korea, Japan, the Philippines, Taiwan, and India. P. africanus occurs in West Africa; Paragonimus mexicanus occurs in Central and South America. In the United States, the disease is observed most frequently among immigrants from endemic countries, but local transmission has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/5\">",
"     5",
"    </a>",
"    ]. A few cases of P. kellicotti have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. In 2010, nine cases of human paragonimiasis were reported in Missouri among patients who had eaten raw or undercooked crayfish from rivers while canoeing or camping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle of paragonimiasis begins with expectoration of unembryonated eggs in the sputum; alternatively eggs may be swallowed and passed in the stool (",
"    <a class=\"graphic graphic_figure graphicRef56115 \" href=\"mobipreview.htm?24/62/25576\">",
"     figure 1",
"    </a>",
"    ). In fresh water, the eggs become embryonated; after a few weeks, the resulting miracidia hatch and penetrate the soft tissues of a snail (the first intermediate host). Miracidia go through several developmental stages inside the snail (sporocysts, rediae, and cercariae) over three to five months. Cercariae emerge from the snail and invade a crustacean such as a crab or crayfish (the second intermediate host) where they encyst and become metacercariae over six to eight weeks.",
"   </p>",
"   <p>",
"    Metacercariae are the infective form for the mammalian host (humans, pigs, dogs, cats, and rodents).&nbsp;Infection is acquired by eating inadequately cooked or pickled crab or crayfish that harbor metacercariae.&nbsp;The metacercariae excyst in the duodenum, penetrate the intestinal wall into the peritoneal cavity, and migrate through the abdominal wall and diaphragm into the lung parenchyma, where they become encapsulated and develop into adults over five to six weeks.&nbsp;",
"   </p>",
"   <p>",
"    Upon reaching maturity, the adult worms deposit eggs that pass into the bronchioles and are coughed up with sputum or swallowed and passed in the stool. Adult flukes can produce as many as 20,000 eggs per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/12\">",
"     12",
"    </a>",
"    ]. The time from infection to oviposition is 65 to 90 days.&nbsp;An individual generally carries &le;20 worms, which can persist within humans for 20 years.",
"   </p>",
"   <p>",
"    The worms can also reach other tissues such as the brain and striated muscles. When this occurs, however, completion of the life cycle cannot be achieved because the eggs laid cannot exit these sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical infections are asymptomatic. The likelihood of symptomatic infection depends upon the intensity of infection and the organs involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/3\">",
"     3",
"    </a>",
"    ]. Most symptomatic infections consist of pulmonary disease; extrapulmonary disease is relatively uncommon. The incubation period is typically from 2 to 20 days following ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725518\">",
"    <span class=\"h2\">",
"     Pulmonary paragonimiasis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725712\">",
"    <span class=\"h3\">",
"     Early infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early phase of paragonimiasis occurs between the time of infection and the first egg production (about two months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/13\">",
"     13",
"    </a>",
"    ]. During the period of larval migration within the peritoneal cavity, some patients experience fever, malaise, diarrhea, or epigastric pain. Urticaria may also develop. As larvae penetrate the diaphragm and migrate within the pleural cavity, pleuritic chest pain (often bilateral) may develop. At this time (about one month after infection), the chest radiograph may demonstrate pneumothorax or pleural effusions. Pleural effusions are generally exudative and laden with eosinophils.",
"   </p>",
"   <p>",
"    As migration progresses, symptoms may include chest pain, dyspnea, cough, and malaise. Less common symptoms include low grade fever and blood streaked sputum. Radiographic findings associated with pulmonary parenchymal migration consist of transient, migratory pulmonary infiltrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/13\">",
"     13",
"    </a>",
"    ]. Leukocytosis and peripheral eosinophilia (10 to 30 percent) are common.",
"   </p>",
"   <p>",
"    Early pulmonary paragonimiasis may resemble Loeffler's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/25/11668?source=see_link\">",
"     \"Pulmonary manifestations of ascariasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725719\">",
"    <span class=\"h3\">",
"     Late infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second phase of infection refers to the period when mature flukes inhabit the lungs; this phase may last for years, during which worms induce inflammation and fibrosis in the lung or ectopic locations. Clinical manifestations depend on the duration and intensity of infection.",
"   </p>",
"   <p>",
"    Recurrent hemoptysis is the most common symptom during this phase; malaise may be observed although patients may not feel or appear ill. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The expectorated material typically has a characteristic chocolate color; it is composed of blood, inflammatory cells, and eggs released when the capsules around mature flukes rupture into a bronchiole. Fever and eosinophilia are generally absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/13\">",
"     13",
"    </a>",
"    ]. Pleural effusions may be a presenting manifestation of the disease in the absence of radiographic evidence for parenchymal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Bronchopleural fistula is an uncommon complication.",
"   </p>",
"   <p>",
"    Chest radiograph may demonstrate one or more lesions at the sites of localized encysted flukes or their burrowing tracts in about 80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/13,14,17,18\">",
"     13,14,17,18",
"    </a>",
"    ]. Findings may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ring shadow lesions, due to the relative lucency of cystic cavities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Irregular linear streaks, often adjacent to the ring shadows, these represent burrowing tracts of the flukes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Parenchymal mass lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pleural thickening",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographic findings may resolve spontaneously, and new lesions may appear. The pulmonary lesions may be mistaken for tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/24\">",
"     24",
"    </a>",
"    ] or malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/23\">",
"     23",
"    </a>",
"    ]. Paragonimiasis lesions are located more peripherally and are much more common in the mid- and lower lung zones; tuberculous cavities are predominantly apical lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16993301\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    On computed tomography (CT), focal fibrotic pleural thickening adjacent to a pulmonary nodule can be an important clue to the diagnosis of pleuropulmonary paragonimiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, subpleural or subfissural nodules, often containing a necrotic low-attenuation area, may be observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725526\">",
"    <span class=\"h2\">",
"     Extrapulmonary paragonimiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immature flukes can also migrate to extrapulmonary tissues, such as the brain, abdomen (including the intestinal wall, liver, spleen, kidney, adrenal glands, peritoneal cavity, and mesenteric lymph nodes), and subcutaneous tissues. Other ectopic localizations such as the heart, mediastinum, striated muscle, spinal cord, testes, and breasts have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/1,26,27\">",
"     1,26,27",
"    </a>",
"    ]. Eggs can be deposited in ectopic sites, either via release from mature worms that have migrated to these sites or via carriage of eggs to distal sites following their release from worms in the lung. Eggs or flukes in ectopic sites can provoke an inflammatory reaction, resulting in cyst, abscess, or granuloma formation.",
"   </p>",
"   <p>",
"    Extrapulmonary manifestations seem to occur more frequently with certain species of Paragonimus, particularly P. skrjabini, which is endemic in China.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cerebral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral paragonimiasis is the most common form of extrapulmonary disease, but is relatively rare; it occurs in less than 1 percent of individuals with symptomatic paragonimiasis infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/28\">",
"     28",
"    </a>",
"    ]. It is more common in younger patients; 90 percent of patients are &lt;30 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The parasite can penetrate the meninges and invade brain parenchyma, leading to meningitis, encephalitis, arachnoiditis, or a space-occupying lesion. Meningitis tends to occur as an acute manifestation and is the initial presenting feature in one-third of cases of cerebral paragonimiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/29\">",
"     29",
"    </a>",
"    ]. It is commonly associated with headache, fever, and vomiting, and may persist for as long as one to two months.",
"   </p>",
"   <p>",
"    Chronic manifestations include headache, vomiting, seizures, visual disturbances (particularly diplopia and homonymous hemianopsia), and motor or sensory disturbances related to a space-occupying lesion. Up to 10 cerebral cysts may be seen, predominantly in the temporal and occipital lobes. Examination may demonstrate papilledema, paresis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paresthesia.",
"   </p>",
"   <p>",
"    In the setting of chronic cerebral paragonimiasis, CT scans or MRI may demonstrate multiple, conglomerated, cystic, ring-enhancing lesions (1 to 3 cm), with surrounding edema. Calcification of the lesions occurs in approximately 50 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/12\">",
"     12",
"    </a>",
"    ]. The appearance has been described as being like \"soap-bubble calcifications\" on skull imaging or as having a \"grape-cluster\"-like quality on CT or MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73979 \" href=\"mobipreview.htm?22/53/23380\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Hydrocephalus may also be evident, and localized hemorrhages may be seen.",
"   </p>",
"   <p>",
"    Spinal cord involvement is rare; it can cause focal neurologic signs, such as paralysis or sensory loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Abdominal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysts may develop in the intestinal wall, causing nausea, vomiting, or bloody diarrhea. Cysts or abscess formation in the liver, spleen, peritoneal cavity, or mesenteric lymph nodes can lead to abdominal pain and palpable masses. Renal involvement results in hematuria, and eggs may be detectable in the urine (",
"    <a class=\"graphic graphic_picture graphicRef63741 \" href=\"mobipreview.htm?13/6/13412\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the setting of abdominal paragonimiasis CT scanning in may demonstrate show a cystic mass or conglomerate of ring-enhancing nodules (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53976 \" href=\"mobipreview.htm?41/53/42833\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The most common findings on CT in the setting of hepatic involvement are peripheral lesions, connected cysts with tortuous tract formation, and tubular enhancement due to migration of the worm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Subcutaneous infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paragonimus infection can be associated with painless, migratory subcutaneous swellings of various sizes or tender, firm mobile nodules containing immature flukes. These occur most commonly on the lower abdominal wall, inguinal area, and proximal lower extremities (",
"    <a class=\"graphic graphic_picture graphicRef73458 \" href=\"mobipreview.htm?43/39/44657\">",
"     picture 2",
"    </a>",
"    ). The manifestations are similar to those of cutaneous larva migrans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36229?source=see_link\">",
"     \"Cutaneous larva migrans (creeping eruption)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tools include microscopy, serology, and imaging. The diagnostic approach depends on the stage of infection, the nature of clinical manifestations and the diagnostic tools available.",
"   </p>",
"   <p>",
"    Establishing the diagnosis of paragonimiasis during early infection (prior to egg production) is difficult. It can be made only presumptively on the basis of compatible clinical manifestations in a patient with eosinophilia and appropriate exposure history.",
"   </p>",
"   <p>",
"    In the late phase of infection, the diagnosis is suggested by a history of recurrent hemoptysis in a patient from an endemic area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/37\">",
"     37",
"    </a>",
"    ]. It can usually be confirmed by finding the characteristic eggs of Paragonimus in the sputum or bronchoalveolar lavage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic screening of family members of index cases is warranted since treatment for asymptomatic infection is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2733666\">",
"    <span class=\"h2\">",
"     Microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the late phase of infection (following egg production, 8 to 10 weeks after infection), the diagnosis can be made by finding the characteristic eggs in the sputum, bronchoalveolar lavage or stool (",
"    <a class=\"graphic graphic_picture graphicRef63741 \" href=\"mobipreview.htm?13/6/13412\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/6\">",
"     6",
"    </a>",
"    ]. The eggs are brown, ovoid, measure approximately 100 &micro;m by 55 &micro;m, and have a thick shell. A 24-hour sputum collection enhances the sensitivity of egg detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/12\">",
"     12",
"    </a>",
"    ]. Eggs are also detectable with Ziehl Nielsen staining, which appears to be superior to wet mount [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/38\">",
"     38",
"    </a>",
"    ]. The diagnosis can also be made by visualization of eggs on fine needle aspiration or transbronchial biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/23,39\">",
"     23,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cerebral infection, the cerebrospinal fluid is typically bloody and contains numerous eosinophils, but visualization of eggs is rare. Biopsy of cerebral, intraabdominal, or subcutaneous nodules or cysts may contain eggs or adult flukes that confirm the diagnosis, although biopsy is not required for diagnosis if noninvasive microscopy, serologic or radiographic tools can be used to establish the diagnosis.",
"   </p>",
"   <p>",
"    Species identification can be confirmed by examination of immature or adult flukes (",
"    <a class=\"graphic graphic_picture graphicRef77590 \" href=\"mobipreview.htm?23/36/24131\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/40\">",
"     40",
"    </a>",
"    ]. The adult parasites are approximately 10 by 5 mm. They are reddish-brown, ovoid or coffee-bean shaped, and are covered with cuticular spines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests include complement fixation, countercurrent immunoelectrophoresis, and enzyme-linked immunosorbent assay (ELISA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/41\">",
"     41",
"    </a>",
"    ]. Serology is particularly helpful in extrapulmonary disease when eggs are not being shed in sputum or stool. The ELISA test is highly sensitive and specific (92 and &gt;90 percent, respectively) and can be performed on serum or cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/30,42-44\">",
"     30,42-44",
"    </a>",
"    ]. It has limited utility for monitoring patients following therapy, since antibody levels may not decrease for two years after successful therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/45\">",
"     45",
"    </a>",
"    ]. Antigen detection techniques using monoclonal antibodies against P. westermani antigens have also been developed. These immunoblot tests have a reported sensitivity and specificity of 96 and 99 to 100 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/41,46,47\">",
"     41,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complement fixation is no longer used; problems with this test included cross reactivity with other trematodes, labor intensity, and false negative results in the setting of chronic infection with calcification. It has been replaced by immunoblot (available from the Centers for Disease Control and Prevention [CDC]) or ELISA (available from some commercial laboratories) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16993430\">",
"    <span class=\"h2\">",
"     Other laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) is in development for species diagnosis of paragonimiasis, but it is not yet commercially available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin tests consisting of an extract of adult Paragonimus spp have been used for epidemiologic screening. Sensitivity is 80 to 90 percent, but they remain positive for many years after cure and cannot determine disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A radiographic clue for pulmonary paragonimiasis is the combination of pleural effusion (present in 20 to 60 percent of cases) and multiple cysts, irregular linear lesions, or nodular opacities in the lung parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/19\">",
"     19",
"    </a>",
"    ]. Several cases of pulmonary paragonimiasis with high uptake on FDG-PET computed tomography (CT) images have been described (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59176 \" href=\"mobipreview.htm?31/61/32724\">",
"     image 3",
"    </a>",
"    ). Such findings can be difficult to distinguish from malignancy radiographically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Chest imaging is also discussed above. (See",
"    <a class=\"local\" href=\"#H2725719\">",
"     'Late infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the setting of acute cerebral paragonimiasis, imaging may be normal. In one review of brain magnetic resonance imaging (MRI) images of six children with early cerebral infection, the most common findings were irregular hemorrhage and conglomerated, irregular lesions with surrounding edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/52\">",
"     52",
"    </a>",
"    ]. One patient had a \"tunnel sign,\" demonstrating the migrating track of the adult worm.",
"   </p>",
"   <p>",
"    Imaging in the setting of chronic cerebral paragonimiasis and abdominal paragonimiasis are described above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cerebral infection'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Abdominal infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16993301\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of pulmonary paragonimiasis includes tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/24\">",
"     24",
"    </a>",
"    ], malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/23\">",
"     23",
"    </a>",
"    ], Loeffler&rsquo;s syndrome, coccidioidomycosis, aspergillosis, histoplasmosis, nocardiosis, bronchitis and bronchiectasis. Paragonimiasis lesions are located peripherally and are common in the mid- and lower lung zones; tuberculous cavities are predominantly apical lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/1\">",
"     1",
"    </a>",
"    ]. The differential diagnosis of cerebral paragonimiasis includes neurocysticercosis, bacterial meningitis, amebic meningoencephalitis, and strongyloidiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of paragonimiasis consists of anthelminthic therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    ; triclabendazole is an acceptable alternative agent. Treatment is indicated for individuals with symptomatic as well as asymptomatic paragonimiasis, given the potential for chronic complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Praziquantel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"     Praziquantel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in three divided doses, for three days) is generally considered the treatment of choice for paragonimiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/53\">",
"     53",
"    </a>",
"    ]. The cure rate in the setting of pulmonary infection is almost 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/12,46\">",
"     12,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anticonvulsant therapy and an intraventricular shunt for hydrocephalus may also be warranted in some cases. The mortality of untreated cerebral paragonimiasis is approximately 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/4\">",
"     4",
"    </a>",
"    ]. Even when symptoms wane, it may take at least a few weeks for eggs to disappear, and radiographic improvement may lag behind improvement in clinical manifestations.",
"   </p>",
"   <p>",
"    Treatment for involvement of other ectopic sites must be individualized based upon the patient's clinical response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Triclabendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triclabendazole (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally, once or twice) is an acceptable first-line agent for treatment of paragonimiasis in areas where available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/2,54,55\">",
"     2,54,55",
"    </a>",
"    ]. In general, triclabendazole is better tolerated than praziquantel.",
"   </p>",
"   <p>",
"    In one study comparing triclabendazole and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    for treatment of 62 patients with pulmonary P. mexicanus infection in Ecuador, efficacy was comparable between groups; resolution of symptoms and parasite clearance were more rapid among those who received triclabendazole. In addition, triclabendazole was better tolerated than praziquantel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study comparing dosing for triclabendazole (a single 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose versus two 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    doses), at three months after treatment the cure rates were 84 and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Triclabendazole is not routinely available in the United States but is available through the CDC under an investigational protocol (telephone 1-404-718-4745 or email",
"    <a class=\"external\" href=\"file://parasites@cdc.gov/\">",
"     parasites@cdc.gov",
"    </a>",
"    ). It may also be obtained from Victoria Pharmacy in Zurich, Switzerland (www.pharmaworld.com).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of bithionol (30 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on alternate days for 10 to 15 doses) has been largely supplanted because of side effects; in the United States it is available only from the CDC. Niclosamide (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    as a single dose) has also been used, but is also associated with significant adverse effects.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/42/12965?source=see_link\">",
"     Mebendazole",
"    </a>",
"    is not effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection can be prevented by avoiding eating raw crabs and crayfish in endemic areas. Education about the potential for contamination of utensils is also important. Strict hygiene measures are needed to decrease fecal contamination of water and thereby prevent transmission. In China and Korea, local control programs have been successful in reducing prevalence rates of paragonimiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36967/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726966\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paragonimiasis is a trematode (fluke) infection transmitted via consumption of raw or undercooked crab or crayfish. The infection occurs in several parts of the Far East, West Africa, and the Americas. When clinical manifestations are present, pulmonary symptoms are most common; extrapulmonary manifestations have also been described. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection is acquired by ingestion of inadequately cooked or pickled crab or crayfish. Metacercariae excyst in the duodenum, penetrate the intestinal wall into the peritoneal cavity, and migrate into the lung parenchyma (",
"      <a class=\"graphic graphic_figure graphicRef56115 \" href=\"mobipreview.htm?24/62/25576\">",
"       figure 1",
"      </a>",
"      ). Upon reaching maturity, the adult worms deposit eggs that pass into the bronchioles and are coughed up with sputum or swallowed and passed in the stool. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most clinical infections are asymptomatic; most symptomatic infections consist of pulmonary disease. Pulmonary manifestations consist of early and late phases. The early phase occurs between initial infection and first egg production (about two months). During this period of larval migration within the peritoneal cavity, fever, malaise, diarrhea, epigastric pain,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urticaria may be observed. As larvae penetrate the diaphragm and migrate within the pleural cavity, pleuritic chest pain may develop. Additional symptoms may include dyspnea, cough, and malaise. (See",
"      <a class=\"local\" href=\"#H2725712\">",
"       'Early infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The second phase of pulmonary infection refers to the period when mature flukes inhabit the lungs; this phase may last for years, during which worms induce inflammation and fibrosis. Recurrent hemoptysis is the most common symptom; malaise may be observed although patients may not feel or appear ill. (See",
"      <a class=\"local\" href=\"#H2725719\">",
"       'Late infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extrapulmonary disease is relatively uncommon. Immature flukes can migrate to the brain, abdomen (including the intestinal wall, liver, spleen, kidney, adrenal glands, peritoneal cavity, and mesenteric lymph nodes), subcutaneous tissues and other ectopic localizations. Cerebral paragonimiasis is the most common form of extrapulmonary disease; it occurs in less than 1 percent of individuals with symptomatic paragonimiasis infection. (See",
"      <a class=\"local\" href=\"#H2725526\">",
"       'Extrapulmonary paragonimiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic approach depends on the stage of infection and the nature of clinical manifestations. A diagnosis during early infection (prior to egg production) can be made only presumptively based on clinical manifestations in the setting of eosinophilia and appropriate exposure history. During late infection, the diagnosis is suggested by a history of recurrent hemoptysis in a patient with epidemiologic risk factors. It can usually be confirmed by identifying Paragonimus eggs in the sputum or bronchoalveolar lavage (",
"      <a class=\"graphic graphic_picture graphicRef63741 \" href=\"mobipreview.htm?13/6/13412\">",
"       picture 1",
"      </a>",
"      ). Serology and imaging may also be helpful tools. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"       praziquantel",
"      </a>",
"      or triclabendazole for treatment of paragonimiasis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Dosing is outlined above. Infection can be prevented by avoiding eating raw crabs and crayfish in endemic areas. Strict hygiene measures are needed to decrease fecal contamination of water and thereby prevent transmission. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/1\">",
"      Zarrin-Khameh N, Citron DR, Stager CE, Laucirica R. Pulmonary paragonimiasis diagnosed by fine-needle aspiration biopsy. J Clin Microbiol 2008; 46:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/2\">",
"      Keiser J, Engels D, B&uuml;scher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005; 14:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/3\">",
"      Harinasuta T, Pungpak S, Keystone JS. Trematode infections. Opisthorchiasis, clonorchiasis, fascioliasis, and paragonimiasis. Infect Dis Clin North Am 1993; 7:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/4\">",
"      Choo JD, Suh BS, Lee HS, et al. Chronic cerebral paragonimiasis combined with aneurysmal subarachnoid hemorrhage. Am J Trop Med Hyg 2003; 69:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/5\">",
"      Fried B, Abruzzi A. Food-borne trematode infections of humans in the United States of America. Parasitol Res 2010; 106:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/6\">",
"      Procop GW, Marty AM, Scheck DN, et al. North American paragonimiasis. A case report. Acta Cytol 2000; 44:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/7\">",
"      Mariano EG, Borja SR, Vruno MJ. A human infection with Paragonimus kellicotti (lung fluke) in the United States. Am J Clin Pathol 1986; 86:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/8\">",
"      DeFrain M, Hooker R. North American paragonimiasis: case report of a severe clinical infection. Chest 2002; 121:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/9\">",
"      Castilla EA, Jessen R, Sheck DN, Procop GW. Cavitary mass lesion and recurrent pneumothoraces due to Paragonimus kellicotti infection: North American paragonimiasis. Am J Surg Pathol 2003; 27:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/10\">",
"      Procop GW. North American paragonimiasis (Caused by Paragonimus kellicotti) in the context of global paragonimiasis. Clin Microbiol Rev 2009; 22:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Human paragonimiasis after eating raw or undercooked crayfish --- Missouri, July 2006-September 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/12\">",
"      Johnson RJ, Jong EC, Dunning SB, et al. Paragonimiasis: diagnosis and the use of praziquantel in treatment. Rev Infect Dis 1985; 7:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/13\">",
"      YANG SP, HUANG CT, CHENG CS, CHIANG LC. The clinical and roentgenological courses of pulmonary paragonimiasis. Dis Chest 1959; 36:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/14\">",
"      Nwokolo C. Endemic paragonimiasis in Eastern Nigeria. Clinical features and epidemiology of the recent outbreak following the Nigerian civil war. Trop Geogr Med 1972; 24:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/15\">",
"      Romeo DP, Pollock JJ. Pulmonary paragonimiasis: diagnostic value of pleural fluid analysis. South Med J 1986; 79:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/16\">",
"      Johnson RJ, Johnson JR. Paragonimiasis in Indochinese refugees. Roentgenographic findings with clinical correlations. Am Rev Respir Dis 1983; 128:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/17\">",
"      SUWANIK R, HARINSUTA C. Pulmonary paragonimiasis; an evaluation of roentgen findings in 38 positive sputum patients in an endemic area in Thailand. Am J Roentgenol Radium Ther Nucl Med 1959; 81:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/18\">",
"      Ogakwu M, Nwokolo C. Radiological findings in pulmonary paragonimiasis as seen in Nigeria: a review based on one hundred cases. Br J Radiol 1973; 46:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/19\">",
"      Kanpittaya J, Sawanyawisuth K, Vannavong A, et al. Different chest radiographic findings of pulmonary paragonimiasis in two endemic countries. Am J Trop Med Hyg 2010; 83:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/20\">",
"      Im JG, Whang HY, Kim WS, et al. Pleuropulmonary paragonimiasis: radiologic findings in 71 patients. AJR Am J Roentgenol 1992; 159:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/21\">",
"      Singcharoen T, Rawd-Aree P, Baddeley H. Computed tomography findings in disseminated paragonimiasis. Br J Radiol 1988; 61:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/22\">",
"      Singcharoen T, Silprasert W. CT findings in pulmonary paragonimiasis. J Comput Assist Tomogr 1987; 11:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/23\">",
"      Tomita M, Matsuzaki Y, Nawa Y, Onitsuka T. Pulmonary paragonimiasis referred to the department of surgery. Ann Thorac Cardiovasc Surg 2000; 6:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/24\">",
"      Mukerjee CM, Simpson SE, Bell RJ, Walker JC. Pleuropulmonary paragonimiasis in a Laotian immigrant to Australia. Chest 1992; 101:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/25\">",
"      Kim TS, Han J, Shim SS, et al. Pleuropulmonary paragonimiasis: CT findings in 31 patients. AJR Am J Roentgenol 2005; 185:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/26\">",
"      Saborio P, Lanzas R, Arrieta G, Arguedas A. Paragonimus mexicanus pericarditis: report of two cases and review of the literature. J Trop Med Hyg 1995; 98:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/27\">",
"      Jun SY, Jang J, Ahn SH, et al. Paragonimiasis of the breast. Report of a case diagnosed by fine needle aspiration. Acta Cytol 2003; 47:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/28\">",
"      Kusner DJ, King CH. Cerebral paragonimiasis. Semin Neurol 1993; 13:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/29\">",
"      Oh SJ. Paragonimus meningitis. J Neurol Sci 1968; 6:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/30\">",
"      Cha SH, Chang KH, Cho SY, et al. Cerebral paragonimiasis in early active stage: CT and MR features. AJR Am J Roentgenol 1994; 162:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/31\">",
"      Chang KH, Han MH. MRI of CNS parasitic diseases. J Magn Reson Imaging 1998; 8:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/32\">",
"      Nomura M, Nitta H, Nakada M, et al. MRI findings of cerebral paragonimiasis in chronic stage. Clin Radiol 1999; 54:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/33\">",
"      Kaw GJ, Sitoh YY. Clinics in diagnostic imaging (58). Chronic cerebral paragonimiasis. Singapore Med J 2001; 42:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/34\">",
"      Jeong MG, Yu JS, Kim KW, et al. Retroperitoneal paragonimiasis: a case of ectopic paragonimiasis presenting as periureteral masses. J Comput Assist Tomogr 1999; 23:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/35\">",
"      Kim MJ, Park S, Kim NK, et al. Perirectal cystic paragonimiasis: endorectal coil MRI. J Comput Assist Tomogr 1999; 23:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/36\">",
"      Li XM, Yu JQ, Yang ZG, et al. Correlations between MDCT features and clinicopathological findings of hepatic paragonimiasis. Eur J Radiol 2012; 81:e421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/37\">",
"      Yee B, Hsu JI, Favour CB, Lohne E. Pulmonary paragonimiasis in Southeast Asians living in the central San Joaquin Valley. West J Med 1992; 156:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/38\">",
"      Slesak G, Inthalad S, Basy P, et al. Ziehl-Neelsen staining technique can diagnose paragonimiasis. PLoS Negl Trop Dis 2011; 5:e1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/39\">",
"      Rangdaeng S, Alpert LC, Khiyami A, et al. Pulmonary paragonimiasis. Report of a case with diagnosis by fine needle aspiration cytology. Acta Cytol 1992; 36:31.",
"     </a>",
"    </li>",
"    <li>",
"     Maclean J, Cross J, Mahanty S. Liver, lung, and intestinal infections. In: Tropical Infectious Diseases, 1st ed, Guerrant RL, Weller PF (Eds), Churchill Livingstone, Philadelphia 1999. p.1039.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/41\">",
"      Slemenda SB, Maddison SE, Jong EC, Moore DD. Diagnosis of paragonimiasis by immunoblot. Am J Trop Med Hyg 1988; 39:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/42\">",
"      Waikagul J. Serodiagnosis of paragonimiasis by enzyme-linked immunosorbent assay and immunoelectrophoresis. Southeast Asian J Trop Med Public Health 1989; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/43\">",
"      Voller A, Bidwell DE, Bartlett A, Edwards R. A comparison of isotopic and enzyme-immunoassays for tropical parasitic diseases. Trans R Soc Trop Med Hyg 1977; 71:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/44\">",
"      Imai J. Evaluation of ELISA for the diagnosis of paragonimiasis westermani. Trans R Soc Trop Med Hyg 1987; 81:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/45\">",
"      Cho SY, Kong Y, Yun DH, et al. Persisting antibody reaction in paragonimiasis after praziquantel treatment is elicited mainly by egg antigens. Korean J Parasitol 2000; 38:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/46\">",
"      Udonsi JK. Clinical field trials of praziquantel in pulmonary paragonimiasis due to Paragonimus uterobilateralis in endemic populations of the Igwun Basin, Nigeria. Trop Med Parasitol 1989; 40:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/47\">",
"      Zhang Z, Zhang Y, Shi Z, et al. Diagnosis of active Paragonimus westermani infections with a monoclonal antibody-based antigen detection assay. Am J Trop Med Hyg 1993; 49:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/48\">",
"      Kagawa FT. Pulmonary paragonimiasis. Semin Respir Infect 1997; 12:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/49\">",
"      Sugiyama H, Morishima Y, Kameoka Y, Kawanaka M. Polymerase chain reaction (PCR)-based molecular discrimination between Paragonimus westermani and P. miyazakii at the metacercarial stage. Mol Cell Probes 2002; 16:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/50\">",
"      Kim KU, Lee K, Park HK, et al. A pulmonary paragonimiasis case mimicking metastatic pulmonary tumor. Korean J Parasitol 2011; 49:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/51\">",
"      Song JU, Um SW, Koh WJ, et al. Pulmonary paragonimiasis mimicking lung cancer in a tertiary referral centre in Korea. Int J Tuberc Lung Dis 2011; 15:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/52\">",
"      Zhang JS, Huan Y, Sun LJ, et al. MRI features of pediatric cerebral paragonimiasis in the active stage. J Magn Reson Imaging 2006; 23:569.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, Med Lett Drug Ther, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/54\">",
"      Ripert C, Couprie B, Moyou R, et al. Therapeutic effect of triclabendazole in patients with paragonimiasis in Cameroon: a pilot study. Trans R Soc Trop Med Hyg 1992; 86:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/55\">",
"      Calvopi&ntilde;a M, Guderian RH, Paredes W, et al. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Trans R Soc Trop Med Hyg 1998; 92:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36967/abstract/56\">",
"      Calvopi&ntilde;a M, Guderian RH, Paredes W, Cooper PJ. Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis. Trans R Soc Trop Med Hyg 2003; 97:451.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5679 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-CE19846B1C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36967=[""].join("\n");
var outline_f36_6_36967=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2726966\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2725518\">",
"      Pulmonary paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2725712\">",
"      - Early infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2725719\">",
"      - Late infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2725526\">",
"      Extrapulmonary paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cerebral infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Abdominal infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Subcutaneous infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2733666\">",
"      Microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16993430\">",
"      Other laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16993301\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Praziquantel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Triclabendazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2726966\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5679|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/53/23380\" title=\"diagnostic image 1\">",
"      Cerebral paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/53/42833\" title=\"diagnostic image 2\">",
"      Abdominal paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/61/32724\" title=\"diagnostic image 3\">",
"      Pulmonary paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5679|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/62/25576\" title=\"figure 1\">",
"      Paragonimiasis life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5679|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/6/13412\" title=\"picture 1\">",
"      Paragonimiasis egg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/39/44657\" title=\"picture 2\">",
"      Subcutaneous paragonimiasis - finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/36/24131\" title=\"picture 3\">",
"      Paragonimiasis adult worm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36229?source=related_link\">",
"      Cutaneous larva migrans (creeping eruption)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/25/11668?source=related_link\">",
"      Pulmonary manifestations of ascariasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_6_36968="Neonatal polycythemia";
var content_f36_6_36968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal polycythemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36968/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36968/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36968/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36968/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36968/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36968/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/6/36968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30680530\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal polycythemia is characterized by a venous hematocrit that greatly exceeds normal values for gestational and postnatal age. This condition affects approximately 1 to 5 percent of newborns. Although many affected infants are asymptomatic, the characteristic clinical features are thought to result from hyperviscosity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the metabolic effects of an increased red blood cell mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25989135\">",
"    <span class=\"h2\">",
"     Polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia is defined as a hematocrit or hemoglobin concentration that is greater than two standard deviations above the normal value for gestational and postnatal age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/1\">",
"     1",
"    </a>",
"    ]. Accordingly, a term infant is considered to be polycythemic if the hematocrit from a",
"    <strong>",
"     peripheral venous",
"    </strong>",
"    sample is greater than 65 percent or the hemoglobin is greater than 22",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In clinical circumstances, the definition typically is based upon the hematocrit, rather than the hemoglobin concentration.",
"   </p>",
"   <p>",
"    The diagnosis of polycythemia is based upon peripheral venous samples because of the variability in measurements obtained from capillary samples. Hematocrits of blood from venous samples may be as much as 15 percent lower than those obtained from capillary samples. In one study of newborns with peripheral venous hematocrits &ge;65 percent, the mean values for capillary, peripheral venous, and umbilical venous hematocrits were 75, 71, and 63 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean hematocrit and hemoglobin concentrations from",
"    <strong>",
"     capillary",
"    </strong>",
"    samples in normal term infants at birth are 61 &plusmn; 7.4 (SD) percent and 19.3 &plusmn; 2.2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (SD), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/1\">",
"     1",
"    </a>",
"    ]. These values reflect an increased red cell mass as compared with older infants and children, which is caused by the fetal response of increased hemoglobin production to a relatively hypoxic intrauterine environment and possibly vasomotor instability and venous pooling in newborn immediately after birth. Polycythemia is suspected when the hematocrit and hemoglobin greatly exceed these values, and is diagnosed only if the elevated hematocrit or hemoglobin is confirmed in a venous sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Hyperviscosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia must be distinguished from hyperviscosity, which is defined as a blood viscosity greater than 12 centipoise, measured at a shear rate of 11.5 per second; or greater than 6 centipoise, measured at a shear rate of 106 per second [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/7\">",
"     7",
"    </a>",
"    ]. Whole blood viscosity can be affected by significant increases in any of the elements of whole blood including red cells, white cells, platelets, plasma proteins, immunoglobulins or clotting factors. In neonates, the focus is generally on red cell excess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood viscosity and hematocrit have a linear relationship when the hematocrit is less than 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. This relationship becomes exponential when the hematocrit exceeds 65 percent, such that a small increase in hematocrit is associated with a dramatic increase in viscosity. The relationship is less predictable for intermediate values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/5\">",
"     5",
"    </a>",
"    ]. In one report, for example, hyperviscosity was present in 23 percent of infants with hematocrits in the range of 60 to 64 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even for hematocrit values above 65 percent, the relationship between hematocrit and hyperviscosity is somewhat inconsistent. This was examined in a study of cord blood in 2461 infants of &gt;34 weeks gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/10\">",
"     10",
"    </a>",
"    ]. Hyperviscosity was defined as more than two standard deviations above the mean for viscosity at each week of gestation, and polycythemia as a hematocrit greater than 65 percent. Hyperviscosity occurred in only 47.4 percent of infants with polycythemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of polycythemia ranges from 1 to 5 percent of healthy newborns screened for this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/3,4,11-13\">",
"     3,4,11-13",
"    </a>",
"    ]. The wide range in reported incidence is due in part to differences in the population tested. In addition, other factors influence the hematocrit during the first day after birth. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Time delay between birth and clamping of the umbilical cord &mdash; The amount of placental transfusion is increased when cord clamping is delayed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Site of blood sampling &mdash; Hematocrit values are highest in capillary samples, intermediate in peripheral venous samples, and lowest in samples drawn from the umbilical vein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age at the time of sampling &mdash; Hematocrits increase from birth, reaching a maximum at approximately two hours of age, then decrease to levels in cord blood by 18 hours of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/6,15,16\">",
"       6,15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Method of hematocrit measurement &mdash; Values obtained from centrifuged samples are higher than those using cell counters and correlate better with blood viscosity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperviscosity measured in venous samples occurred in only 3 to 5 percent of polycythemic infants detected by routine capillary screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/4,9,18\">",
"     4,9,18",
"    </a>",
"    ]. Using cord blood samples, hyperviscosity occurred in approximately one-half of infants with polycythemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/10\">",
"     10",
"    </a>",
"    ]. No matter how one measures the occurrence rate, neonatal hyperviscosity is still an uncommon clinical entity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood flow is determined by resistance to flow, which varies directly with the viscosity of the blood and inversely with the fourth power of the radius of the vessel through which the blood is passing. This is expressed by the equation derived from Poiseuille's law:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;R = 8hL",
"    <span class=\"nowrap\">",
"     /&pi;",
"    </span>",
"    r(4)",
"   </p>",
"   <p>",
"    Where R = resistance to blood flow, h = viscosity, L = length of the vessel, and r = radius of the vessel. According to this relationship, a decrease in the radius of the vessel affects resistance to flow more strongly than does an increase in viscosity. Thus, an increase in viscosity will reduce blood flow only if the vessel radius remains constant.",
"   </p>",
"   <p>",
"    Hyperviscosity is thought to result in reduced blood flow to organs, leading to poor tissue perfusion. However, studies in newborn lambs suggest that decreased cerebral blood flow in polycythemia may be due in part to a vascular response to increased arterial oxygen content related to the increased hemoglobin concentration, rather than to hyperviscosity. When polycythemia was maintained in these lambs but the oxygen delivery was reduced by infusing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    , brain blood flow increased to baseline values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of polycythemia are multifactorial, but are due to two major mechanisms: passive (erythrocyte transfusion) and active (increased intrauterine erythropoiesis). The table lists those conditions that have been associated with polycythemia (",
"    <a class=\"graphic graphic_table graphicRef85757 \" href=\"mobipreview.htm?6/9/6300\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30680686\">",
"    <span class=\"h2\">",
"     Erythrocyte transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of polycythemia in normal term infants is delayed clamping of the umbilical cord, which results in increased transfer of placental blood to the infant (erythrocyte transfusion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. This can occur intentionally or unintentionally (eg, at an unattended delivery) and may be exaggerated if the baby is held at a level below the mother immediately following birth, before clamping of the cord.",
"   </p>",
"   <p>",
"    In a meta-analysis of the effect of early versus late cord clamping in term infants, there was an increased incidence of polycythemia and hyperviscosity noted in the newborn patients who had late clamping of their umbilical cord (defined as delayed by at least two minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/21\">",
"     21",
"    </a>",
"    ]. However, there was no evidence of harm in these patients and some evidence of improved long-term hematologic outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33114?source=see_link&amp;anchor=H30#H30\">",
"     \"Management of normal labor and delivery\", section on 'Cord clamping'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33114?source=see_link&amp;anchor=H31#H31\">",
"     \"Management of normal labor and delivery\", section on 'Cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intrapartum hypoxia has also been associated with increased placental transfusion. Other associations include twin-to-twin transfusion, which occurs in 10 to 15 percent of monochorionic twins, and maternal-fetal transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/22\">",
"     22",
"    </a>",
"    ], which is less common. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30680679\">",
"    <span class=\"h2\">",
"     Increased intrauterine erythropoiesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased intrauterine erythropoiesis usually results from placental insufficiency and chronic intrauterine hypoxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. This typically is seen in infants who are small for gestational age or whose mothers have preeclampsia or other hypertensive or vascular disorders. Polycythemia may occur in pregnancies complicated by maternal hypoxemia due to cardiac or pulmonary disorders, drugs such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    , smoking, high altitude, or postterm delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31142?source=see_link\">",
"     \"Postterm infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polycythemia thought to be due predominantly to erythropoiesis, occurs in 13 to 33 percent of infants of diabetic mothers and may be seen in other infants who are large for gestational age, including those with Beckwith-Wiedemann syndrome. The disorder may also be associated with other endocrine abnormalities, such as congenital adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/23\">",
"     23",
"    </a>",
"    ], hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/24\">",
"     24",
"    </a>",
"    ], or hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/25\">",
"     25",
"    </a>",
"    ]. Polycythemia may also occur in infants with some chromosomal anomalies, such as trisomy 21, 18, and 13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20823?source=see_link\">",
"     \"Large for gestational age newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most polycythemic infants have no clinical signs of the condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/13\">",
"     13",
"    </a>",
"    ]. In two large prospective studies of infants with polycythemia that included matched controls, the majority of polycythemic infants were asymptomatic (74 to 90 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The most commonly identified symptoms compared with the controls were",
"    <span class=\"nowrap\">",
"     cyanosis/apnea",
"    </span>",
"    (&lt;10 percent) and gastrointestinal symptoms (poor feeding or vomiting) (17 percent), and hypoglycemia (12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/27\">",
"     27",
"    </a>",
"    ]. Necrotizing enterocolitis was reported in both study and control groups, but no statistically significant difference was demonstrated. Other findings often attributed to polycythemia, such as plethora, respiratory distress, tachycardia, hematuria, renal vein thrombosis, priapism, gallstones, hypotonia, irritability, increased pulmonary vascular resistance, abnormal cry, lethargy, jitteriness, and seizures are a compilation from retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/3\">",
"     3",
"    </a>",
"    ] or small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/6,29-31\">",
"     6,29-31",
"    </a>",
"    ] with no control patients and, therefore, may reflect observer bias.",
"   </p>",
"   <p>",
"    Symptoms, when present, often begin by two hours after birth, after fluid shifts have occurred and the hematocrit is highest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/9\">",
"     9",
"    </a>",
"    ]. Onset may be delayed to the second or third day of life in some infants who develop an increased hematocrit because of excessive extracellular fluid loss. In this case, the volume depletion may exaggerate the expression of an already increased red cell mass or, in extreme cases, it may be the primary cause of the high hematocrit. Infants with no symptoms by 48 to 72 hours of age are likely to remain asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/15,32\">",
"     15,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms usually attributed to this disorder are thought to be due to reduced tissue perfusion or associated metabolic abnormalities. However, animal data raises some questions as to whether this indeed is the pathophysiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/19\">",
"     19",
"    </a>",
"    ]. These signs and symptoms occur with many other neonatal disorders and may be associated with, but not caused by, the polycythemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiorespiratory effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiorespiratory signs, such as cyanosis and tachycardia, are uncommon, with reported occurrence of less than 15 percent of prospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Respiratory symptoms, including tachypnea, develop in less than 5 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastrointestinal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal symptoms, which occur in as many as 17 percent of affected patients, include vomiting and poor feeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28105?source=see_link\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia appears to be a common metabolic problem in patients with polycythemia. It occurs in 12 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/3,27,30,33\">",
"     3,27,30,33",
"    </a>",
"    ]. The mechanism may be increased glucose utilization by the increased number of circulating red cells; however, there are no data to support a causal relationship and this may be related to the multifactorial causes of polycythemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least one-third of infants with polycythemia develop hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/3\">",
"     3",
"    </a>",
"    ], most likely due to the breakdown of an increased number of circulating red cells. This may occasionally lead to the development of gallstones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/13\">",
"     13",
"    </a>",
"    ]. The actual effect of polycythemia on hyperbilirubinemia is difficult to quantify, since interventions for polycythemia, such as exchange transfusion and hydration, also mitigate the hyperbilirubinemia. These treatment effects may explain why some studies do not show an association between polycythemia and hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4356714\">",
"    <span class=\"h2\">",
"     Which infants should be screened?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematocrit should be measured in infants who have signs or symptoms that may be due to polycythemia, including cyanosis, tachypnea, and poor feeding and vomiting. We do",
"    <strong>",
"     not",
"    </strong>",
"    routinely measure the hematocrit in term infants who appear well, because asymptomatic newborns with polycythemia do not appear to benefit from treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4356738\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematocrit is often first measured on a capillary blood sample, usually taken from a warmed heel. If the capillary hematocrit is &gt;65 percent, the hematocrit should be repeated on a sample of venous blood. The venous hematocrit usually will be 5 to 15 percent lower than the capillary hematocrit. The diagnosis of polycythemia is made if the",
"    <strong>",
"     venous",
"    </strong>",
"    hematocrit is &gt;65 percent.",
"   </p>",
"   <p>",
"    As noted above, less than half of infants with polycythemia have hyperviscosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/6\">",
"     6",
"    </a>",
"    ]. Conversely, some infants with hyperviscosity are not polycythemic. However, measurement of viscosity is not widely available. Thus, hematocrit remains the best laboratory tool to consider initiating evaluation and intervention. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Hyperviscosity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4356762\">",
"    <span class=\"h2\">",
"     Exclusion of other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a diagnosis of polycythemia is made, infants should be evaluated for possible etiologies, including delayed clamping of the cord, maternal factors such as preeclampsia and diabetes, and the possibility of infant factors such as macrosomia and endocrine abnormalities including congenital adrenal hyperplasia or thyroid abnormalities (",
"    <a class=\"graphic graphic_table graphicRef85757 \" href=\"mobipreview.htm?6/9/6300\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, because symptoms attributed to polycythemia can occur in many neonatal disorders, other possible causes of the symptoms should be investigated. These include respiratory disorders (eg, pneumonia), cardiovascular abnormalities (eg, congenital heart disease, persistent pulmonary hypertension), and neurologic disorders (eg, intracranial hemorrhage, venous thrombosis, intracranial anomalies, or metabolic abnormalities), as in any other neonate with these symptoms. The possibility of dehydration can be evaluated by comparison of birth weight and current weight; loss of more than 7 percent of birthweight during the first five days of life may suggest dehydration (",
"    <a class=\"graphic graphic_table graphicRef78906 \" href=\"mobipreview.htm?9/1/9243\">",
"     table 2",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36105?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the routine management of the healthy newborn infant\", section on 'Weight loss'",
"    </a>",
"    ). If the symptoms are not severe, these possibilities usually can be excluded by a thorough physical examination and close observation. However, if these symptoms worsen or persist, then a thorough review of the maternal labor and delivery course, and metabolic screening tests of glucose and ionized calcium and a chest radiograph are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25988256\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25988548\">",
"    <span class=\"h2\">",
"     Overview of approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;All polycythemic infants should be observed closely for neurologic and cardiovascular symptoms and monitored for common complications, such as hypoglycemia and hyperbilirubinemia. Once the clinician makes the diagnosis of polycythemia, careful monitoring of blood glucose should be undertaken; if hypoglycemia is discovered, adequate glucose supplementation should be given. Hypoglycemia in a neonate is typically defined as a blood glucose &lt;45",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Use of the parenteral route for glucose supplementation is generally advisable for hypoglycemic infants with symptoms (including polycythemia), and definitely for those with severe hypoglycemia (eg, plasma glucose &lt;25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.4",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Serum bilirubin also should be measured and followed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/63/25593?source=see_link\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of partial exchange transfusion (PET) in the management of polycythemia is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Although PET improves cerebral blood flow and hemodynamic parameters in infants with hyperviscosity, there is no evidence that the procedure improves long-term outcome of these infants, and it may be associated with some gastrointestinal morbidity. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Partial exchange transfusion'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The management approach outlined below is based on expert opinion. We acknowledge the lack of evidence supporting the long-term benefits of PET but also the limitations in those studies; weak observational evidence suggests that there may be a few",
"    <strong>",
"    </strong>",
"    short-term benefits of PET. Several groups have published similar clinical approaches, with minor variations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25988283\">",
"    <span class=\"h3\">",
"     Asymptomatic infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of infants with polycythemia but no symptoms is usually guided by the hematocrit (",
"    <a class=\"graphic graphic_algorithm graphicRef85758 \" href=\"mobipreview.htm?18/12/18625\">",
"     algorithm 1",
"    </a>",
"    ) (in this context, plethora is not considered a symptom):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants who are asymptomatic and have a peripheral venous hematocrit between 60 and 70 percent should be observed. Adequate hydration and glucose intake should be ensured by monitoring oral intake, body weight, and urine output. Bilirubin and blood glucose levels should be checked, and monitored as needed. The venous hematocrit should be repeated in 12 to 24 hours, while monitoring closely for the development of symptoms. If it remains less than 70 percent and the infant continues to be asymptomatic, this approach is continued for 24 hours and the hematocrit rechecked.",
"     </li>",
"     <li>",
"      When the hematocrit is &gt;70 percent, several different approaches are used:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Many clinicians manage such infants with continued observation, with or without intravenous hydration.",
"     </li>",
"     <li>",
"      Some groups perform PET in asymptomatic infants only if the venous hematocrit is &gt;75 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/35,38\">",
"       35,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some clinicians perform a PET for any infant with a venous hematocrit &gt;70 percent, even if the infant is asymptomatic (this approach is less common) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/37,39,40\">",
"       37,39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25988290\">",
"    <span class=\"h3\">",
"     Symptomatic infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of polycythemic infants with symptoms",
"    <span class=\"nowrap\">",
"     (cyanosis/apnea,",
"    </span>",
"    gastrointestinal symptoms [poor feeding or vomiting] or hypoglycemia) has not been established and varies among providers (",
"    <a class=\"graphic graphic_algorithm graphicRef85758 \" href=\"mobipreview.htm?18/12/18625\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For infants with a peripheral venous hematocrit is &gt;65 percent and symptoms that may be attributed to hyperviscosity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some clinicians perform a PET to lower the hematocrit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/35\">",
"       35",
"      </a>",
"      ]. When the decision is made to perform PET, it should be done as soon as possible because the neonatal hematocrit and blood viscosity peaks between two and four hours after birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Technique'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Other clinicians intervene with intravenous hydration and close observation; this is our preferred method of management. Intravenous fluid is provided for the first 24 to 48 hours of age at a rate of at least 100",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per day, including glucose at a rate of 6 to 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per min, while the infant is closely monitored. A PET may be performed only if there is worsening of symptoms, such as persistent hypoglycemia, or worsening",
"      <span class=\"nowrap\">",
"       cyanosis/apnea",
"      </span>",
"      or gastrointestinal symptoms. In addition, infants with worsening symptoms should be evaluated for causes of the symptoms other than polycythemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Partial exchange transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isovolumetric partial exchange transfusion (PET) reduces the hematocrit without causing hypovolemia. There is some evidence that PET has beneficial short-term effects on measures of perfusion. However, PET does not appear to affect long-term outcome in infants with polycythemia. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9683510\">",
"    <span class=\"h3\">",
"     Short-term effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the clinical setting, PET has not been demonstrated to alter the symptoms associated with polycythemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Research studies have shown that PET reverses the reduction in cerebral blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/34,41-44\">",
"     34,41-44",
"    </a>",
"    ], cardiac index, and oxygen transport attributed to hyperviscosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/7,45\">",
"     7,45",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 14 infants with polycythemia (hct &gt;70 percent, or &ge;65 percent with symptoms), PET increased cerebral oxygenation and microvascular flow velocity, as determined by near-infrared spectroscopy (NIRS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An older study used Doppler measurements of cerebral artery blood flow in 59 infants with hyperviscosity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/34\">",
"       34",
"      </a>",
"      ]. Asymptomatic infants (n = 14) had normal cerebral blood flow before and after PET. Symptomatic infants (n = 17) had reduced cerebral blood flow before PET, and this normalized after PET. Because this study focused on infants with documented hyperviscosity, it may not be generalizable to infants with polycythemia in whom blood viscosity is not usually measured.",
"     </li>",
"     <li>",
"      Other studies have demonstrated acute hemodynamic improvements following PET in infants with polycythemia or hyperviscosity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/7,45\">",
"       7,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET can be performed in several ways. One approach is to remove blood from an umbilical venous or arterial catheter and infuse",
"    <strong>",
"     normal saline",
"    </strong>",
"    into a peripheral vein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The exchange volume (in mL) is calculated using the following formula:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; Exchange volume = [(observed hct - desired hct) x blood volume] &divide; observed hct",
"   </p>",
"   <p>",
"    Where hct = hematocrit, and blood volume is calculated at 80 to 100",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    body weight. Higher volumes are associated with lower gestational ages and or delayed cord clamping. The desired hct is usually set at 55 percent.",
"   </p>",
"   <p>",
"    In general, the exchange volume is 15 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    body weight. Blood can be removed and saline infused continuously (isovolumetric technique, the best approach in unstable infants) or the process can be accomplished using serial aliquots of 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of necrotizing enterocolitis (NEC) may be increased in infants treated with PET for polycythemia. In a small trial, NEC developed in 8 of 43 patients with hyperviscosity who underwent the procedure and in none of the controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/48\">",
"     48",
"    </a>",
"    ]. Treated infants also had significantly more gastrointestinal symptoms (eg, abdominal distension, bloody stools, and emesis). Contrasting results were reported in a retrospective analysis of 185 polycythemic term infants treated with PET, in which no evidence of severe gastrointestinal injury was detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/49\">",
"     49",
"    </a>",
"    ]. The contrasting findings might be explained by differences between the PET techniques used in the two studies: in the second study, the umbilical vein was used to withdraw the allotted volume of blood to be exchanged, and the replacement volume was administered via peripheral vein. Because this study did not test and select patients for hyperviscosity, the population studied was probably at lower risk for complications. The study is also limited by its retrospective nature and lack of a control group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether neonatal polycythemia or its treatment affect long-term outcome is uncertain. The available evidence suggests that the clinical outcome may depend more upon associated conditions, such as hypoglycemia, or on the underlying disorder, such as placental insufficiency, rather than on polycythemia itself.",
"   </p>",
"   <p>",
"    Measurable clinical benefits from partial exchange transfusion (PET) have not been established. These conclusions are based on limited clinical evidence, including the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 71 newborns with polycythemia identified by routine screening, PET was performed in 17 infants with symptomatic hyperviscosity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/34\">",
"       34",
"      </a>",
"      ]. Infants with asymptomatic hyperviscosity were randomly assigned to receive partial exchange transfusion (n = 14) or observation (n = 14). Asymptomatic infants with normal viscosity served as controls (n = 26). Among the 46 infants evaluated at an average age of 30 months, neurodevelopmental outcomes were similar in infants with hyperviscosity and controls, in those with hyperviscosity who were symptomatic or asymptomatic, and in treated or observed patients.",
"     </li>",
"     <li>",
"      Neurodevelopment at eight months of age was similar in 49 polycythemic infants who were randomly assigned to receive either PET or observation as well as in controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/29\">",
"       29",
"      </a>",
"      ]. Development was normal in those evaluated at two years of age (86 percent of the group).",
"     </li>",
"     <li>",
"      Infants with neonatal hyperviscosity randomly assigned to receive PET or observation frequently had abnormal neurodevelopmental outcome at eight months of age, regardless of assignment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/30\">",
"       30",
"      </a>",
"      ]. Abnormalities such as developmental delay, spastic diplegia, monoparesis, and tremor occurred in 5 of 10 treated and 4 of 6 (of the initial group of 10) untreated infants.",
"     </li>",
"     <li>",
"      Outcome was poorer at one to three years of age in a study of 111 newborns with hyperviscosity, of whom 42 received PET, compared with 110 controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/28\">",
"       28",
"      </a>",
"      ]. Infants with hyperviscosity had more motor and neurologic abnormalities (38 versus 11 percent) than controls and did not differ according to treatment. However, maternal preeclampsia and neonatal hypoglycemia were more common in the hyperviscosity group than controls; many infants in both groups were lost to follow-up, including approximately one-third of the patients with hyperviscosity.",
"     </li>",
"     <li>",
"      A similar study compared neurodevelopmental outcomes of 93 infants with hyperviscosity, half of whom were randomly assigned to receive PET, with 93 controls (matched for birthweight, gestational age, Apgar score, and sex) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/27\">",
"       27",
"      </a>",
"      ]. The hyperviscosity was associated with significant effects on speech and fine motor development at one and two years of age, and persistent effects on IQ scores and academic achievement also were seen in the patients available for follow up at seven years of age (53 percent of the original cohort) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/50\">",
"       50",
"      </a>",
"      ]. Among the infants with hyperviscosity, treatment with PET was not associated with effects on any of these neurodevelopmental outcomes, except for neurologic diagnoses and fine motor abnormalities at two years of age. Thus, although hyperviscosity was associated with adverse long-term neurological outcomes, beneficial effects of PET were not seen at seven years of age.",
"     </li>",
"     <li>",
"      A systematic review of the literature did not find any long-term benefit from PET in the treatment of polycythemic infants, and that the incidence of gastrointestinal injury is probably increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/51\">",
"       51",
"      </a>",
"      ]. A second systematic review also concluded that there are no proven short- or long-term clinical benefits of PET for polycythemic infants &ldquo;who are clinically well or have minor symptoms related to hyperviscosity&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36968/abstract/52\">",
"       52",
"      </a>",
"      ]. However, this review did not comment on the role of PET for infants with marked clinical symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are important limitations to these studies that preclude a clear understanding of the effects of polycythemia, or a firm answer on the clinical benefits of PET. Most reports include patients with polycythemia detected by routine screening who also had documented hyperviscosity. Thus, the results may not apply to infants with polycythemia alone or those in whom polycythemia was detected because they were symptomatic. Most studies did not control for preexisting confounders such as maternal diabetes, smoking, or intrauterine growth retardation, so the observed differences in neurodevelopmental outcomes may not be caused by the polycythemia. In studies evaluating PET, the intervention was usually performed after six hours of life, so the effect of earlier intervention is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30680580\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycythemia may be suspected based on an elevated hematocrit from capillary samples, but the diagnosis must be confirmed by a peripheral venous sampling. A term infant is considered to be polycythemic if the hematocrit from a",
"      <strong>",
"       peripheral venous",
"      </strong>",
"      sample is greater than 65 percent or the hemoglobin is greater than 22",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperviscosity occurs in about 50 percent of infants with polycythemia, and the risk of hyperviscosity increases sharply as the hematocrit increases above 65 percent. Polycythemia is associated with reduced blood flow to organs, but it is unclear whether this is due to the hyperviscosity or to the increased arterial oxygen content related to the polycythemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hyperviscosity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common association of polycythemia in normal term infants is delayed clamping of the umbilical cord, which results in increased transfer of placental blood to the infant. Other associations include twin-to-twin transfusion, placental insufficiency, maternal hypoxemia or diabetes, and infant risk factors including macrosomia and endocrine abnormalities (",
"      <a class=\"graphic graphic_table graphicRef85757 \" href=\"mobipreview.htm?6/9/6300\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of infants (74 to 90 percent) with polycythemia are asymptomatic. In other infants, symptoms associated with polycythemia may include",
"      <span class=\"nowrap\">",
"       cyanosis/apnea,",
"      </span>",
"      vomiting or poor feeding. The primary laboratory abnormality associated with polycythemia is hypoglycemia. Symptoms, when present, often begin by two hours after birth, but may be delayed to the second or third day of life in some infants. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All polycythemic infants should be observed closely for hydration status, and monitored for common complications, such as hypoglycemia and hyperbilirubinemia. (See",
"      <a class=\"local\" href=\"#H25988256\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For selected infants with polycythemia, partial exchange transfusion (PET) may be used to reduce the hematocrit. There is some evidence that partial exchange transfusion may reduce short-term effects on clinical symptoms and measures of perfusion. However, PET does not appear to affect long-term outcome in infants with polycythemia, but the evidence underlying this conclusion is limited. Therefore, the management approach outlined below is based on expert opinion and only weak clinical evidence. (See",
"      <a class=\"local\" href=\"#H9683510\">",
"       'Short-term effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For infants with polycythemia who are",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      management is based on the venous hematocrit (",
"      <a class=\"graphic graphic_algorithm graphicRef85758 \" href=\"mobipreview.htm?18/12/18625\">",
"       algorithm 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that asymptomatic infants with a peripheral venous hematocrit between 60 and 70 percent NOT undergo PET (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Adequate hydration and glucose intake should be ensured by monitoring oral intake, body weight, and urine output. The venous hematocrit should be repeated in 12 to 24 hours, while monitoring closely for the development of symptoms.",
"     </li>",
"     <li>",
"      Asymptomatic infants with a hematocrit &gt;70 percent can be treated with supportive care such as intravenous hydration, or (less often) with PET.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants with polycythemia (venous hematocrit &gt;65 percent) who are",
"      <strong>",
"       symptomatic",
"      </strong>",
"      we suggest supportive treatment with intravenous hydration, glucose and urine output monitoring, in addition to the pursuit of other possible reasons for the symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). PET is a possible alternative treatment, understanding that there appears to be no data that PET has any long-term benefits, and that PET may be associated with possible risks.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Luchtman-Jones L, Wilson DB. Hematologic problems in the fetus and neonate. In: Neonatal-Perinatal Medicine, 9, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. p.1303.",
"    </li>",
"    <li>",
"     Oski FA, Naiman JL. Polycythemia and hyperviscosity in the neonatal period. In: Hematologic Problems in the Newborn, 3 ed, Oski FA (Ed), WB Saunders, New York 1982. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/3\">",
"      Wiswell TE, Cornish JD, Northam RS. Neonatal polycythemia: frequency of clinical manifestations and other associated findings. Pediatrics 1986; 78:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/4\">",
"      Stevens K, Wirth FH. Incidence of neonatal hyperviscosity at sea level. J Pediatr 1980; 97:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/5\">",
"      Ramamurthy, RS. Neonatal polycythemia and hyperviscosity; state of the art. Perinatology-Neonatology 1979; 3:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/6\">",
"      Ramamurthy RS, Brans YW. Neonatal polycythemia: I. Criteria for diagnosis and treatment. Pediatrics 1981; 68:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/7\">",
"      Swetnam SM, Yabek SM, Alverson DC. Hemodynamic consequences of neonatal polycythemia. J Pediatr 1987; 110:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/8\">",
"      Lowe GD. Rheological influences on thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/9\">",
"      Gross GP, Hathaway WE, McGaughey HR. Hyperviscosity in the neonate. J Pediatr 1973; 82:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/10\">",
"      Drew JH, Guaran RL, Grauer S, Hobbs JB. Cord whole blood hyperviscosity: measurement, definition, incidence and clinical features. J Paediatr Child Health 1991; 27:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/11\">",
"      Brooks GI, Backes CR. Hyperviscosity secondary to polycythemia in the appropriate for gestational age neonate. J Am Osteopath Assoc 1981; 80:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/12\">",
"      Rawlings JS, Pettett G, Wiswell TE, Clapper J. Estimated blood volumes in polycythemic neonates as a function of birth weight. J Pediatr 1982; 101:594.",
"     </a>",
"    </li>",
"    <li>",
"     Mentzer WC, Glader BE. Erythrocyte disorders in infancy. In: Avery's Diseases of the Newborn, 7 ed, Taeusch HW, Ballard RA (Eds), WB Saunders, Philadelphia 1998. p.1080.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/14\">",
"      Capasso L, Raimondi F, Capasso A, et al. Early cord clamping protects at-risk neonates from polycythemia. Biol Neonate 2003; 83:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/15\">",
"      Shohat M, Reisner SH, Mimouni F, Merlob P. Neonatal polycythemia: II. Definition related to time of sampling. Pediatrics 1984; 73:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/16\">",
"      Ramamurthy RS, Berlanga M. Postnatal alteration in hematocrit and viscosity in normal and polycythemic infants. J Pediatr 1987; 110:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/17\">",
"      Villalta IA, Pramanik AK, Diaz-Blanco J, Herbst JJ. Diagnostic errors in neonatal polycythemia based on method of hematocrit determination. J Pediatr 1989; 115:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/18\">",
"      Wirth FH, Goldberg KE, Lubchenco LO. Neonatal hyperviscosity: I. Incidence. Pediatrics 1979; 63:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/19\">",
"      Rosenkrantz TS, Stonestreet BS, Hansen NB, et al. Cerebral blood flow in the newborn lamb with polycythemia and hyperviscosity. J Pediatr 1984; 104:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/20\">",
"      Strauss RG, Mock DM, Johnson K, et al. Circulating RBC volume, measured with biotinylated RBCs, is superior to the Hct to document the hematologic effects of delayed versus immediate umbilical cord clamping in preterm neonates. Transfusion 2003; 43:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/21\">",
"      Hutton EK, Hassan ES. Late vs early clamping of the umbilical cord in full-term neonates: systematic review and meta-analysis of controlled trials. JAMA 2007; 297:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/22\">",
"      MICHAEL AF Jr, MAUER AM. Maternal-fetal transfusion as a cause of plethora in the neonatal period. Pediatrics 1961; 28:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/23\">",
"      GOLD AP, MICHAEL AF Jr. Congenital adrenal hyperplasia associated with polycythemia. Pediatrics 1959; 23:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/24\">",
"      Weinblatt ME, Fort P, Kochen J, DiMayio M. Polycythemia in hypothyroid infants. Am J Dis Child 1987; 141:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/25\">",
"      Bussmann YL, Tillman ML, Pagliara AS. Neonatal thyrotoxicosis associated with the hyperviscosity syndrome. J Pediatr 1977; 90:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/26\">",
"      Mentzer WC. Polycythaemia and the hyperviscosity syndrome in newborn infants. Clin Haematol 1978; 7:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/27\">",
"      Black VD, Lubchenco LO, Koops BL, et al. Neonatal hyperviscosity: randomized study of effect of partial plasma exchange transfusion on long-term outcome. Pediatrics 1985; 75:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/28\">",
"      Black VD, Lubchenco LO, Luckey DW, et al. Developmental and neurologic sequelae of neonatal hyperviscosity syndrome. Pediatrics 1982; 69:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/29\">",
"      Malan AF, de V Heese H. The management of polycythaemia in the newborn infant. Early Hum Dev 1980; 4:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/30\">",
"      Goldberg K, Wirth FH, Hathaway WE, et al. Neonatal hyperviscosity. II. Effect of partial plasma exchange transfusion. Pediatrics 1982; 69:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/31\">",
"      Katz J, Rodriguez E, Mandani G, Branson HE. Normal coagulation findings, thrombocytopenia, and peripheral hemoconcentration in neonatal polycythemia. J Pediatr 1982; 101:99.",
"     </a>",
"    </li>",
"    <li>",
"     Phibbs RH. Neonatal polycythemia. In: Rudolph's Pediatrics, 20 ed, Rudolph AM (Ed), Appleton &amp; Lange, Stamford, CT 1996. p.252.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/33\">",
"      Black VD, Lubchenco LO. Neonatal polycythemia and hyperviscosity. Pediatr Clin North Am 1982; 29:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/34\">",
"      Bada HS, Korones SB, Pourcyrous M, et al. Asymptomatic syndrome of polycythemic hyperviscosity: effect of partial plasma exchange transfusion. J Pediatr 1992; 120:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/35\">",
"      Schimmel MS, Bromiker R, Soll RF. Neonatal polycythemia: is partial exchange transfusion justified? Clin Perinatol 2004; 31:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/36\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn: Routine evaluation of blood pressure, hematocrit, and glucose in newborns. Pediatrics 1993; 92:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/37\">",
"      Mimouni FB, Merlob P, Dollberg S, et al. Neonatal polycythaemia: critical review and a consensus statement of the Israeli Neonatology Association. Acta Paediatr 2011; 100:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/38\">",
"      Sankar MJ, Agarwal R, Deorari A, Paul VK. Management of polycythemia in neonates. Indian J Pediatr 2010; 77:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/39\">",
"      Acunas B, Celtik C, Vatansever U, Karasalihoglu S. Thrombocytopenia: an important indicator for the application of partial exchange transfusion in polycythemic newborn infants? Pediatr Int 2000; 42:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/40\">",
"      Kumar A, Ramji S. Effect of partial exchange transfusion in asymptomatic polycythemic LBW babies. Indian Pediatr 2004; 41:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/41\">",
"      Rosenkrantz TS, Oh W. Cerebral blood flow velocity in infants with polycythemia and hyperviscosity: effects of partial exchange transfusion with Plasmanate. J Pediatr 1982; 101:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/42\">",
"      Bada HS, Korones SB, Kolni HW, et al. Partial plasma exchange transfusion improves cerebral hemodynamics in symptomatic neonatal polycythemia. Am J Med Sci 1986; 291:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/43\">",
"      Maertzdorf WJ, Tangelder GJ, Slaaf DW, Blanco CE. Effects of partial plasma exchange transfusion on cerebral blood flow velocity in polycythaemic preterm, term and small for date newborn infants. Eur J Pediatr 1989; 148:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/44\">",
"      Ergenekon E, Hirfanoglu IM, Turan O, et al. Partial exchange transfusion results in increased cerebral oxygenation and faster peripheral microcirculation in newborns with polycythemia. Acta Paediatr 2011; 100:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/45\">",
"      Murphy DJ Jr, Reller MD, Meyer RA, Kaplan S. Effects of neonatal polycythemia and partial exchange transfusion on cardiac function: an echocardiographic study. Pediatrics 1985; 76:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/46\">",
"      de Waal KA, Baerts W, Offringa M. Systematic review of the optimal fluid for dilutional exchange transfusion in neonatal polycythaemia. Arch Dis Child Fetal Neonatal Ed 2006; 91:F7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/47\">",
"      Dempsey EM, Barrington K. Crystalloid or colloid for partial exchange transfusion in neonatal polycythemia: a systematic review and meta-analysis. Acta Paediatr 2005; 94:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/48\">",
"      Black VD, Rumack CM, Lubchenco LO, Koops BL. Gastrointestinal injury in polycythemic term infants. Pediatrics 1985; 76:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/49\">",
"      Hein HA, Lathrop SS. Partial exchange transfusion in term, polycythemic neonates: absence of association with severe gastrointestinal injury. Pediatrics 1987; 80:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/50\">",
"      Delaney-Black V, Camp BW, Lubchenco LO, et al. Neonatal hyperviscosity association with lower achievement and IQ scores at school age. Pediatrics 1989; 83:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/51\">",
"      Dempsey EM, Barrington K. Short and long term outcomes following partial exchange transfusion in the polycythaemic newborn: a systematic review. Arch Dis Child Fetal Neonatal Ed 2006; 91:F2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36968/abstract/52\">",
"      Ozek E, Soll R, Schimmel MS. Partial exchange transfusion to prevent neurodevelopmental disability in infants with polycythemia. Cochrane Database Syst Rev 2010; :CD005089.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5940 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36968=[""].join("\n");
var outline_f36_6_36968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30680580\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30680530\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25989135\">",
"      Polycythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Hyperviscosity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30680686\">",
"      Erythrocyte transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30680679\">",
"      Increased intrauterine erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiorespiratory effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4356714\">",
"      Which infants should be screened?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4356738\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4356762\">",
"      Exclusion of other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25988256\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25988548\">",
"      Overview of approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25988283\">",
"      - Asymptomatic infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25988290\">",
"      - Symptomatic infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Partial exchange transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9683510\">",
"      - Short-term effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30680580\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5940|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?18/12/18625\" title=\"algorithm 1\">",
"      Algorithm for management of neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5940|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/9/6300\" title=\"table 1\">",
"      Causes of neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/1/9243\" title=\"table 2\">",
"      Early postnatal weight",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20823?source=related_link\">",
"      Large for gestational age newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36105?source=related_link\">",
"      Overview of the routine management of the healthy newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=related_link\">",
"      Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28105?source=related_link\">",
"      Pathology and pathogenesis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31142?source=related_link\">",
"      Postterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_6_36969="Antiepileptic drugs and bone disease";
var content_f36_6_36969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiepileptic drugs and bone disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36969/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36969/contributors\">",
"     Alison M Pack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36969/contributors\">",
"     Elizabeth Shane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36969/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36969/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36969/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36969/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/6/36969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy is a chronic condition that affects over two million people in the United States, approximately 1 percent of the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/1\">",
"     1",
"    </a>",
"    ]. Antiepileptic drugs (AEDs) remain the mainstay of treatment for epilepsy. In addition, these agents now have numerous other indications, including the treatment of migraine headaches, bipolar disorder, and chronic pain.",
"   </p>",
"   <p>",
"    Both epilepsy and AEDs are associated with adverse effects on bone health. Persons with epilepsy treated with AEDs have increased rates of bone loss and abnormalities in bone and mineral metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These adverse effects may contribute to an increased risk of fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the association between AEDs and disorders of bone and mineral metabolism, including",
"    <span class=\"nowrap\">",
"     osteomalacia/rickets",
"    </span>",
"    and osteoporosis or low bone mass. In addition, the screening, treatment, and prevention of AED-related bone disease will be discussed.",
"   </p>",
"   <p>",
"    The management of epilepsy and the pharmacology of AEDs are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METABOLIC BONE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first reports linking antiepileptic drug (AED) therapy to skeletal disease were published in the late 1960s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/8\">",
"     8",
"    </a>",
"    ]. Affected patients had florid bone disease with clinical, biochemical, and histological abnormalities consistent with rickets and osteomalacia. However, these early reports included mostly institutionalized patients.",
"   </p>",
"   <p>",
"    Current studies of community-dwelling, ambulatory patients with epilepsy generally describe more subtle radiographic and biochemical abnormalities, including decreased bone mineral density (BMD), abnormal vitamin D metabolism, and biochemical evidence of increased bone remodeling activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Each of these abnormalities is associated with decreased bone strength and increased risk of fractures in individuals who do not have epilepsy and do not take AEDs. Patients with epilepsy have an even higher risk for fracture, owing to the increased risk of falls and physical trauma associated with the seizures themselves, the neurological disease that underlies the epilepsy (stroke, cerebral palsy), and the effects of certain AEDs that impair gait stability. Thus, the identification of individuals with epilepsy who are predisposed to fracture because of decreased bone strength is an important aspect of their management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is defined as a skeletal disorder characterized by decreased bone strength leading to an increased risk of fracture. Bone strength represents the integration of the amount of bone present (bone mass or density) and the quality of that bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/12\">",
"     12",
"    </a>",
"    ]. Although fractures are the only clinical symptom of osteoporosis, osteoporosis may be diagnosed radiographically, before fractures occur, by measuring the amount of bone present (bone mineral density or BMD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteoporosis, whether manifested by low BMD or fractures, is most common in postmenopausal women and elderly men, in whom the effects of aging, estrogen and testosterone deficiency, cause bone to be lost more rapidly than it can be restored. This leads to deterioration of the bone microarchitecture and associated reductions in strength.",
"   </p>",
"   <p>",
"    However, osteoporosis can also develop as a result of a host of underlying medical conditions and medications, in which case it is termed secondary osteoporosis. AEDs are one of the classes of medications associated with secondary osteoporosis (",
"    <a class=\"graphic graphic_table graphicRef54926 \" href=\"mobipreview.htm?35/45/36573\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/13\">",
"     13",
"    </a>",
"    ]. Concomitantly occurring secondary causes of osteoporosis can increase the severity of osteoporosis in postmenopausal women and elderly men, and cause osteoporosis in young men, women, and children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=see_link\">",
"     \"Epidemiology and etiology of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=see_link\">",
"     \"Epidemiology and etiology of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture is the most important manifestation of osteoporosis. Several studies have reported that fracture rates are higher in patients with epilepsy than in control populations, and among patients with epilepsy, fractures are more common in postmenopausal women and older men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/4-7,14-18\">",
"     4-7,14-18",
"    </a>",
"    ]. In a meta-analysis of 11 studies that assessed the effects of epilepsy on fracture risk, fracture was significantly increased with a relative risk of 2.2 (95% CI 1.9-2.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/10\">",
"     10",
"    </a>",
"    ]. In another meta-analysis of five studies evaluating clinical risk factors for fracture, AED use was a significant risk factor for fracture with a relative risk of 2.64 (95% CI 1.82-3.82) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent report from the Women's Health Initiative (WHI) Study, which included 1385 users of AEDs and 137,282 nonusers aged 50 to 79 years followed for a mean of 7.7 years, use of AEDs was associated with a significantly increased risk of total fractures (HR 1.4, 95% CI 1.3-1.6) and site specific fractures, including hip fracture (HR 1.5, 95% CI 1.0-2.2) and clinical vertebral fracture (HR 1.6, 95% CI 1.2-2.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/19\">",
"     19",
"    </a>",
"    ]. Both the number (more than one AED compared with one) and type (enzyme-inducing versus nonenzyme-inducing) were significantly associated with fracture risk. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Effect of AED type'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other factors associated with higher fracture risk in adults with epilepsy in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/16,20\">",
"     16,20",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/21,22\">",
"     21,22",
"    </a>",
"    ] studies include older age, female gender, greater severity of epilepsy, and duration of AED use. Children and young adults may also have an increased risk of fractures compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several observations indicate that the increase in fracture rate is due to seizure-related injuries and the effects of certain AEDs that impair gait stability, rather than the adverse effects of AEDs on bone strength alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with generalized tonic-clonic seizures are at higher risk for fracture than patients with partial seizures, suggesting that seizure-related injuries contribute [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The observation that epilepsy was associated with an even higher relative risk (RR) of hip versus forearm fracture (5.3 versus 1.7) suggests a possible preponderance of falls occurring in patients unable to use their hand to break the fall, a situation that might occur during a seizure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/10,16,24\">",
"       10,16,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Women's Health Initiative Study, there was a significant association between AED use and the risk of falls (HR 1.6, 95% CI 1.5-1.7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some AEDs alter bone and mineral metabolism. Several studies have reported low bone mineral density (BMD) at multiple sites in adult patients receiving AEDs, with measurements generally ranging between 10 and 16 percent below controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/9,25-29\">",
"     9,25-29",
"    </a>",
"    ]. Men and women appear to be affected similarly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/29\">",
"     29",
"    </a>",
"    ]. A meta-analysis of 12 studies measuring BMD in patients with epilepsy found an overall significant deficit of BMD in both hip and spine with mean Z-score deviations of -0.56 and -0.38, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of dual-energy x-ray absorptiometry\", section on 'DXA technology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, however, a cross-sectional study of premenopausal women found BMD to be normal despite AED monotherapy for an average of 8 to 13 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/30\">",
"     30",
"    </a>",
"    ]. In children, reduced BMD at axial and appendicular sites has been described, but not as consistently as in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/27,31-40\">",
"     27,31-40",
"    </a>",
"    ]. Increasing age is associated with decreased BMD among patients using AEDs, perhaps contributing to these discrepancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. Other potential confounders include body mass index, number and type of AEDs, and duration of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/27,41\">",
"     27,41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Effect of AED type'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/31,32,39,42\">",
"     31,32,39,42",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/25\">",
"     25",
"    </a>",
"    ], cross-sectional studies demonstrate that duration of AED treatment is associated with the degree of BMD loss. In some prospective studies, progressive bone loss occurred over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/9,28,43\">",
"     9,28,43",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 81 men aged 25 to 54 years, followed for 12 to 29 months, there was a 1.8 percent annualized loss of BMD by DXA, much higher than would be expected in men of this age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of elderly women followed prospectively for an average of 4.4 years, the rate of bone loss at the total hip (after adjusting for confounders) was -0.70 percent per year in 4094 non-AED users, -0.87 percent per year in 61 intermittent AED users and -1.16 percent per year in 41 continuous AED users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, in the subset of AED users (84 women) in the Women's Health Initiative (WHI) study who had BMD measured prospectively, there was no significant difference in three-year change in BMD of the hip, spine, or total body between users and nonusers of AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/19\">",
"     19",
"    </a>",
"    ]. The small number of women who had BMD measured, combined with the fact that many AED users were taking hormone therapy, may have reduced the ability of the study to show an association between AED use and change in BMD. Alternatively, these observations indicate that the increase in fracture rate may be due to seizure-related injuries and the effects of certain AEDs that impair gait stability, rather than the adverse effects of AEDs on bone strength alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Markers of bone turnover",
"    </span>",
"    &nbsp;&mdash;&nbsp;Markers of bone formation and resorption, measured in the serum and urine, may be elevated in adults with epilepsy receiving AEDs. Elevated levels have been reported during long-term AED therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/26,35,43,44\">",
"     26,35,43,44",
"    </a>",
"    ], and increases have been reported to occur after initiation of AED therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/26,30,35,43-46\">",
"     26,30,35,43-46",
"    </a>",
"    ]. Elevated bone turnover markers are considered to reflect increased bone remodeling activity, are associated with higher rates of bone loss, and are independent predictors of fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=see_link\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings in adults with epilepsy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased serum alkaline phosphatase activity in adults receiving some AEDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/44,45,47-49\">",
"       44,45,47-49",
"      </a>",
"      ]. In those studies that measured isoenzymes of alkaline phosphatase, the increase in total alkaline phosphatase activity appeared to be related to increases in the bone isoenzyme fraction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/30,50,51\">",
"       30,50,51",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      has been associated with the most consistent and marked elevations of alkaline phosphatase. However, increases have also been reported with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of AED type'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      High serum levels of other bone formation markers. High levels of osteocalcin (or bone Gla protein) and C-terminal extension peptide of type I procollagen (PICP) have been described in persons receiving AEDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/26,35,44-46\">",
"       26,35,44-46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated markers of bone resorption. Carboxyl-terminal telopeptide of human type I collagen (CTX) and cross-linked N-telopeptides of type I collagen (NTX) are also elevated in patients treated with AEDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/26,44-46\">",
"       26,44-46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone turnover markers are not useful in the diagnosis of bone disease in individual patients taking AEDs, because values overlap substantially in normal subjects and patients with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=see_link\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Osteomalacia and rickets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomalacia is a disorder of bone mineralization in which the deposition of calcium and phosphate into newly formed bone matrix (osteoid) at sites of bone remodeling or periosteal or endosteal apposition is either insufficient or completely absent. On histologic examination, thickened layers of unmineralized osteoid cover a higher than normal proportion of the bone surface.",
"   </p>",
"   <p>",
"    Clinically, patients with osteomalacia complain of bone pain, which is particularly prominent in the lower extremities and is exacerbated by weightbearing. They may also notice muscle weakness, particularly of the upper arms and thighs. Physical examination often reveals tenderness to pressure over the anterior tibiae, an antalgic gait and proximal muscle weakness. Although there are many causes of osteomalacia, when osteomalacia occurs in association with AED treatment, it is generally associated with profound vitamin D deficiency. Serum calcium and phosphorous and serum 25-hydroxyvitamin D may be low, and parathyroid hormone levels and total alkaline phosphatase activity may be elevated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rickets, a failure of or delay in mineralization of cartilage at growth plates, occurs only in children and results in profusion of disorganized, nonmineralized, degenerating cartilage and consequent widening of the epiphyseal plates with flaring or cupping and irregularity of the epiphyseal-metaphyseal junctions. If untreated, the disorder may progress to include bowing of the lower extremities. In adults, joint enlargement due to the profusion of cartilage and ultimate formation of excess bone is sometimes evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, early reports of bone disease in patients with epilepsy describe osteomalacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/8,53,54\">",
"     8,53,54",
"    </a>",
"    ]. However, these reports primarily included institutionalized patients, and in ambulatory, community-dwelling persons with epilepsy, osteomalacia is rarely seen today.",
"   </p>",
"   <p>",
"    Biopsy studies published in the 1980s found normal osteoid seam width and mineralization rates that were consistently normal or increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. These results are inconsistent with osteomalacia and suggest that bone disease associated with AED use is a disorder of increased remodeling rather than abnormal mineralization, resulting in osteoporosis rather than osteomalacia. Similarly, while rickets has been reported in older studies of children treated with AEDs, most of the subjects were institutionalized, and the findings likely reflect the additive effects of AED and lack of sun exposure on vitamin D metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/57\">",
"     57",
"    </a>",
"    ]. More recent studies of ambulatory, community-dwelling children taking AEDs do not report clinical rickets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/31-34\">",
"     31-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFECT OF AED TYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between AED type and fracture risk remains uncertain. Large case control studies have found no differences in BMD and the risk of fractures between users of AEDs that induce, versus users of AEDS that do not induce, the cytochrome P450 system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/20,25\">",
"     20,25",
"    </a>",
"    ]. However, in the prospective Women's Health Initiative study, users of enzyme-inducing AEDS had a significantly higher risk of total fractures than nonenzyme-inducing AED users (HR 1.4, 95% CI 1.1-1.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Induction of the cytochrome P450 system by AEDs leads to increased catabolism of vitamin D to inactive metabolites and a subsequent rise in parathyroid hormone, which increases the mobilization of bone calcium stores and subsequent bone turnover [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/47,58-60\">",
"     47,58-60",
"    </a>",
"    ]. However, this mechanism does not account for the studies that have shown accelerated bone turnover or bone loss independent of vitamin D deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/27,28,30,44-46,56\">",
"     27,28,30,44-46,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other mechanisms that have been implicated in the pathogenesis of AED-induced bone disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A direct inhibitory effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      on intestinal absorption of calcium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hyperparathyroidism with normal serum 25-hydroxyvitamin D level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Direct effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      to stimulate osteoclastic bone resorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/63\">",
"       63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Direct effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      to inhibit proliferation of human osteoblast-like cells at concentrations equivalent to therapeutic doses for the treatment of epilepsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vitamin K deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/64\">",
"       64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Calcitonin deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/65\">",
"       65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated homocysteine levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Suppression of long bone growth by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      by inhibiting cartilage formation and accelerating ossification of the growth plate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Enzyme-inducing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiepileptic drugs (AEDs) most commonly associated with altered bone and mineral metabolism and decreased bone density are those that induce the cytochrome P450 enzyme system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/30-32,43-48\">",
"     30-32,43-48",
"    </a>",
"    ]. The AEDs that induce the cytochrome P450 enzyme system are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/26,30,32,43,44,47,48\">",
"     26,30,32,43,44,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Induction of the cytochrome P450 system by AEDs leads to increased catabolism of vitamin D to inactive metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/47,58-60\">",
"     47,58-60",
"    </a>",
"    ]. Decreased availability of active vitamin D metabolites leads in turn to decreased gastrointestinal absorption of calcium, hypocalcemia, and a rise in circulating parathyroid hormone (PTH). PTH increases the mobilization of bone calcium stores and subsequent bone turnover. This mechanism is the one most often purported to underlie the bone disease associated with AED use.",
"   </p>",
"   <p>",
"    Laboratory findings in patients taking these drugs often, but not consistently, include hypocalcemia, hypophosphatemia, reduced serum 25-hydroxyvitamin D levels, elevated PTH levels and elevated markers of bone formation and resorption. All of these have been described in adults taking enzyme-inducing AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/47,48,50,51,68-72\">",
"     47,48,50,51,68-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Basic studies have evaluated the effect of these AEDs on the expression of specific cytochrome P450 isoenzymes involved in vitamin D metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Phenobarbital, phenytoin, and carbamazepine are among a class of drugs known as xenobiotics. Xenobiotics activate a nuclear receptor known as either the steroid and xenobiotic receptor (SXR) or pregnane X receptor (PXR):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study found that xenobiotics upregulate 25-hydroxyvitamin D3-24-hydroxylase (CYP24) in the kidney through activation of PXR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/74\">",
"       74",
"      </a>",
"      ]. This enzyme catalyzes the conversion of 25-hydroxyvitamin D to its inactive metabolite, 24,25-dihyroxyvitamin, rather than to its active metabolite, 1,25-dihyroxyvitamin D.",
"     </li>",
"     <li>",
"      Other investigators found that xenobiotic activation of PXR did not upregulate CYP24 but did increase expression of a different isoenzyme, CYP3A4, in the liver and small intestine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/73\">",
"       73",
"      </a>",
"      ]. This enzyme converts vitamin D to more polar inactive metabolites. They also found that xenobiotic activation of PXR represses CYP24 expression in the liver and intestine suggesting a dual role in mediating vitamin D metabolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies that have compared AED regimens often find that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    is associated with the most marked increases in bone turnover markers and decreases in BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/26,30,43,44,75\">",
"     26,30,43,44,75",
"    </a>",
"    ]. In a prospective study of premenopausal women with epilepsy receiving a single AED, treatment with phenytoin for one year was associated with a 2.6 percent decrease in femoral neck BMD, whereas treatment with other AEDs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ) did not have such an adverse effect on BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/75\">",
"     75",
"    </a>",
"    ]. Animal studies suggest that phenytoin may also have direct toxicity on bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/42,63\">",
"     42,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    appears to be less commonly associated with bone disease than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . While hypocalcemia, hypophosphatemia, decreased vitamin D metabolites, and elevated markers of bone turnover have all been reported with carbamazepine, these findings have not been observed as consistently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/11,31,36,37,45,46\">",
"     11,31,36,37,45,46",
"    </a>",
"    ]. One short-term (10 week) study of normal young men found that carbamazepine was not associated with any change in markers of bone turnover [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/76\">",
"     76",
"    </a>",
"    ]. In contrast, significant increases in markers of bone turnover were documented in children and adolescents after initiation of carbamazepine treatment for epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone mass has been reported to be normal or decreased in children and young adults treated with long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/27,37,44,77,78\">",
"     27,37,44,77,78",
"    </a>",
"    ]. In a prospective study of premenopausal women with epilepsy receiving a single AED, treatment with carbamazepine was not associated with any changes in markers of bone turnover or BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/75\">",
"     75",
"    </a>",
"    ]. However, fracture risk has been reported to be increased in adults treated with carbamazepine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nonenzyme-inducing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Valproate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    is an inhibitor of the cytochrome P450 enzyme system. Although studies published in the 1980s did not find any association with bone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/47,68\">",
"     47,68",
"    </a>",
"    ], subsequent studies have consistently reported bone loss, abnormal biochemical indices of bone and mineral metabolism, and higher fracture rates with valproate in both children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/5,26,31,34,35\">",
"     5,26,31,34,35",
"    </a>",
"    ]. Both dose and duration of valproate therapy have been associated with increased rates of bone loss and higher incidence of fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/5,35\">",
"     5,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study compared two groups of patients, one on long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    monotherapy and one on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , with controls matched for age and gender [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/26\">",
"     26",
"    </a>",
"    ]. Both AEDs were associated with decreased BMD and increased markers of bone turnover. In contrast, a study of Korean women and men na&iuml;ve to treatment did not find any changes in BMD six months after initiation of valproate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cell culture studies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    has been shown to suppress longitudinal bone growth by inhibiting cartilage formation and accelerating ossification of the growth plate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/67\">",
"     67",
"    </a>",
"    ]. Perhaps consistent with this effect, short stature has been reported in children treated with valproate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/34\">",
"     34",
"    </a>",
"    ]. In the same study, low BMD, short stature, and elevated markers of bone turnover were more pronounced in children treated with valproate in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/34\">",
"     34",
"    </a>",
"    ]. In this study, physical inactivity was identified as a possible confounder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other AEDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have evaluated the effect of newer AEDs on bone and mineral metabolism and BMD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      is increasingly used to treat epilepsy. A study of premenopausal women on AED monotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      or lamotrigine) found no significant effect of lamotrigine on BMD, calciotropic hormones or bone turnover markers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/30,75\">",
"       30,75",
"      </a>",
"      ]. Although treatment duration was shorter for patients on lamotrigine, there was no association between duration of therapy and BMD or any marker of bone and mineral metabolism. Similarly, eight Korean men and women did not have any changes in BMD after six months of treatment with lamotrigine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/78\">",
"       78",
"      </a>",
"      ]. In contrast, children treated with lamotrigine were significantly shorter, and had lower BMD and higher markers of bone turnover compared with children not receiving AEDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/34\">",
"       34",
"      </a>",
"      ]. These findings were most pronounced in children treated with both lamotrigine and valproate.",
"     </li>",
"     <li>",
"      A large case control study found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      were among the AEDs associated with small increases in the relative risk of fracture, after controlling for epilepsy diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 45 patients found reduced serum 25-hydroxyvitamin D and slightly elevated osteocalcin levels among patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no published clinical studies on the effects on bone of the two carbonic anhydrase inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    ) used as AEDs. However, as carbonic anhydrase inhibitors are potent inhibitors of osteoclastic bone resorption, one might expect lower rates of bone loss to be associated with their use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/79\">",
"     79",
"    </a>",
"    ]. On the other hand, these agents also cause metabolic acidosis, which could foster dissolution of calcium from hydroxyapatite and also decrease bone formation by osteoblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/80\">",
"     80",
"    </a>",
"    ]. In one study, women who received the carbonic anhydrase inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41652?source=see_link\">",
"     methazolamide",
"    </a>",
"    ) for glaucoma had higher spinal BMD than controls, which suggests that beneficial effects may predominate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis screening is typically recommended in postmenopausal women and older men with risk factors for fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .) For patients with epilepsy, we consider the risk factors for bone disease related to AED use in addition to more general risk factors for osteoporosis and fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical risk factor assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for bone disease in AED users include high-dose, multiple drug regimens, long-term therapy, inadequate intakes of vitamin D, limited sunlight exposure, chronic illness, old age, institutionalization, low physical activity, adjuvant therapy to induce chronic metabolic acidosis (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    or ketogenic diets), and concomitant therapy with other drugs that induce hepatic enzymes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , glutethimide).",
"   </p>",
"   <p>",
"    Risk factors for osteoporosis and fractures include female gender, postmenopausal status, Caucasian and Asian race, old age, tobacco, low body mass index, and low dietary calcium and vitamin D intake (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 3",
"    </a>",
"    ). AEDs are an accepted secondary cause of osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is reasonable to recommend measuring BMD in patients with epilepsy who have risk factors for osteoporosis and risk factors for AED-related bone disease. Persons treated with long-term (&gt;five years) enzyme-inducing AEDs or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    are likely at risk, and therefore should be screened. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link&amp;anchor=H13#H13\">",
"     \"Screening for osteoporosis\", section on 'Candidates for BMD testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a person with a normal baseline BMD, the frequency of testing should depend upon the age and gender of the patient. More frequent testing (every two years) is appropriate in a postmenopausal woman or elderly man, and less frequent in a premenopausal woman or young man. Because multiple risk factors further increase risk of fracture, earlier and more frequent screening is prudent in such patients (",
"    <a class=\"graphic graphic_table graphicRef54926 \" href=\"mobipreview.htm?35/45/36573\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with epilepsy who are taking AEDs, we typically measure serum calcium, phosphate, and 25-hydroxyvitamin D levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/41,82-84\">",
"     41,82-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have rigorously evaluated strategies for prevention and treatment of bone disease associated with AEDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lifestyle measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with epilepsy who are taking AEDs should adopt the same lifestyle measures that are recommended for all patients at risk for osteoporosis and fracture. These include regular weight-bearing exercise, smoking cessation, limiting alcohol intake, and preventing falls. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of osteoporosis in men\", section on 'Lifestyle measures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Calcium and vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the optimal doses of calcium and vitamin D for patients with epilepsy who are taking AEDs.",
"   </p>",
"   <p>",
"    In a study that included both institutionalized and ambulatory subjects receiving AEDs who had low baseline serum 25-hydroxyvitamin D levels, vitamin D supplementation was titrated to achieve a normal serum 25OHD concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/85\">",
"     85",
"    </a>",
"    ]. All achieved normal 25-hydroxyvitamin D levels over a period of 12 to 15 months. Dose requirements ranged from 400 to 4000 int. units daily.",
"   </p>",
"   <p>",
"    In two randomized trials in adults and children given either low dose vitamin D (400 int.",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    or high dose vitamin D (4000 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    adults and 2000 int.",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    in children), there were no significant differences in BMD at one year between the adult groups, although BMD had increased from baseline in the high-dose group only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/86\">",
"     86",
"    </a>",
"    ]. In children, both dose groups had comparable increases in BMD after one year.",
"   </p>",
"   <p>",
"    As a general rule, patients should receive adequate calcium (1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in younger patients, 1200 to 1500 mg daily in older men and women) and vitamin D (400 to 800 int.",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    supplementation. Because studies have shown that much higher doses (up to 4000 int. units) may be necessary to normalize serum levels of 25-hydroxyvitamin D in some patients, we typically measure serum 25-hydroxyvitamin D levels to determine whether vitamin D intake is sufficient to maintain levels above 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36969/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. This is particularly important in the case of elderly or institutionalized patients who may have limited access to sunshine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of studies specifically targeting osteoporosis in individuals treated with AEDs, treatment recommendations should follow other guidelines, such as for postmenopausal women and men. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .) However, it is of particular importance to make certain that individuals receiving AEDs are vitamin D replete before initiating therapy for osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with epilepsy are at higher risk for fracture because of a higher risk for falls and physical trauma related to seizures themselves, the neurological disease that underlies the epilepsy (stroke, cerebral palsy), and the effects of certain AEDs that impair gait stability and alter bone and mineral metabolism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relationship between AED type and fracture risk remains uncertain. However, AEDs that induce the hepatic cytochrome P450 enzyme system (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ) are those most commonly implicated as affecting bone and mineral metabolism (",
"      <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"       table 2",
"      </a>",
"      ). The most commonly implicated pathogenetic mechanism is via accelerated catabolism of vitamin D. In addition, there is growing evidence to suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , a cytochrome P450 enzyme inhibitor, also affects bone and mineral metabolism. To date, there are limited data available on the skeletal effects of newer AEDs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of AED type'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several additional mechanisms for AED-associated bone loss have been proposed, including direct effects on intestinal calcium absorption and also on osteoblasts and osteoclasts. It is likely that more than one mechanism contributes to AED-associated bone disease, and that these are to some extent specific to the particular AED. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of AED type'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For individuals with a history of prolonged use (&gt;five years) of AEDs, especially those using enzyme-inducing AEDs or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , those with other risk factors for AED-induced bone disease (high-dose, multi-drug regimens, low vitamin D intake, limited sunlight exposure, chronically ill, elderly or institutionalized patients, low physical activity levels, exposure to drugs that induce chronic metabolic acidosis, and concomitant therapy with other drugs that induce hepatic enzymes) or risk factors for osteoporosis, we suggest bone mineral density testing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients receiving AEDs, we suggest calcium and vitamin D supplementation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although the optimal intake (diet plus supplement) has not been clearly established in this patient population, approximately 1200 mg of calcium and 800 int. units of vitamin D daily are the typical doses used. However, patients receiving AEDs, particularly enzyme-inducing AEDs, may require higher doses of vitamin D. We typically measure serum 25-hydroxyvitamin D levels in such patients to determine whether vitamin D intake is sufficient to maintain levels within the normal range. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Calcium and vitamin D'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of vitamin D deficiency in adults\", section on 'Vitamin D repletion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pharmacologic treatment of osteoporosis and fracture in patients taking AEDs is the same as the treatment of osteoporosis in postmenopausal women and men. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"       \"Treatment of osteoporosis in men\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/1\">",
"      Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/2\">",
"      Pack AM. Bone disease in epilepsy. Curr Neurol Neurosci Rep 2004; 4:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/3\">",
"      Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004; 5 Suppl 2:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/4\">",
"      Vestergaard P, Tigaran S, Rejnmark L, et al. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999; 99:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/5\">",
"      Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/6\">",
"      Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/7\">",
"      Desai KB, Ribbans WJ, Taylor GJ. Incidence of five common fracture types in an institutional epileptic population. Injury 1996; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/8\">",
"      Kruse R. [Osteopathies in antiepileptic long-term therapy (preliminary report)]. Monatsschr Kinderheilkd 1968; 116:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/9\">",
"      Ensrud KE, Walczak TS, Blackwell TL, et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008; 71:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/10\">",
"      Vestergaard P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand 2005; 112:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/11\">",
"      Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006; 47:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/12\">",
"      NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/13\">",
"      Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006; 12:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/14\">",
"      Jaglal SB, Kreiger N, Darlington GA. Lifetime occupational physical activity and risk of hip fracture in women. Ann Epidemiol 1995; 5:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/15\">",
"      Espallargues M, Sampietro-Colom L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int 2001; 12:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/16\">",
"      Souverein PC, Webb DJ, Petri H, et al. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005; 46:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/17\">",
"      Tsiropoulos I, Andersen M, Nymark T, et al. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia 2008; 49:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/18\">",
"      Jett&eacute; N, Lix LM, Metge CJ, et al. Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 2011; 68:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/19\">",
"      Carbone LD, Johnson KC, Robbins J, et al. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). J Bone Miner Res 2010; 25:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/20\">",
"      Souverein PC, Webb DJ, Weil JG, et al. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006; 66:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/21\">",
"      Koppel BS, Harden CL, Nikolov BG, Labar DR. An analysis of lifetime fractures in women with epilepsy. Acta Neurol Scand 2005; 111:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/22\">",
"      Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002; 43:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/23\">",
"      Sheth RD. Bone health in pediatric epilepsy. Epilepsy Behav 2004; 5 Suppl 2:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/24\">",
"      Annegers JF, Melton LJ 3rd, Sun CA, Hauser WA. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia 1989; 30:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/25\">",
"      Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999; 8:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/26\">",
"      Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001; 57:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/27\">",
"      Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/28\">",
"      Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002; 59:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/29\">",
"      Pack AM, Olarte LS, Morrell MJ, et al. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003; 4:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/30\">",
"      Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005; 57:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/31\">",
"      Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995; 127:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/32\">",
"      Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994; 16:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/33\">",
"      Tsukahara H, Kimura K, Todoroki Y, et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002; 44:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/34\">",
"      Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001; 42:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/35\">",
"      Oner N, Kaya M, Karasaliholu S, et al. Bone mineral metabolism changes in epileptic children receiving valproic acid. J Paediatr Child Health 2004; 40:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/36\">",
"      Akin R, Okutan V, Sarici U, et al. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 1998; 19:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/37\">",
"      Erbayat Altay E, Serdarolu A, T&uuml;mer L, et al. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000; 13:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/38\">",
"      Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006; 35:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/39\">",
"      Sheth RD, Binkley N, Hermann BP. Progressive bone deficit in epilepsy. Neurology 2008; 70:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/40\">",
"      Coppola G, Fortunato D, Auricchio G, et al. Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 2009; 50:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/41\">",
"      Heller HJ, Sakhaee K. Anticonvulsant-induced bone disease: a plea for monitoring and treatment. Arch Neurol 2001; 58:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/42\">",
"      Feldkamp J, Becker A, Witte OW, et al. Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000; 108:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/43\">",
"      Ensrud KE, Walczak TS, Blackwell T, et al. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004; 62:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/44\">",
"      V&auml;lim&auml;ki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994; 9:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/45\">",
"      Verrotti A, Greco R, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000; 47:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/46\">",
"      Verrotti A, Greco R, Latini G, et al. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002; 43:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/47\">",
"      Gough H, Goggin T, Bissessar A, et al. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 1986; 59:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/48\">",
"      O'Hare JA, Duggan B, O'Driscoll D, Callaghan N. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 1980; 62:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/49\">",
"      Bogliun G, Beghi E, Crespi V, et al. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986; 74:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/50\">",
"      Skillen AW, Pierides AM. Serum gamma glutamyl transferase and alkaline phosphatase activities in epileptics receiving anticonvulsant therapy. Clin Chim Acta 1976; 72:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/51\">",
"      Okesina AB, Donaldson D, Lascelles PT. Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy. J Clin Pathol 1991; 44:480.",
"     </a>",
"    </li>",
"    <li>",
"     Pettifor JM. Nutritional and drug-induced rickets and osteomalacia. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th, ASBMR, Favus MJ (Eds), Lippincott, Williams and Wilkins, Washington, DC 2006. p.330.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/53\">",
"      Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J 1970; 4:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/54\">",
"      Richens A, Rowe DJ. Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 1970; 4:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/55\">",
"      Mosekilde, L, Melsen, F. Dynamic differences in trabecular bone remodeling between patients after jejunoileal bypass for obesity and epileptic patients receiving anticonvulsant therapy. Metab Bone Dis Relat Res 1980; 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/56\">",
"      Weinstein RS, Bryce GF, Sappington LJ, et al. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984; 58:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/57\">",
"      Borgstedt AD, Bryson MF, Young LW, Forbes GB. Long-term administration of antiepileptic drugs and the development of rickets. J Pediatr 1972; 81:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/58\">",
"      Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987; 33:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/59\">",
"      Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001; 15:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/60\">",
"      Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 2004; 5 Suppl 2:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/61\">",
"      Mosekilde L, Hansen HH, Christensen MS, et al. Fractional intestinal calcium absorption in epileptics on anticonvulsant therapy. Short-term effect of 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol. Acta Med Scand 1979; 205:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/62\">",
"      Koch HU, Kraft D, von Herrath D, Schaefer K. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 1972; 13:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/63\">",
"      Takahashi A, Onodera K, Shinoda H, Mayanagi H. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol 2000; 82:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/64\">",
"      Onodera K, Takahashi A, Sakurada S, Okano Y. Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci 2002; 70:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/65\">",
"      Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 1990; 11:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/66\">",
"      Elliott JO, Jacobson MP, Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 2007; 16:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/67\">",
"      Wu S, Legido A, De Luca F. Effects of valproic acid on longitudinal bone growth. J Child Neurol 2004; 19:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/68\">",
"      Davie MW, Emberson CE, Lawson DE, et al. Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D. Q J Med 1983; 52:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/69\">",
"      Hoikka V, Savolainen K, Alhava EM, et al. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 1981; 64:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/70\">",
"      Bouillon R, Reynaert J, Claes JH, et al. The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975; 41:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/71\">",
"      Hahn TJ, Hendin BA, Scharp CR, Haddad JG Jr. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972; 287:900.",
"     </a>",
"    </li>",
"    <li>",
"     Berry JL, Mawer EB, Walker DA, et al. Effect of antiepileptic drug therapy and exposure to sunlight on vitamin D status in institutionalized patients. In: Antiepileptic therapy: Chronic toxicity of antiepileptic drugs, Oxley J, Janz D, Meinardi H (Eds), Raven Press, New York 1983. p.185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/73\">",
"      Zhou C, Assem M, Tay JC, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006; 116:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/74\">",
"      Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/75\">",
"      Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008; 70:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/76\">",
"      Br&auml;mswig S, Zittermann A, Berthold HK. Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adults. Calcif Tissue Int 2003; 73:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/77\">",
"      Tjellesen L, Nilas L, Christiansen C. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol Scand 1983; 68:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/78\">",
"      Kim SH, Lee JW, Choi KG, et al. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007; 10:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/79\">",
"      Hall TJ, Higgins W, Tardif C, Chambers TJ. A comparison of the effects of inhibitors of carbonic anhydrase on osteoclastic bone resorption and purified carbonic anhydrase isozyme II. Calcif Tissue Int 1991; 49:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/80\">",
"      Yildizdas D, Topaloglu AK, Mungan NO, et al. Bone mineral changes in acute metabolic acidosis due to acute gastroenteritis. Calcif Tissue Int 2004; 75:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/81\">",
"      Pierce WM Jr, Nardin GF, Fuqua MF, et al. Effect of chronic carbonic anhydrase inhibitor therapy on bone mineral density in white women. J Bone Miner Res 1991; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/82\">",
"      Harden CL. Menopause and bone density issues for women with epilepsy. Neurology 2003; 61:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/83\">",
"      Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004; 5 Suppl 2:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/84\">",
"      Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001; 58:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/85\">",
"      Collins N, Maher J, Cole M, et al. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991; 78:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/86\">",
"      Mikati MA, Dib L, Yamout B, et al. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 2006; 67:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/87\">",
"      Sherk HH, Cruz M, Stambaugh J. Vitamin D prophylaxis and the lowered incidence of fractures in anticonvulsant rickets and osteomalacia. Clin Orthop Relat Res 1977; :251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36969/abstract/88\">",
"      Heaney RP. The case for improving vitamin D status. J Steroid Biochem Mol Biol 2007; 103:635.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2063 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36969=[""].join("\n");
var outline_f36_6_36969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METABOLIC BONE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Osteomalacia and rickets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFECT OF AED TYPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Enzyme-inducing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nonenzyme-inducing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Valproate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other AEDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical risk factor assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lifestyle measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Calcium and vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2063|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/45/36573\" title=\"table 1\">",
"      Secondary causes osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/46/27374\" title=\"table 2\">",
"      AED pharmacologic properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/21/2395\" title=\"table 3\">",
"      Risk factors for osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=related_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_6_36970="Etiology and pathogenesis of Parkinson disease";
var content_f36_6_36970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and pathogenesis of Parkinson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36970/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36970/contributors\">",
"     Joseph Jankovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36970/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/6/36970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/6/36970/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/6/36970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parkinson disease (PD) is the most common cause of parkinsonism, a syndrome manifested by rest tremor, rigidity, bradykinesia, and postural instability. The disorder was first described by James Parkinson in his 1817 Essay on the Shaking Palsy. Although it has been proposed that PD emerged as a result of the industrial revolution, there is some evidence that a disease known as \"kampavata\", consisting of shaking (kampa) and lack of muscular movement (vata), existed in ancient Indian medical system, Ayurveda, as long as 4500 years ago [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/1\">",
"     1",
"    </a>",
"    ]. The Mucuna pruriens plant was used in ancient times to treat the symptoms, and was later discovered to contain levodopa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathology of PD was not well understood until the early 20th century, when the German pathologist Frederick Lewy in 1912 reported neuronal cytoplasmic inclusions in a variety of brain regions. In 1919, Tretiakoff observed that the most critical abnormality in PD was the loss of neurons in the substantia nigra pars compacta of the midbrain. In the 1950s, investigators discovered the importance of dopamine and its depletion from the basal ganglia as the key to understanding the pathophysiology and pathologic biochemistry of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the cause of PD is still unknown, remarkable advances have been made in understanding the possible underlying mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/4\">",
"     4",
"    </a>",
"    ]. This extraordinary progress has been fueled by new discoveries about the anatomy and function of the basal ganglia, improved characterization of neuropathologic and neurochemical abnormalities in PD, and by studies of genetic and experimental forms of parkinsonism.",
"   </p>",
"   <p>",
"    This topic will review the etiology and pathogenesis of PD. Clinical issues related to PD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26089?source=see_link\">",
"     \"Diagnosis of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine depletion from the basal ganglia results in major disruptions in the connections to the thalamus and motor cortex, and leads to parkinsonian signs such as bradykinesia.",
"   </p>",
"   <p>",
"    A number of compensatory mechanisms may operate to mask or reduce the deleterious effects of dopamine depletion, particularly in the presymptomatic phase of PD, but they are eventually overwhelmed by disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Basal ganglia circuits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basal ganglia, sometimes referred to as the extrapyramidal system, include the substantia nigra (SN), striatum (caudate and putamen), globus pallidus (GP), subthalamic nucleus (STN), and thalamus.",
"   </p>",
"   <p>",
"    The cortical input to the basal ganglia from the prefrontal supplementary motor area, amygdala and hippocampus is excitatory, mediated by the neurotransmitter glutamate. Neurons in the substantia nigra pars compacta (SNc) provide major dopaminergic input to the striatum and exert both excitatory and inhibitory influences on the striatal output neurons. The interaction between the afferent and efferent pathways is mediated by striatal interneurons which utilize acetylcholine as the main neurotransmitter.",
"   </p>",
"   <p>",
"    The striatal output system is mediated by the inhibitory neurotransmitter gamma-amino-butyric-acid (GABA). The connection between the STN and the internal (medial) globus pallidus (GPi) and between STN and the lateral (or external) globus pallidus (GPe) is excitatory, mediated by glutamate.",
"   </p>",
"   <p>",
"    Five distinct dopamine receptors (D1 through D5) have been cloned and characterized; they are found throughout the basal ganglia and limbic system. The D1 and D2 receptors are highly concentrated in the dorsal (motor) striatum and are the most relevant to the pathophysiology of PD because they are activated by the dopaminergic pathway originating in the SNc and terminating in the caudate and putamen. Receptors designated as D3, D4, and D5 are more abundant in the mesolimbic or emotional part of the brain (D3, D4) and",
"    <span class=\"nowrap\">",
"     hippocampus/hypothalamus",
"    </span>",
"    (D5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dopamine deficiency in the nigrostriatal pathway, such as seen in PD, causes denervation hypersensitivity of D1 and D2 receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/6\">",
"     6",
"    </a>",
"    ]. When compared with normal matched controls, D2 receptors in the dorsal putamen are increased by 15 percent in patients with PD, whereas D3 receptors in the mesolimbic system are decreased by 40 to 45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/7\">",
"     7",
"    </a>",
"    ]. These results may explain the basis for the hypersensitivity of the nigrostriatal (D2) dopaminergic receptors that is observed in PD.",
"   </p>",
"   <p>",
"    There are two output pathways from the striatum (",
"    <a class=\"graphic graphic_figure graphicRef82136 \" href=\"mobipreview.htm?9/19/9535\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The indirect pathway is mediated chiefly via dopamine's inhibitory influence on striatal D2 dopamine receptors. In the indirect pathway, the striatum projects to the neurons in the lateral GP (GPe) utilizing GABA, and the GPe in turn projects to the STN, which provides excitatory input via glutamate to the internal segment of the GP (GPi) and SN pars reticulata (SNr). GPi neurons are GABAergic and synapse in the ventrolateral nucleus of the thalamus. Thalamic input to the cortex is excitatory.",
"     </li>",
"     <li>",
"      The direct pathway is mediated via dopamine's excitatory influence on striatal D1 dopamine receptors. In the direct pathway, the striatum projects directly to the GPi and SNr.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In PD, a reduction of dopamine-producing neurons from the normal complement of approximately 550,000 to the critically low level of 100,000 leads to dopamine depletion in the SN and in the nigrostriatal pathway to the caudate and putamen. This, in turn, results in relative overactivity of the indirect pathway, functionally disinhibiting the STN. Decreased inhibition of the direct pathway causes additional disinhibition of the output nuclei (GPi and SNr). Increased output from GPi causes increased inhibition of the thalamus and reduced excitatory input to the motor cortex, which is ultimately expressed as bradykinesia and other parkinsonian signs.",
"   </p>",
"   <p>",
"    In PD, synchronized oscillatory activity in the 10 to 50 Hz band (often termed the beta-band), prevalent in the basal ganglia thalamocortical circuit, may be important in mediating certain parkinsonian features, including bradykinesia and tremor, and can be reduced by dopaminergic treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/8\">",
"     8",
"    </a>",
"    ]. Therefore, surgical treatments of PD, such as lesion placement within or stimulation of GPi or STN, may act by desynchronizing the oscillatory basal ganglia-thalamo-cortical network activity.",
"   </p>",
"   <p>",
"    Models of basal ganglia dysfunction, such as illustrated in the Figure (",
"    <a class=\"graphic graphic_figure graphicRef82136 \" href=\"mobipreview.htm?9/19/9535\">",
"     figure 1",
"    </a>",
"    ), are useful for conceptualizing how the motor symptoms of PD arise. However, the actual pathophysiology of the basal ganglia associated with PD is much more complex than indicated by the current models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/9\">",
"     9",
"    </a>",
"    ]. Existing models should be constantly reevaluated as new findings become available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Compensatory mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brain has a remarkable capacity to compensate for the presynaptic dopamine depletion by increasing the synthesis of dopamine in surviving neurons and by increasing the afferents to the dendrites of dopaminergic neurons. Furthermore, dopaminergic denervation has been shown to result in a proliferation of D2 receptors, as well as a co-localization of D1 and D2 receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/10\">",
"     10",
"    </a>",
"    ]. Similarly, gap junctions, which allow rapid communications between striatal neurons, increase dramatically after dopaminergic denervation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the brains of patients with PD, the number of tyrosine hydroxylase-staining neurons in the striatum is markedly decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/12\">",
"     12",
"    </a>",
"    ]. Since tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of dopamine, is still present in surviving neurons, the synthesis of dopamine could be increased in these striatal neurons, thereby compensating for the presynaptic dopamine loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Another compensatory mechanism may be downregulation of the dopamine transporter, resulting in less dopamine reuptake and higher synaptic dopamine levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three stages of compensation during the presymptomatic period of PD have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early period during which the dopamine homeostatic compensatory mechanisms discussed above are capable of \"masking\" the disease",
"     </li>",
"     <li>",
"      Increased activity of the basal ganglia output nuclei (eg, internal segment of the globus pallidus) as striatal dopamine homeostasis breaks down",
"     </li>",
"     <li>",
"      Increased intensity of compensation in structures outside of the basal ganglia (eg, supplementary motor area of the cortex) as parkinsonian motor abnormalities emerge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depigmentation, neuronal loss, and gliosis, particularly in the substantia nigra pars compacta and in the pontine locus ceruleus, are typical abnormalities found in the brains of patients with PD. Neuronal degeneration is also present in the dorsal nucleus of the vagus in the medulla and other brainstem nuclei.",
"   </p>",
"   <p>",
"    Using a quantitative method, one study of seven patients with PD and seven controls found that the number of pigmented neurons in the substantia nigra, normally 550,000, was reduced by 66 percent in those with PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, the number of nonpigmented neurons, normally 260,000, was reduced by 24 percent. By the time the first symptoms of PD emerge, about 60 percent of the neurons in the substantia nigra pars compact have been lost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ventrolateral portion of the substantia nigra that projects to the dorsal putamen is preferentially affected early in the course of PD, resulting in the gradual loss of dopaminergic neurons in the substantia nigra pars compacta and a nearly complete depletion of dopamine, particularly in the putamen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/17\">",
"     17",
"    </a>",
"    ]. This contrasts with normal aging, which is usually associated with neuronal loss in the dorsal tier of the substantia nigra pars compacta, and depletion of dopamine, predominantly in the caudate nucleus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the apparent discrepancy between loss of striatal dopamine (&gt;80 percent) and the degree of loss of neurons in the substantia nigra (50 to 60 percent), some have suggested that the initial site of pathology is in the striatum and that retrograde degeneration may be responsible for the neuronal loss in the substantia nigra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/3\">",
"     3",
"    </a>",
"    ]. An alternative explanation is that each dopaminergic neuron has multiple projections that terminate in the striatum, so that death of the cell body has a multiplying effect on loss of terminals.",
"   </p>",
"   <p>",
"    In addition to the degeneration of the substantia nigra pars compacta, other nuclei are affected by the pathology of PD, including the internal segment of the globus pallidus, the center median-parafascicular complex, the pedunculopontine tegmental nucleus, and the glutamatergic caudal intralaminar thalamic nuclei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/19\">",
"     19",
"    </a>",
"    ]. Moreover, volumetric MRI studies have found significant hippocampal atrophy in patients with PD, with or without cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lewy bodies and other intracellular inclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is yet no consensus as to what pathologic criteria are necessary for the diagnosis of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/4\">",
"     4",
"    </a>",
"    ], but most investigators believe that Lewy bodies, named for Frederick Lewy, constitute the pathologic hallmark of PD.",
"   </p>",
"   <p>",
"    Lewy bodies are round, eosinophilic, intracytoplasmic inclusions in the nuclei of neurons. They are 3 to 25 nm in diameter with a dense granular core (1 to 8 nm) and loosely arranged fibrillary elements extending towards a peripheral \"halo\". Immunohistochemical studies have demonstrated that Lewy bodies are made up mainly of alpha-synuclein and ubiquitin, and also contain calbindin, complement proteins, microfilament subunits, tubulin, microtubule associated protein 1 and 2, and a parkin substrate protein called Pael-R [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/21\">",
"     21",
"    </a>",
"    ]. However, Lewy bodies do not contain the tau protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted, Lewy bodies stain for alpha-synuclein, a 140 amino acid presynaptic protein found mutated in rare families with PD. Lewy bodies also contain synphilin-1 and other cytoskeletal proteins associated with alpha-synuclein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'SNCA-associated PD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with PD, Lewy bodies are seen in the substantia nigra, the basal nucleus of Meynert, locus ceruleus, cerebral cortex, sympathetic ganglia, the dorsal vagal nucleus, the myenteric plexus of the intestines, and even in the cardiac sympathetic plexus. Lewy bodies appear to arise from the peripheral portion of other inclusions known as pale bodies, which are found in the substantia nigra and locus ceruleus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lewy bodies are not specific for PD, since they are found in as many as 10 percent of brains of normal elderly persons, and in patients with other neurodegenerative diseases, such as neurodegeneration with brain iron accumulation (NBIA), ataxia-telangiectasia, progressive supranuclear palsy, corticobasal degeneration, Down's syndrome, and Alzheimer disease. There is growing evidence that Lewy bodies occur not only in synucleinopathies such as PD, or amyloidopathies such as Alzheimer disease, but also in tauopathies, such as frontotemporal dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of specificity of the pathologic findings raises the possibility that PD may not be a specific disease entity, but rather a clinically prototypical syndrome with different pathologic causes (",
"    <a class=\"graphic graphic_table graphicRef80669 \" href=\"mobipreview.htm?39/19/40253\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Inclusions such as Lewy bodies have traditionally been considered toxic. However, some studies suggest that they may actually be neuroprotective, and that compounds that promote the formation of inclusions lessen the pathology of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/23,25\">",
"     23,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Braak staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the traditional view, the pathologic process of PD starts with degeneration of dopaminergic neurons in the substantia nigra. This view has been challenged by the neuropathologist Heiko Braak, who has proposed that the pathologic changes of PD start in the medulla of the brainstem and in the olfactory bulb, progressing rostrally over many years to the cerebral cortex in a predictable six-stage process (",
"    <a class=\"graphic graphic_figure graphicRef69456 \" href=\"mobipreview.htm?23/7/23671\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to Braak staging, the progression of pathologic changes occurs as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During presymptomatic stages 1 and 2, the pathologic changes are found in the medulla oblongata and olfactory bulb.",
"     </li>",
"     <li>",
"      In stages 3 and 4, the pathology has migrated rostrally to the substantia nigra pars compacta and other neuronal clusters of the midbrain and basal forebrain, at which time the classic motor symptoms of PD first appear.",
"     </li>",
"     <li>",
"      In end-stages 5 and 6, the pathologic process encroaches upon the telencephalic cortex of the temporal and frontal lobes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the validity and predictive utility of Braak's staging has been questioned, as there are no cell counts to correlate with the described synuclein pathology and no observed asymmetry in the pathologic findings that correlate with the well-recognized asymmetry of clinical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, there is controversy as to the classification of dementia with Lewy bodies (DLB), considered by some to be a separate entity from PD. Braak did not include DLB his observations on the progression of PD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/41/34455?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF CELL DEGENERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irrespective of the initial trigger (etiology) of the neuronal degeneration in PD, the pathogenesis of neurodegeneration probably involves either programmed cell death (apoptosis) or necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apoptosis is characterized by condensation of cytoplasm and chromatin, DNA fragmentation, and cell fragmentation into apoptotic bodies, followed by lysosome-mediated phagocytosis. The other mechanism of cell death, called autophagy, is characterized by accumulation of autophagic vesicles (autophagosomes and autophagolysosomes), and also plays an important role in neurodegeneration in PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that only 0.5 percent of substantia nigra neurons in normal brains are undergoing apoptosis, but this number is increased fourfold to 2 percent in those with PD. Some experimental models of PD suggest that apoptosis is the primary mechanism of substantia nigra neuronal degeneration in PD, but convincing evidence from careful neuropathologic studies is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the precise mechanisms of neurodegeneration in PD are not yet understood, they most likely involve a cascade of events that include interaction between genetic factors and abnormalities in protein processing, oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammation, immune regulation, glial-specific factors, lack of trophic factors, and other, yet unknown, mechanisms (",
"    <a class=\"graphic graphic_algorithm graphicRef82386 \" href=\"mobipreview.htm?36/33/37406\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72207 \" href=\"mobipreview.htm?22/55/23415\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One of the emerging hypotheses is that neurodegeneration in PD is due to disruption of intracellular vesicular transport as a result of destabilizing of microtubules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/36\">",
"     36",
"    </a>",
"    ]. Another area of increasing interest is the role of astrocytes in various neurodegenerative disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some have suggested that PD arises from a prenatal event or process that predisposes some individuals to have fewer dopaminergic neurons at the time of birth because of abnormalities in the genes that code for factors important in the development of the dopaminergic system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, it is possible that prenatal or early postnatal exposure to certain dopaminergic neuronal toxins, such as the MPTP-like herbicide paraquat and the manganese-containing fungicide maneb, may reduce the number of dopamine neurons in the substantia nigra in early development and enhance vulnerability to these toxins when individuals are subsequently exposed in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/39\">",
"     39",
"    </a>",
"    ]. This is consistent with the so-called \"multiple-hit hypothesis\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Protein misfolding, aggregation, and toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the gene on chromosome 4q21.3-q22 that codes for alpha-synuclein have emerged as one of the most important elements of cell death in various neurodegenerative disorders, together known as synucleinopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/40\">",
"     40",
"    </a>",
"    ]. These include not only PD, but also dementia with Lewy bodies, multiple system atrophy, and neurodegeneration with brain iron accumulation (NBIA).",
"   </p>",
"   <p>",
"    Although alpha-synuclein is quite abundant in the central nervous system (CNS), accounting for one percent of total CNS protein, its physiologic role, if any, is still not fully understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/41\">",
"     41",
"    </a>",
"    ]. However, a number of observations suggest that abnormal alpha-synuclein processing plays a role in the pathogenesis of PD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in the alpha-synuclein (SNCA) gene may cause the natively unfolded alpha-synuclein protein to alter its secondary structure and self-aggregate after being targeted for proteasomal degradation by ubiquitin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/42\">",
"       42",
"      </a>",
"      ]. Misfolding of proteins and subsequent formation of insoluble aggregates can occur due to gene mutations that result in abnormal structure of the gene product, or as a result of age-related phenomenon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An aggregated and insoluble form of alpha-synuclein is a major component of Lewy bodies, intracellular inclusions that are the pathologic hallmark of PD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lewy bodies and other intracellular inclusions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of observations in transgenic and normal mice and in humans suggest that misfolded forms of alpha-synuclein can somehow be transmitted from diseased neurons to healthy ones.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In normal mice, a single injection of synthetic misfolded alpha-synuclein fibrils into the striatum leads to cell-to-cell transmission of pathologic alpha-synuclein and Lewy body-like pathology with progressive loss of dopaminergic neurons in the substantia nigra pars compacta and impaired motor coordination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Pathologic alpha-synuclein appears to act as a template that corrupts normal alpha-synuclein, so it too becomes pathologic and thereby spreads the disease from an affected neuron to a normal one, which in turn becomes diseased.",
"     </li>",
"     <li>",
"      Human fetal nigral neurons transplanted into the brains of patients with PD developed Lewy bodies that are demonstrable at autopsy in long term survivors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hydrophobic portion of SNCA can spontaneously form fibrillar protein aggregates, and SNCA mutations may promote the development of these aggregates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/49\">",
"       49",
"      </a>",
"      ]. Furthermore, SNCA protoaggregates or oligomers can disrupt cell membranes, including dopamine vesicles and mitochondria, possibly by causing pores in the membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/49\">",
"       49",
"      </a>",
"      ]. A protofibrillar form of SNCA appears to be more toxic than the normal or fibrillar form.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Defective proteasomal degradation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impairment of the ubiquitin-proteasome system may cause or contribute to the development of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Abnormal proteins, such as mutated alpha-synuclein, are normally broken down by the ubiquitin-proteasome system, but when this process is impaired, the degraded proteins misfold, aggregate, and clog the normal molecular traffic of the cell, leading to cell death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental evidence regarding impairment of the ubiquitin-proteasome system in the development of PD is conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Of particular interest, however, is the finding in mice that the proteins Parkin, Pink1, and DJ-1 bind to each other to form a complex that promotes degradation of unfolded or misfolded proteins via the ubiquitin-proteasome system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/56\">",
"     56",
"    </a>",
"    ]. This observation is notable because gene mutations of Parkin, PINK1, and DJ-1 are individually associated with autosomal recessive forms of PD. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Genetics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mitochondrial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of mitochondria in the pathogenesis of PD was first suggested by discovery of the association between the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    analogue 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and parkinsonism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The oxidation of MPTP produces 1-methyl-4-phenylpyridium (MPP+), which is taken up by dopaminergic terminals, selectively inhibits mitochondrial complex I activity, disrupts calcium homeostasis, and induces endoplasmic reticulum stress, resulting in cell damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Direct evidence of mitochondrial dysfunction is supported by the finding that complex I activity is decreased by 32 to 38 percent in the substantia nigra of patients with sporadic PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], and by the finding that mitochondrial membrane potential and intracellular ATP levels are significantly decreased in skin fibroblasts of patients with PD who carry the LRRK2 G2019S mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following cascade of intracellular events has been postulated to lead to neurodegeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cellular insult (eg, oxidative stress, excitotoxicity, DNA damage) increases cytosolic calcium and oxidative radicals, and activates nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) leading to the formation of poly(ADP-ribose PAR)",
"     </li>",
"     <li>",
"      This leads to decreased mitochondrial membrane potential, which in turn opens mitochondrial permeability transition pores (PTP)",
"     </li>",
"     <li>",
"      Release of NAD+ through the PTP leads to NAD+ depletion",
"     </li>",
"     <li>",
"      Release of mitochondrial apoptosis initiating factors promotes release of cytochrome c, which leads to activation of the \"executioner\" enzyme caspase and to apoptosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on epidemiologic studies supporting an association between exposure to pesticides and PD (see",
"    <a class=\"local\" href=\"#H7541764\">",
"     'Risk factors'",
"    </a>",
"    below), and evidence of mitochondrial complex I deficiency in PD, an animal model of PD pathogenesis has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/65\">",
"     65",
"    </a>",
"    ]. The lipophilic pesticide rotenone is a potent inhibitor of mitochondrial complex I. Continuous infusion of rotenone into the jugular vein of rats for several weeks produced highly selective degeneration of the nigrostriatal dopaminergic pathway, associated clinically with bradykinesia and rigidity, and pathologically with fibrillary cytoplasmic inclusions staining for ubiquitin and alpha-synuclein.",
"   </p>",
"   <p>",
"    Unlike MPTP, rotenone does not require the dopamine transporter for neuronal uptake. The degeneration actually begins in the dopaminergic nerve terminals in the central and dorsolateral striatum, leading to retrograde apoptotic death of the cell body. Rotenone infusion is associated with marked and uniform depletion of complex I in the brain and generation of reactive oxygen species, or oxygen-free radicals, resulting in oxidative damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/65\">",
"     65",
"    </a>",
"    ]. This can also lead to release of cytochrome c from the mitochondria into the cytoplasm and aggregation of proteins, such as alpha-synuclein, and formation of cytoplasmic inclusions.",
"   </p>",
"   <p>",
"    The rotenone model provides support for the theory that neurodegeneration results from an interaction between environmental exposure and mitochondrial dysfunction. Further evidence for the role of mitochondria in the pathogenesis of PD is provided by the increasing number of genes (such as PINK1) coding for mitochondrial proteins, and implicated in cellular protection against oxidative damage, that have been associated with the PD phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'PINK1-associated PD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Oxidative stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oxidative stress hypothesis postulates that inappropriate production of reactive oxygen species leads to neurodegeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/61,68\">",
"     61,68",
"    </a>",
"    ]. Dopamine is normally metabolized not only by monoamine oxidase-mediated enzymatic oxidation, but also by auto-oxidation to neuromelanin.",
"   </p>",
"   <p>",
"    Intraneuronal neuromelanin appears to have a dual role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/69\">",
"     69",
"    </a>",
"    ]. First, it may be neuroprotective, preventing toxic accumulation of metabolites of catechol amines, and scavenging reactive metals, pesticides and other oxidants. Second, dying neurons may release neuromelanin, leading to chronic inflammation.",
"   </p>",
"   <p>",
"    These metabolic pathways generate byproducts, including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , superoxide anions, and hydroxyradicals. Free radicals, through interaction with membrane lipids, cause toxic lipid peroxidation, which has been found to be increased in the substantia nigra of PD brains. The oxidative products may cause neurotoxicity and, therefore, may play an important role in the development of PD.",
"   </p>",
"   <p>",
"    It is possible that increased oxidative stress also contributes to misfolding of proteins. This notion is supported by the finding that nitric oxide, a free radical increased in the brains of patients with PD, attacks disulfide isomerase, an aggregation-preventing chaperone protein localized to the endoplasmic reticulum and normally responsible for unfolding and transport of proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24078938\">",
"    <span class=\"h2\">",
"     Iron metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elemental iron plays a critical role in oxidative metabolism and it also serves as a cofactor in the synthesis of neurotransmitters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/71\">",
"     71",
"    </a>",
"    ]. It is increased by about 50 percent in substantia nigra of PD brains relative to controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/72\">",
"     72",
"    </a>",
"    ], suggesting that abnormal iron metabolism plays a pathologic role in the development of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/73\">",
"     73",
"    </a>",
"    ]. One study found that mice lacking the tau protein developed parkinsonism due to toxic iron accumulation and neuronal loss in the substantia nigra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, loss of tau in neuronal culture caused intracellular iron retention. Brain permeable iron chelators prevent experimentally-induced degeneration of nigrostriatal dopamine neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immunologic and inflammatory mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunologic mechanisms have been implicated in the pathogenesis of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/69,76\">",
"     69,76",
"    </a>",
"    ]. Supporting evidence comes from the finding of elevated levels of the proinflammatory cytokines TNF-alpha, interleukin-1 beta, and interferon-gamma in patients with PD.",
"   </p>",
"   <p>",
"    The role of inflammatory processes in the pathogenesis of PD is further supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cyclooxygenase-2, the rate-limiting enzyme in prostaglandin E2 synthesis, appears to be upregulated in patients with PD and in the MPTP mouse model of PD; cyclooxygenase-2 inhibition prevents the formation of potentially toxic dopamine-quinones in MPTP mice and presumably in patients with PD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a positron emission tomography study that used markers for activated microglia and for dopamine transporter, microglial activity in patients with PD correlated with decreased density of dopamine transporter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infiltration of CD4+ T lymphocytes contributed to neuronal cell death in a mouse model of PD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of PD varies depending on the diagnostic criteria, study population, and epidemiologic methods used. With these caveats in mind, the prevalence of PD (number of cases at a particular point in time) is generally thought to be about 0.3 percent in the general population, and approximately 1 percent in people &gt;60 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Worldwide, there are approximately five million people with PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/82\">",
"     82",
"    </a>",
"    ]. Estimates of the incidence of PD (number of new cases per year) range from 8 to 18.6 per 100,000 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The range of epidemiologic observations for PD is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based on a joint analysis of five European communities, the overall prevalence of PD was 1.6 percent in the population over age 65 and 3.5 percent in those older than 85 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study involving 142,902 health care professionals, the incidence of PD was estimated to be",
"      <span class=\"nowrap\">",
"       18.6/100,000",
"      </span>",
"      person-years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/84\">",
"       84",
"      </a>",
"      ]. The rate was much higher for men than for women (43.2 versus 10.7 per 100,000 person-years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study that used membership information from a large California health maintenance organization, 588 newly diagnosed (incident) cases of PD were identified, giving an annualized incidence, adjusted for age and gender, of",
"      <span class=\"nowrap\">",
"       13.4/100,000",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/85\">",
"       85",
"      </a>",
"      ]. Only 4 percent of the cases were younger than age 50, and the rate was higher for men than for women",
"      <span class=\"nowrap\">",
"       (19.0/100,000",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       9.9/100,000).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A male preponderance of PD has been observed in many but not all epidemiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/81\">",
"     81",
"    </a>",
"    ], suggesting that men have a higher risk than women for developing PD. The male preponderance may be due to deficiency in a sex determining gene on the Y chromosome, the SRY gene, which is expressed in the substantia nigra only in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Associated factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies may provide important clues to potential risk factors associated with PD. Data for most putative PD risk factors are conflicting, but there is consistent evidence that older age and a family history of PD are associated with increased risk, while cigarette smoking is a protective factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/81,87\">",
"     81,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7541729\">",
"    <span class=\"h3\">",
"     Protective factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inverse correlation between PD and smoking is supported by the findings of large cohort studies and meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. As an example, a 2012 meta-analysis reported that the risk of PD was significantly lower for current smokers compared with never smokers (relative risk [RR] 0.44, 95% CI 0.39-0.50) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87\">",
"     87",
"    </a>",
"    ]. In addition, the risk of PD was lower for ever smokers compared with never smokers (RR 0.64, 95% CI 0.60-0.69). A neuroprotective effect of nicotine has been proposed as one possible explanation for these observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/91\">",
"     91",
"    </a>",
"    ]. The relatively high frequency of nonsmokers among patients with PD does not explain the relatively low prevalence of most cancers, except for melanoma and possibly breast cancer, reported in patients with PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite some controversy, the evidence suggests that the reduced risk of PD associated with smoking should not simply be attributed to a \"nonsmoking\" personality in PD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. This alternative explanation posits that since dopamine is an integral component of the brain's reward system, people who will later develop signs of PD do not engage in reward-seeking behaviors, such as smoking, because dopamine is significantly depleted in the basal ganglia years before symptoms of PD appear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/94\">",
"     94",
"    </a>",
"    ]. One study showed that patients with PD had lower impulsive sensation seeking scores (and higher depression and anxiety scores) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/95\">",
"     95",
"    </a>",
"    ]. However, impulse control disorders and compulsive behavior become markedly increased with dopaminergic therapy, particularly with the dopamine agonists (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link&amp;anchor=H21#H21\">",
"     \"Pharmacologic treatment of Parkinson disease\", section on 'Impulse control disorders'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Coffee and caffeine intake also have been associated with lower risk of PD in meta-analyses and large cohort studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87,90,96,97\">",
"     87,90,96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from several prospective studies suggest that moderate to vigorous physical activity and exercise is associated with a reduced risk for developing PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/98-102\">",
"     98-102",
"    </a>",
"    ]. However, an alternative explanation for the association is reversed causality, given that reduced physical activity may be a preclinical sign of PD.",
"   </p>",
"   <p>",
"    There is evidence from several meta-analyses that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    may be associated with a reduced risk of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. The data regarding other nonsteroidal antiinflammatory drugs (NSAIDs) are conflicting, with some meta-analyses finding that NSAIDs are associated with a reduced risk of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87,104\">",
"     87,104",
"    </a>",
"    ], and others finding no significant association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/103,105,106\">",
"     103,105,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7541764\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of PD is an important risk factor for developing PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87\">",
"     87",
"    </a>",
"    ]. The risk for PD associated with specific genes and genetic loci is discussed below (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Genetics'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Accumulating evidence suggests that exposure to pesticides is a risk factor for PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87,107-112\">",
"     87,107-112",
"    </a>",
"    ]. The evidence is inconclusive for other putative risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/81\">",
"     81",
"    </a>",
"    ], which include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Living in urban or industrial areas with high release of copper, manganese, or lead [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/113\">",
"       113",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exposure to hydrocarbon solvents, particularly trichloroethylene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/114\">",
"       114",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Living in rural areas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87\">",
"       87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Farming or agriculture work [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87\">",
"       87",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The use of well water [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87,115\">",
"       87,115",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Milk consumption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/116\">",
"       116",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High dietary intake of iron, especially in combination with high manganese intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/117\">",
"       117",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Excess body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/118\">",
"       118",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Higher levels of education [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/119\">",
"       119",
"      </a>",
"      ], and in the same cohort, a history of anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/120\">",
"       120",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the prevalence of most cancers among patients with PD is relatively low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/92\">",
"     92",
"    </a>",
"    ], there is some evidence that a history of melanoma or prostate cancer is associated with an increased risk for PD, and vice versa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/121-123\">",
"     121-123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Earlier concern that welding might be a risk factor for PD or parkinsonism, possibly by causing manganese toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/124\">",
"     124",
"    </a>",
"    ], has been refuted. A systematic review that searched the literature through the end of 2011 identified 13 epidemiologic studies of welding and 3 of manganese exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/125\">",
"     125",
"    </a>",
"    ]. In the meta-analyses, there was no increased risk of PD with welding (pooled risk ratio [RR] 0.86, 95% CI 0.80-0.92) or manganese exposure (pooled RR 0.76, 95% CI 0.41-1.42). The finding that welding was associated with a significantly reduced risk of PD may be explained by confounding related to smoking or a healthy worker effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of cases of PD appear to be sporadic, there is increasing evidence that genetic factors play a role in the pathogenesis of PD, particularly when the age at symptom onset is younger than 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/126-129\">",
"     126-129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A genetic contribution to the etiology of PD is suggested by the observation that approximately 20 to 25 percent of patients with sporadic PD have at least one first-degree relative with PD. Furthermore, a large case-control study found that first-degree relatives of patients with PD were 2.3 times as likely to develop PD as first-degree relatives of controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Utilizing the World War II Veteran Twin Registry, one study identified 193 twins with PD and concluded that genetic factors were important when the disease began before (but not after) age 50 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study using the Swedish Twin Registry screened 33,780 twins by telephone interview, but found only two concordant pairs for PD, both female dizygotic, and concluded that \"the importance of genetic effects in PD is notably low\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most cogent evidence for a genetic contribution to the pathogenesis of PD comes from reports of large multicase kindreds with a PD phenotype of monogenetic origin. These familial forms of parkinsonism (designated PARK1 through PARK13) have been associated with causative mutations in a number of nuclear genes (",
"    <a class=\"graphic graphic_table graphicRef78658 \" href=\"mobipreview.htm?32/25/33182\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/128\">",
"     128",
"    </a>",
"    ]. Autosomal dominant, autosomal recessive, and x-linked forms of PD have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/126,128\">",
"     126,128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is accumulating evidence that specific genes and genetic loci are risk factors for PD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of five PD genome-wide association studies identified 11 loci that were significantly associated with an increased genetic risk of PD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/132\">",
"       132",
"      </a>",
"      ]. These included six genes previously associated with PD (MAPT, SNCA, HLA-DRB5, BST1, GAK and LRRK2) and five newly identified loci (ACMSD, STK39,",
"      <span class=\"nowrap\">",
"       MCCC1/LAMP3,",
"      </span>",
"      SYT11, and",
"      <span class=\"nowrap\">",
"       CCDC62/HIP1R).",
"      </span>",
"      The population attributable risk of PD for these loci combined was 60 percent (95% CI 44-70 percent). A second meta-analysis from the same group identified five more susceptibility loci for PD (PARK16, STX1B, FGF20, STBD1, GPNMB) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/133\">",
"       133",
"      </a>",
"      ], while a meta-analysis from another group identified the RIT2 gene as a susceptibility factor for PD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/134\">",
"       134",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One of the largest individual genome-wide association studies of PD, with 3426 cases and 29,624 controls, confirmed 20 previously discovered genetic associations (including LRRK2, GBA, SNCA, MAPT, GAK, and the HLA region) and identified two novel associations with PD (rs6812193 near SCARB2 and rs11868035 near",
"      <span class=\"nowrap\">",
"       SREBF1/RAI1)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/135\">",
"       135",
"      </a>",
"      ]. The heritability of PD was estimated to be 0.27, suggesting that genetic factors account for at least one-fourth of the total variation in risk for developing PD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, caution is warranted since genome-wide association studies may overestimate the risk related to specific loci due to the inherent bias of the case-control design. In addition, the results do not provide enough accuracy to be clinically useful as a basis for PD risk assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several of the most important genetic risk factors and monogenetic forms of PD are discussed in greater detail in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glucocerebrosidase gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence suggests that genetic variance in the glucocerebrosidase gene (GBA) &mdash; the gene associated with Gaucher disease in Ashkenazi Jews &mdash; is an important risk factor for PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/137-140\">",
"     137-140",
"    </a>",
"    ]. One of the largest studies analyzed data from 16 centers around the world, including 5691 patients (780 Ashkenazi Jews) with PD and 4898 controls (387 Ashkenazi Jews) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/138\">",
"     138",
"    </a>",
"    ]. All centers screened for two relatively frequent GBA mutations (N370S and L444P). Compared with controls, either GBA mutation was more common in patients with PD, both among Ashkenazi Jewish subjects (15 percent, versus 3 percent of controls) and among non&ndash;Ashkenazi Jewish subjects (3 percent, versus &lt;1 percent of controls). Overall, the likelihood of finding any GBA mutation was significantly higher in patients with PD than in controls (odds ratio 5.43, 95% CI 3.89-7.57).",
"   </p>",
"   <p>",
"    Among all patients with PD, the clinical profile was generally similar. However, when compared with patients who had PD but lacked a GBA mutation, those with PD who carried a GBA mutation were significantly more likely to have the following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/138\">",
"     138",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age at onset",
"     </li>",
"     <li>",
"      Less prominent tremor, bradykinesia, and rigidity",
"     </li>",
"     <li>",
"      Lower frequency of asymmetric onset",
"     </li>",
"     <li>",
"      Higher frequency of a family history of PD",
"     </li>",
"     <li>",
"      Greater likelihood of cognitive impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that mutations of GBA are more likely to be genetic susceptibility factors than Mendelian causes of PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     SNCA-associated PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-synuclein (SNCA) gene missense mutations (PARK1) or multiplications (PARK4) are associated with autosomal dominant parkinsonism; the phenotype varies from classic PD to dementia with Lewy bodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/128,141,142\">",
"     128,141,142",
"    </a>",
"    ]. However, SNCA mutations or multiplications appear to be rare causes of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of SNCA-associated neurodegeneration is not yet fully understood, but is probably due to a toxic gain-of-function effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/128\">",
"     128",
"    </a>",
"    ]. As discussed earlier, there is evidence that impaired processing of alpha-synuclein leads to abnormal protein aggregation and misfolding, Lewy body formation, cellular oxidative stress, and energy depletion. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Protein misfolding, aggregation, and toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The SNCA gene was the first to be associated with parkinsonism when a genome scan in the Greek-Italian Contursi kindred identified a genetic marker on chromosome 4q21-q23 linked to the PD phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/144\">",
"     144",
"    </a>",
"    ]. This finding led to the discovery of a mutation in the single base pair (Ala53Thr) of the SNCA gene, designated PARK1 in the hierarchy of genes associated with PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/144,145\">",
"     144,145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Contursi kindred, the clinical features of the disease are similar to otherwise typical PD, except for younger age at onset (mean 46), greater cognitive decline, and more rapid progression, with a mean time from onset to death of nine years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/146,147\">",
"     146,147",
"    </a>",
"    ]. The pattern of nigrostriatal degeneration, with preservation of D2 receptors, as demonstrated by positron emission tomography, is similar to that seen in idiopathic PD.",
"   </p>",
"   <p>",
"    Subsequently, a second mutation in the SNCA gene involving an alanine for proline substitution at amino acid 30 (Ala30Pro) was found in a German family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/141\">",
"     141",
"    </a>",
"    ], and a third mutation involving a glutamic acid-to-lysine substitution at position 46 (E46K) was identified in a Spanish family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With reports of additional families, the phenotype of PARK1 has expanded to include not only typical PD features, but also dementia, hallucinations, central hypoventilation, orthostatic hypotension, myoclonus, and urinary incontinence, with pathologic involvement of the brainstem pigmented nuclei, hippocampus, and temporal neocortex. Thus, the clinical and pathologic features of families with SNCA mutations and parkinsonism overlap the features of multiple system atrophy and dementia with Lewy bodies.",
"   </p>",
"   <p>",
"    Similarly, overexpression of SNCA may lead to neurodegenerative disease with features that overlap those of PD, dementia with Lewy bodies, and multiple system atrophy, as observed in families with parkinsonism and whole gene duplication or triplication of SNCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/148\">",
"     148",
"    </a>",
"    ]. Duplication of SNCA appears to be associated with late-onset parkinsonism and dysautonomia, while triplication (designated PARK4) leads to early-onset PD and dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/149\">",
"     149",
"    </a>",
"    ]. SNCA triplication was found in one large family with autosomal dominant, young-onset parkinsonism, dysautonomia, cardiac denervation, dementia with Lewy bodies and glial cytoplasmic inclusions at autopsy, features typical of multiple system atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mounting evidence supports the role of common SNCA polymorphisms in sporadic PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/151-154\">",
"     151-154",
"    </a>",
"    ]. In particular, two large genome-wide association studies (GWAS) and a meta-analysis of GWAS studies in PD found that SNCA was a risk locus for PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/132,153,154\">",
"     132,153,154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     LRRK2-associated PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common form of monogenic PD is PARK8, caused by mutations in the leucine-rich repeat kinase-2 (LRRK2) gene on chromosome 12p11.2-q13.1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/155,156\">",
"     155,156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LRRK2 gene product is a protein called dardarin (from the Basque word \"dardara\" meaning tremor) that probably functions as a cytoplasmic kinase involved in phosphorylation of proteins, such as alpha synuclein and microtubule-associated protein tau [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/157-159\">",
"     157-159",
"    </a>",
"    ]. Dardarin is a large molecule, encoded by 51 exons and containing 2527 amino acids. This contrasts with the much smaller alpha-synuclein protein, which contains 140 amino acids.",
"   </p>",
"   <p>",
"    Dardarin is closely associated with a variety of membrane and vesicular structures, membrane-bound organelles and microtubules, suggesting its role in vesicular transport and in membrane and protein turnover, including lysosomal degradation pathway.",
"   </p>",
"   <p>",
"    LRRK2-associated PD may account for a significant proportion of familial PD cases, and a smaller proportion of sporadic PD cases. It is estimated to cause up to 8 percent of autosomal dominant PD in the Basque population and up to 50 percent of familial PD in people of North African and Middle Eastern origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/158,160-163\">",
"     158,160-163",
"    </a>",
"    ]. In addition, LRRK2 mutations have been found in 0.4 to 1.9 percent of patients with idiopathic PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/164-168\">",
"     164-168",
"    </a>",
"    ], although such cases could also be explained by reduced penetrance in familial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic screening studies suggest that the G2019S mutation, the most common of the LRRK2 mutations, accounts for 3 to 13 percent of autosomal dominant PD in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/143,162,169-171\">",
"     143,162,169-171",
"    </a>",
"    ], and 10 to 18 percent of autosomal dominant PD in Ashkenazi Jews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/163,172\">",
"     163,172",
"    </a>",
"    ]. The G2019S mutation has also been identified in asymptomatic carriers, suggesting reduced or age-dependent penetrance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/161,170\">",
"     161,170",
"    </a>",
"    ]. Evidence of age-dependent penetrance was found in a study of 19 families with the G2019S mutation, where the cumulative incidence of PD at ages 60, 70, and 80 years was 15, 21, and 32 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/173\">",
"     173",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LRRK2-associated PD phenotype is often, but not always, associated with late-onset (mean age 65 years) disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/159,170,174-176\">",
"     159,170,174-176",
"    </a>",
"    ]. However, the typical features of PD associated with LRRK2 G2019S mutations are indistinguishable from idiopathic PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/168\">",
"     168",
"    </a>",
"    ]. The course of the disease is relatively benign, usually presenting with unilateral hand or leg tremor without cognitive deficit. The patients respond well to levodopa.",
"   </p>",
"   <p>",
"    Other clinical phenotypes associated with LRRK2 mutations have included parkinsonism with dementia or amyotrophy or both, typical essential tremor, dysautonomia, familial progressive supranuclear palsy, familial multiple system atrophy, corticobasal degeneration, and primary progressive aphasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/177,178\">",
"     177,178",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autopsy findings in patients with LRRK2-associated PD are heterogeneous and range from pure nigral degeneration without Lewy bodies, to pathology consistent with typical PD, diffuse Lewy body disease, and neurofibrillary tangle and other tau pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/177,179\">",
"     177,179",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Parkin-associated PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1997, a study found a linkage between an autosomal recessive, juvenile, levodopa-responsive form of PD (ARPD or AR-JP) and a locus on chromosome 6q25.2-27 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/180\">",
"     180",
"    </a>",
"    ]. The following year, another study identified causative mutations in the gene called Parkin (PARK2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/181\">",
"     181",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the initial report, over one hundred mutations, variants, and polymorphisms have been identified in the Parkin gene, but it is not clear which of these changes lead to functional deficits. Several studies have demonstrated that heterozygous PARK2 variants may not necessarily be disease-causing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/182-184\">",
"     182-184",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parkin, the protein product of the PARK2 gene, is expressed in the substantia nigra and other brain regions, as well as in Lewy bodies. Normal parkin strongly binds to microtubules and is involved in ubiquitination and subsequent degradation of certain proteins by proteasomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/36,185\">",
"     36,185",
"    </a>",
"    ]. However, mutated parkin protein loses this proteasome-enhancing activity, and the result is a hastening of neuronal cell death because the disabled proteasome cannot clear the cell of accumulating aggregated protein. Neurodegeneration associated with the parkin mutation is not usually accompanied by formation of Lewy bodies, although there are exceptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/186\">",
"     186",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with parkin (PARK2) gene mutations usually have a family history consistent with autosomal recessive inheritance. The disease is characterized by early onset of symptoms (before age 50), a slowly progressive course, a symmetric presentation at onset of parkinsonian signs and symptoms (unlike classic PD, which is asymmetric), leg tremor, early dystonia and postural instability, freezing, festination, retropulsion, hyperreflexia, sensory axonal neuropathy, sleep benefit, and autonomic involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/187-189\">",
"     187-189",
"    </a>",
"    ]. On an individual basis, patients with early-onset PD who have parkin mutations are clinically indistinguishable from those with early-onset PD who lack parkin mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/190\">",
"     190",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, there is typically a good response to levodopa with early development of motor fluctuations and dyskinesia. Fluorodopa positron emission tomography (PET) shows a marked reduction in the fluorodopa uptake, similar to idiopathic PD, but asymptomatic carriers may also have abnormal PET studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/191\">",
"     191",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incomplete penetrance and variability of clinical and pathologic expression of PARK2-associated PD may be due to an interaction between the mutated parkin gene and other genes, including SNCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/192\">",
"     192",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     PINK1-associated PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of mitochondrial PTEN-induced putative kinase 1 gene (PINK1; PARK6) are associated with autosomal recessive familial PD, age younger than 50 at onset, slow progression, and excellent response to levodopa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/193-195\">",
"     193-195",
"    </a>",
"    ], similar to Parkin and DJ-1 mutations. Postmortem brain examination of a patient with early-onset PD and two compound heterozygous PINK1 mutations showed Lewy body pathology in the brainstem and Meynert nucleus, but the locus ceruleus and the amygdala were spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/196\">",
"     196",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PINK1 mutations have been found worldwide with a frequency that ranges from 1 to 8 percent of patients, most of whom had early-onset",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    familial PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/128,194,197-199\">",
"     128,194,197-199",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PINK1 mutations may cause disease through a loss-of-function effect resulting in mitochondrial dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     DJ-1-associated PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of the mitochondrial DJ-1 gene (PARK7) are associated with autosomal recessive inheritance, age younger than 40 at onset, slow progression, and good response to levodopa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/200,201\">",
"     200,201",
"    </a>",
"    ]. Wild type DJ-1 is thought to be neuroprotective against oxidative stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other monogenic forms of PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other monogenic forms of PD are reviewed in the Table (",
"    <a class=\"graphic graphic_table graphicRef78658 \" href=\"mobipreview.htm?32/25/33182\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/128,129,202-204\">",
"     128,129,202-204",
"    </a>",
"    ]. Novel genetic forms of parkinsonism are likely to emerge from future research, thereby shrinking the large majority of PD cases currently regarded as sporadic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular genetic testing is available for SNCA, Parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK 7), and LRRK2 (PARK8) gene mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/205\">",
"     205",
"    </a>",
"    ], but the interpretation of these tests is difficult. Routine testing for these genes is not recommended at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/6/36970/abstract/128,202\">",
"     128,202",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13954?source=see_link\">",
"       \"Patient information: Parkinson disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/4/5188?source=see_link\">",
"       \"Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Parkinson disease (PD), dopamine depletion in the substantia nigra and in the nigrostriatal pathway to the caudate and putamen ultimately results in increased inhibition of the thalamus and reduced excitatory input to the motor cortex (",
"      <a class=\"graphic graphic_figure graphicRef82136 \" href=\"mobipreview.htm?9/19/9535\">",
"       figure 1",
"      </a>",
"      ), which is expressed as bradykinesia and other parkinsonian signs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Basal ganglia circuits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compensatory mechanisms may operate to mask or reduce the deleterious effects of dopamine depletion, particularly in the presymptomatic phase of PD. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Compensatory mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical abnormalities found in the brains of patients with PD include depigmentation (from loss of neuromelanin), neuronal loss, and gliosis, particularly in the substantia nigra pars compacta and in the pontine locus ceruleus. Lewy bodies are round, eosinophilic, intracytoplasmic inclusions in the nuclei of neurons that constitute the pathologic hallmark of PD. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The precise mechanisms of neurodegeneration in PD are not yet understood, but they most likely involve a cascade of events that include interaction between genetic and environmental factors, and abnormalities in protein processing, oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammation, immune regulation, and other mechanisms (",
"      <a class=\"graphic graphic_algorithm graphicRef82386 \" href=\"mobipreview.htm?36/33/37406\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef72207 \" href=\"mobipreview.htm?22/55/23415\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis of cell degeneration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of PD is estimated to be 0.3 percent in the general population, and approximately 1 percent in people &gt;60 years old. Worldwide, there are approximately five million people with PD. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is consistent evidence that older age is associated with increased risk of PD, while cigarette smoking is a protective factor. Evidence supporting other potential risk factors for PD, including occupational exposures (eg, pesticides, herbicides, heavy metals), dietary factors, and body weight is inconclusive. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Associated factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the majority of cases of PD appear to be sporadic, there are genetic forms of parkinsonism (designated PARK1 through PARK13) related to nuclear and mitochondrial genes. Novel genetic forms of parkinsonism are likely to emerge from future research, thereby shrinking the large majority of PD cases currently regarded as sporadic. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/1\">",
"      Manyam BV. Paralysis agitans and levodopa in \"Ayurveda\": ancient Indian medical treatise. Mov Disord 1990; 5:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/2\">",
"      Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004; 75:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/3\">",
"      Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 2006; :9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/4\">",
"      Marras C, Lang A. Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 2008; 70:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/5\">",
"      Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 2000; 23:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/6\">",
"      Bamford NS, Robinson S, Palmiter RD, et al. Dopamine modulates release from corticostriatal terminals. J Neurosci 2004; 24:9541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/7\">",
"      Ryoo HL, Pierrotti D, Joyce JN. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 1998; 13:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/8\">",
"      Gatev P, Darbin O, Wichmann T. Oscillations in the basal ganglia under normal conditions and in movement disorders. Mov Disord 2006; 21:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/9\">",
"      Obeso JA, Rodr&iacute;guez-Oroz MC, Rodr&iacute;guez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000; 23:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/10\">",
"      Calabresi P, Centonze D, Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 2000; 23:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/11\">",
"      Moore H, Grace AA. A role for electrotonic coupling in the striatum in the expression of dopamine receptor-mediated stereotypies. Neuropsychopharmacology 2002; 27:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/12\">",
"      Huot P, L&eacute;vesque M, Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 2007; 130:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/13\">",
"      Huot P, Parent A. Dopaminergic neurons intrinsic to the striatum. J Neurochem 2007; 101:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/14\">",
"      Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/15\">",
"      Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005; 128:2777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/16\">",
"      Pakkenberg B, M&oslash;ller A, Gundersen HJ, et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991; 54:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/17\">",
"      Porritt M, Stanic D, Finkelstein D, et al. Dopaminergic innervation of the human striatum in Parkinson's disease. Mov Disord 2005; 20:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/18\">",
"      Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114 ( Pt 5):2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/19\">",
"      Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centr&eacute; median-parafascicular complex in Parkinson's disease. Ann Neurol 2000; 47:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/20\">",
"      Camicioli R, Moore MM, Kinney A, et al. Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003; 18:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/21\">",
"      Murakami T, Shoji M, Imai Y, et al. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann Neurol 2004; 55:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/22\">",
"      Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 2000; 47:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/23\">",
"      Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007; 27:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/24\">",
"      Popescu A, Lippa CF, Lee VM, Trojanowski JQ. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 2004; 61:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/25\">",
"      Bodner RA, Outeiro TF, Altmann S, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A 2006; 103:4246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/26\">",
"      Braak H, Bohl JR, M&uuml;ller CM, et al. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006; 21:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/27\">",
"      Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008; 70:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/28\">",
"      Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008; 64:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/29\">",
"      Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012; 27:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/30\">",
"      Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/31\">",
"      Lang AE. The progression of Parkinson disease: a hypothesis. Neurology 2007; 68:948.",
"     </a>",
"    </li>",
"    <li>",
"     McNaught KSP, Jenner P, Olanow CW. Protein mishandling: Role of the ubiquitin proteasome system in the pathogenesis of Parkinson's disease. In: Parkinson's Disease and Movement Disorders, 5th edition, Jankovic J, Tolosa E (Eds), Lippincott Williams and Wilkins, Philadelphia 2007. p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/33\">",
"      Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008; 131:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/34\">",
"      Jellinger KA. Cell death mechanisms in Parkinson's disease. J Neural Transm 2000; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/35\">",
"      Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003; 53 Suppl 3:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/36\">",
"      Feng J. Microtubule: a common target for parkin and Parkinson's disease toxins. Neuroscientist 2006; 12:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/37\">",
"      Maragakis NJ, Rothstein JD. Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006; 2:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/38\">",
"      Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect 2005; 113:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/39\">",
"      Cory-Slechta DA, Thiruchelvam M, Barlow BK, Richfield EK. Developmental pesticide models of the Parkinson disease phenotype. Environ Health Perspect 2005; 113:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/40\">",
"      Maries E, Dass B, Collier TJ, et al. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 2003; 4:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/41\">",
"      Vekrellis K, Xilouri M, Emmanouilidou E, et al. Pathological roles of &alpha;-synuclein in neurological disorders. Lancet Neurol 2011; 10:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/42\">",
"      Feany MB. New genetic insights into Parkinson's disease. N Engl J Med 2004; 351:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/43\">",
"      Meredith GE, Halliday GM, Totterdell S. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord 2004; 10:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/44\">",
"      Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/45\">",
"      Luk KC, Kehm V, Carroll J, et al. Pathological &alpha;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/46\">",
"      Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological &alpha;-synuclein initiates a rapidly progressive neurodegenerative &alpha;-synucleinopathy in mice. J Exp Med 2012; 209:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/47\">",
"      Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/48\">",
"      Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/49\">",
"      Lashuel HA, Petre BM, Wall J, et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 2002; 322:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/50\">",
"      Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005; 6:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/51\">",
"      Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005; 62:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/52\">",
"      McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 2003; 53 Suppl 3:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/53\">",
"      McNaught KS, Olanow CW. Proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 2006; 60:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/54\">",
"      Beal F, Lang A. The proteasomal inhibition model of Parkinson's disease: \"Boon or bust\"? Ann Neurol 2006; 60:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/55\">",
"      Kordower JH, Kanaan NM, Chu Y, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 2006; 60:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/56\">",
"      Xiong H, Wang D, Chen L, et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 2009; 119:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/57\">",
"      Bov&eacute; J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005; 2:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/58\">",
"      Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 2004; 36:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/59\">",
"      Selvaraj S, Sun Y, Watt JA, et al. Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest 2012; 122:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/60\">",
"      Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/61\">",
"      Greenamyre JT, Hastings TG. Biomedicine. Parkinson's--divergent causes, convergent mechanisms. Science 2004; 304:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/62\">",
"      Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010; 75:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/63\">",
"      Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/64\">",
"      Krantic S, Mechawar N, Reix S, Quirion R. Molecular basis of programmed cell death involved in neurodegeneration. Trends Neurosci 2005; 28:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/65\">",
"      Sherer TB, Betarbet R, Testa CM, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003; 23:10756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/66\">",
"      Abou-Sleiman PM, Muqit MM, McDonald NQ, et al. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol 2006; 60:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/67\">",
"      Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/68\">",
"      Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 2005; 20:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/69\">",
"      Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 2005; 11 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/70\">",
"      Uehara T, Nakamura T, Yao D, et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006; 441:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/71\">",
"      Benarroch EE. Brain iron homeostasis and neurodegenerative disease. Neurology 2009; 72:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/72\">",
"      Oakley AE, Collingwood JF, Dobson J, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007; 68:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/73\">",
"      Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/74\">",
"      Lei P, Ayton S, Finkelstein DI, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012; 18:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/75\">",
"      Zhu W, Xie W, Pan T, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 2007; 21:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/76\">",
"      Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/77\">",
"      Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 2003; 100:5473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/78\">",
"      Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/79\">",
"      Brochard V, Combadi&egrave;re B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/80\">",
"      Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003; 348:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/81\">",
"      de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/82\">",
"      Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 2007; 104:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/83\">",
"      de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/84\">",
"      Chen H, Zhang SM, Hern&aacute;n MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/85\">",
"      Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/86\">",
"      Dewing P, Chiang CW, Sinchak K, et al. Direct regulation of adult brain function by the male-specific factor SRY. Curr Biol 2006; 16:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/87\">",
"      Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012; 72:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/88\">",
"      Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/89\">",
"      Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007; 64:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/90\">",
"      Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol 2012; 175:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/91\">",
"      Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci 2004; 27:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/92\">",
"      Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007; 69:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/93\">",
"      Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL. Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann Neurol 2005; 57:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/94\">",
"      Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist 2008; 14:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/95\">",
"      Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/96\">",
"      Palacios N, Gao X, McCullough ML, et al. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord 2012; 27:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/97\">",
"      Costa J, Lunet N, Santos C, et al. Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis 2010; 20 Suppl 1:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/98\">",
"      Logroscino G, Sesso HD, Paffenbarger RS Jr, Lee IM. Physical activity and risk of Parkinson's disease: a prospective cohort study. J Neurol Neurosurg Psychiatry 2006; 77:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/99\">",
"      Chen H, Zhang SM, Schwarzschild MA, et al. Physical activity and the risk of Parkinson disease. Neurology 2005; 64:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/100\">",
"      Thacker EL, Chen H, Patel AV, et al. Recreational physical activity and risk of Parkinson's disease. Mov Disord 2008; 23:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/101\">",
"      Xu Q, Park Y, Huang X, et al. Physical activities and future risk of Parkinson disease. Neurology 2010; 75:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/102\">",
"      Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology 2011; 77:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/103\">",
"      Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009; 26:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/104\">",
"      Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010; 74:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/105\">",
"      Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011; 76:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/106\">",
"      Rees K, Stowe R, Patel S, et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst Rev 2011; :CD008454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/107\">",
"      Ascherio A, Chen H, Weisskopf MG, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol 2006; 60:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/108\">",
"      Frigerio R, Sanft KR, Grossardt BR, et al. Chemical exposures and Parkinson's disease: a population-based case-control study. Mov Disord 2006; 21:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/109\">",
"      Costello S, Cockburn M, Bronstein J, et al. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009; 169:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/110\">",
"      Firestone JA, Smith-Weller T, Franklin G, et al. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 2005; 62:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/111\">",
"      Elbaz A, Clavel J, Rathouz PJ, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol 2009; 66:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/112\">",
"      Weisskopf MG, Knekt P, O'Reilly EJ, et al. Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology 2010; 74:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/113\">",
"      Willis AW, Evanoff BA, Lian M, et al. Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol 2010; 172:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/114\">",
"      Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012; 71:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/115\">",
"      Petrovitch H, Ross GW, Abbott RD, et al. Plantation work and risk of Parkinson disease in a population-based longitudinal study. Arch Neurol 2002; 59:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/116\">",
"      Park M, Ross GW, Petrovitch H, et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology 2005; 64:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/117\">",
"      Powers KM, Smith-Weller T, Franklin GM, et al. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 2003; 60:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/118\">",
"      Hu G, Jousilahti P, Nissinen A, et al. Body mass index and the risk of Parkinson disease. Neurology 2006; 67:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/119\">",
"      Frigerio R, Elbaz A, Sanft KR, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology 2005; 65:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/120\">",
"      Savica R, Grossardt BR, Carlin JM, et al. Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology 2009; 73:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/121\">",
"      Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011; 76:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/122\">",
"      Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. Arch Neurol 2012; 69:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/123\">",
"      Pan T, Zhu J, Hwu WJ, Jankovic J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One 2012; 7:e45183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/124\">",
"      Racette BA, McGee-Minnich L, Moerlein SM, et al. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 2001; 56:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/125\">",
"      Mortimer JA, Borenstein AR, Nelson LM. Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. Neurology 2012; 79:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/126\">",
"      Kubo S, Hattori N, Mizuno Y. Recessive Parkinson's disease. Mov Disord 2006; 21:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/127\">",
"      Hardy J, Cai H, Cookson MR, et al. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006; 60:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/128\">",
"      Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 2007; 69:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/129\">",
"      Gasser T. Update on the genetics of Parkinson's disease. Mov Disord 2007; 22 Suppl 17:S343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/130\">",
"      Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology 1996; 47:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/131\">",
"      Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999; 281:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/132\">",
"      International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/133\">",
"      International Parkinson's Disease Genomics Consortium (IPDGC), Wellcome Trust Case Control Consortium 2 (WTCCC2). A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet 2011; 7:e1002142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/134\">",
"      Pankratz N, Beecham GW, DeStefano AL, et al. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol 2012; 71:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/135\">",
"      Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 2011; 7:e1002141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/136\">",
"      Klein C, Ziegler A. From GWAS to clinical utility in Parkinson's disease. Lancet 2011; 377:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/137\">",
"      Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/138\">",
"      Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/139\">",
"      Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/140\">",
"      Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012; 11:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/141\">",
"      Kr&uuml;ger R, Kuhn W, M&uuml;ller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/142\">",
"      Zarranz JJ, Alegre J, G&oacute;mez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/143\">",
"      Berg D, Schweitzer KJ, Leitner P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 2005; 128:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/144\">",
"      Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996; 274:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/145\">",
"      Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/146\">",
"      Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996; 40:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/147\">",
"      Bostantjopoulou S, Katsarou Z, Papadimitriou A, et al. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov Disord 2001; 16:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/148\">",
"      Nishioka K, Hayashi S, Farrer MJ, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 2006; 59:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/149\">",
"      Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007; 68:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/150\">",
"      Singleton A, Gwinn-Hardy K, Sharabi Y, et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 2004; 127:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/151\">",
"      Shulman JM, De Jager PL. Evidence for a common pathway linking neurodegenerative diseases. Nat Genet 2009; 41:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/152\">",
"      Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006; 296:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/153\">",
"      Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/154\">",
"      Sim&oacute;n-S&aacute;nchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/155\">",
"      Funayama M, Hasegawa K, Kowa H, et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/156\">",
"      Pais&aacute;n-Ru&iacute;z C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/157\">",
"      Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/158\">",
"      Schapira AH. The importance of LRRK2 mutations in Parkinson disease. Arch Neurol 2006; 63:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/159\">",
"      Whaley NR, Uitti RJ, Dickson DW, et al. Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. J Neural Transm Suppl 2006; :221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/160\">",
"      Deng H, Le W, Guo Y, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci 2006; 251:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/161\">",
"      Brice A. How much does dardarin contribute to Parkinson's disease? Lancet 2005; 365:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/162\">",
"      Lesage S, Ibanez P, Lohmann E, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005; 58:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/163\">",
"      Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006; 67:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/164\">",
"      Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/165\">",
"      Farrer M, Stone J, Mata IF, et al. LRRK2 mutations in Parkinson disease. Neurology 2005; 65:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/166\">",
"      Williams-Gray CH, Goris A, Foltynie T, et al. Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. J Neurol Neurosurg Psychiatry 2006; 77:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/167\">",
"      Lesage S, Janin S, Lohmann E, et al. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol 2007; 64:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/168\">",
"      Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/169\">",
"      Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005; 365:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/170\">",
"      Di Fonzo A, Roh&eacute; CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/171\">",
"      Gaig C, Ezquerra M, Marti MJ, et al. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006; 63:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/172\">",
"      Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/173\">",
"      Goldwurm S, Zini M, Mariani L, et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007; 68:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/174\">",
"      Hedrich K, Winkler S, Hagenah J, et al. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. Mov Disord 2006; 21:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/175\">",
"      Kay DM, Zabetian CP, Factor SA, et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 2006; 21:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/176\">",
"      Pais&agrave;n-Ru&igrave;z C, S&agrave;enz A, L&ograve;pez de Munain A, et al. Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann Neurol 2005; 57:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/177\">",
"      Ross OA, Toft M, Whittle AJ, et al. Lrrk2 and Lewy body disease. Ann Neurol 2006; 59:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/178\">",
"      Chen-Plotkin AS, Yuan W, Anderson C, et al. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 2008; 70:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/179\">",
"      Spanaki C, Latsoudis H, Plaitakis A. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 2006; 67:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/180\">",
"      Matsumine H, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997; 60:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/181\">",
"      Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/182\">",
"      Kay DM, Moran D, Moses L, et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 2007; 61:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/183\">",
"      Langston JW, Tanner CM, Sch&uuml;le B. Parkin gene variations and parkinsonism: association does not imply causation. Ann Neurol 2007; 61:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/184\">",
"      Kay DM, Stevens CF, Hamza TH, et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 2010; 75:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/185\">",
"      Burke RE. Recent advances in research on Parkinson disease: synuclein and parkin. Neurologist 2004; 10:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/186\">",
"      Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005; 58:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/187\">",
"      L&uuml;cking CB, D&uuml;rr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/188\">",
"      Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003; 54:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/189\">",
"      Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003; 126:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/190\">",
"      Lohmann E, Thobois S, Lesage S, et al. A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology 2009; 72:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/191\">",
"      Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001; 49:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/192\">",
"      Deng H, Le WD, Hunter CB, et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol 2006; 63:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/193\">",
"      Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/194\">",
"      Rogaeva E, Johnson J, Lang AE, et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004; 61:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/195\">",
"      Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/196\">",
"      Samaranch L, Lorenzo-Betancor O, Arbelo JM, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010; 133:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/197\">",
"      Hatano Y, Sato K, Elibol B, et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 2004; 63:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/198\">",
"      Bonifati V, Roh&eacute; CF, Breedveld GJ, et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/199\">",
"      Ishihara-Paul L, Hulihan MM, Kachergus J, et al. PINK1 mutations and parkinsonism. Neurology 2008; 71:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/200\">",
"      Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/201\">",
"      Hague S, Rogaeva E, Hernandez D, et al. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 2003; 54:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/202\">",
"      Tan EK, Jankovic J. Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol 2006; 63:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/203\">",
"      Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to \"PARK\" genes and beyond. Mov Disord 2009; 24:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/6/36970/abstract/204\">",
"      Wider C, Ross OA, Wszolek ZK. Genetics of Parkinson disease and essential tremor. Curr Opin Neurol 2010; 23:388.",
"     </a>",
"    </li>",
"    <li>",
"     Pankratz ND, Wojcieszek J, Foroud T. Parkinson Disease Overview. In: GeneReviews. www.ncbi.nlm.nih.gov./books/NBK1223/ (Accessed on January 15, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4906 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36970=[""].join("\n");
var outline_f36_6_36970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Basal ganglia circuits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Compensatory mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lewy bodies and other intracellular inclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Braak staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS OF CELL DEGENERATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Protein misfolding, aggregation, and toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Defective proteasomal degradation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mitochondrial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Oxidative stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24078938\">",
"      Iron metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immunologic and inflammatory mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Associated factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7541729\">",
"      - Protective factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7541764\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glucocerebrosidase gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SNCA-associated PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LRRK2-associated PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Parkin-associated PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PINK1-associated PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DJ-1-associated PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other monogenic forms of PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4906\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4906|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?36/33/37406\" title=\"algorithm 1\">",
"      Pathogenic mechanisms PD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4906|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/19/9535\" title=\"figure 1\">",
"      Models basal ganglia dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/7/23671\" title=\"figure 2\">",
"      Stages neurodegeneration PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/55/23415\" title=\"figure 3\">",
"      Processing proteins PD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4906|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/19/40253\" title=\"table 1\">",
"      Classification parkinsonism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/25/33182\" title=\"table 2\">",
"      Genetic causes parkinsonism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/41/34455?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/4/5188?source=related_link\">",
"      Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_6_36971="Treatment of granuloma inguinale";
var content_f36_6_36971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for the treatment of granuloma inguinale (donovanosis)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recommended regimen:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Doxycycline",
"        </strong>",
"        100 mg orally twice a day for at least 3 weeks and until all lesions have completely healed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alternative regimens:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Azithromycin",
"        </strong>",
"        1 g orally once per week for at least 3 weeks and until all lesions have completely healed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Ciprofloxacin",
"        </strong>",
"        750 mg orally twice a day for at least 3 weeks and until all lesions have completely healed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Erythromycin",
"        </strong>",
"        base 500 mg orally four times a day for at least 3 weeks and until all lesions have completely healed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Trimethoprim-sulfamethoxazole",
"        </strong>",
"        one double-strength (160 mg/800 mg) tablet orally twice a day for at least 3 weeks and until all lesions have completely healed",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb Mortal Wkly Rep 2010; 59(RR-12):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36971=[""].join("\n");
var outline_f36_6_36971=null;
var title_f36_6_36972="Apoptotic program c elegans";
var content_f36_6_36972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F73569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F73569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apoptotic program c elegans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 239px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36972=[""].join("\n");
var outline_f36_6_36972=null;
var title_f36_6_36973="Seizures versus syncope";
var content_f36_6_36973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differentiation of generalized tonic-clonic seizures from pseudoseizures and syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generalized seizure tonic-clonic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pseudoseizure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Circumstances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Situation",
"       </td>",
"       <td>",
"        Awake or sleep",
"       </td>",
"       <td>",
"        Awake",
"       </td>",
"       <td>",
"        Usually upright; any position if cardiogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Precipitating factors",
"       </td>",
"       <td>",
"        Sleep loss, alcohol withdrawal, flashing lights",
"       </td>",
"       <td>",
"        Emotion",
"       </td>",
"       <td>",
"        Emotion, injury, heat, crowds; none if cardiogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Presence of others",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Usual",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Motor phenomena",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vocalization",
"       </td>",
"       <td>",
"        At onset, if any",
"       </td>",
"       <td>",
"        During course",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Location of motor component (if present)",
"       </td>",
"       <td>",
"        Proximal limb",
"       </td>",
"       <td>",
"        Proximal limb",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Generalized motor",
"       </td>",
"       <td>",
"        Tonic, then clonic",
"       </td>",
"       <td>",
"        Tonic; flailing; struggling or thrashing, or both",
"       </td>",
"       <td>",
"        Usually atonic; if syncope lasts &gt;20 seconds: tonic, then clonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tonic posture",
"       </td>",
"       <td>",
"        Partial flexion or straight",
"       </td>",
"       <td>",
"        Opisthotonic",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Head movements",
"       </td>",
"       <td>",
"        To one side or none",
"       </td>",
"       <td>",
"        Side to side",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clonus/limb jerks",
"       </td>",
"       <td>",
"        Bilaterally synchronous",
"       </td>",
"       <td>",
"        Asynchronous",
"       </td>",
"       <td>",
"        Bilaterally synchronous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Purposeful movements",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Occasional, including avoidance",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biting",
"       </td>",
"       <td>",
"        Tongue, inside mouth",
"       </td>",
"       <td>",
"        Lips, arms, other people",
"       </td>",
"       <td>",
"        Tongue biting rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Babinski's sign",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Autonomic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micturition",
"       </td>",
"       <td>",
"        Frequent",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Occasional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eyes",
"       </td>",
"       <td>",
"        Open",
"       </td>",
"       <td>",
"        Closed",
"       </td>",
"       <td>",
"        Open",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pupils",
"       </td>",
"       <td>",
"        Dilated or hippus during attacks",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Dilated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colour",
"       </td>",
"       <td>",
"        Cyanotic or grey",
"       </td>",
"       <td>",
"        Rubor or normal",
"       </td>",
"       <td>",
"        Pale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulse",
"       </td>",
"       <td>",
"        Rapid, strong",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Slow if vasovagal, weak if vasodepressor; that of arrhythmias if cardiogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Timing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Usual duration",
"       </td>",
"       <td>",
"        1 to 5 min",
"       </td>",
"       <td>",
"        5 to 60 min",
"       </td>",
"       <td>",
"        1 to 2 min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Onset",
"       </td>",
"       <td>",
"        Sudden",
"       </td>",
"       <td>",
"        Gradual",
"       </td>",
"       <td>",
"        Gradual; possibly sudden if cardiogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sequence of symptoms",
"       </td>",
"       <td>",
"        Stereotyped",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Stereotyped",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Termination",
"       </td>",
"       <td>",
"        Spontaneous",
"       </td>",
"       <td>",
"        Spontaneous or induced by supraorbital pressure, suggestion",
"       </td>",
"       <td>",
"        Rapid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Sequelae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Injury",
"       </td>",
"       <td>",
"        Frequent, mild; scalp, face, common",
"       </td>",
"       <td>",
"        Rare, but multiple bruises possible; scalp, face, rare",
"       </td>",
"       <td>",
"        If sudden onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postictal",
"       </td>",
"       <td>",
"        Tired, confused, sleepy",
"       </td>",
"       <td>",
"        Alert, emotional outburst",
"       </td>",
"       <td>",
"        Regains consciousness in 2 to 3 min; alert but tired",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Blume WT. Diagnosis and management of epilepsy. CMAJ 2003; 168:441. Copyright &copy; 2003 Canadian Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36973=[""].join("\n");
var outline_f36_6_36973=null;
var title_f36_6_36974="Crohns colitis ulcers BE";
var content_f36_6_36974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 198px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema in a patient with Crohn's disease shows extensive ulceration of the wall of the colon associated with mucosal thickening and inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36974=[""].join("\n");
var outline_f36_6_36974=null;
var title_f36_6_36975="HS sinus1";
var content_f36_6_36975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hidradenitis suppurativa with a sinus tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_6_36975=[""].join("\n");
var outline_f36_6_36975=null;
